No va r t i s  In s t i tu te s  fo r  B ioMed i ca l  Re sea r ch
CFZ533
C l in i ca l  T r ia l  P ro to co l  CCFZ533X2201
A  12- mon th  random ized ,  mu l t ip ledose ,  open- labe l ,
s tudyeva lua t ing  sa fe ty,  to le rab i l i ty ,  
pha rmacok ine t ics /pha rmacodynam ics  (PK /PD )  and  e f f icacy 
o f  an  an t i- CD40  monoc lona l  an t ibody,  CFZ533 ,  
incomb ina t ion  wi th  mycopheno la te  mo fe t i l  (MMF )  and  
co r t icos te ro ids  (CS ) ,  wi th  and  w i thou t  tac ro l imus  (Tac ) ,  
indenovoren a l  t ransp lan t  rec ip ien ts
Do cumen t  t ype : Amended  P ro to co l  Ve r s ion
EUDRACT  numbe r 2015- 000925- 36
Ve rs ion  numbe r : v03(C lean )
S tudy  phase : I I
Re lease  da te : 20- Sep- 2017Pe r sona l  Da ta
P rope r ty  o f  Nova r t is
Con f iden t ia l
May  no t  be  used ,  d ivu lged ,  pub l ished ,  o r  o the rw ise  d isc losed
w i thou t  the  consen t  o f  Nova r t is
No va r t i s Con f iden t ia l Page  2
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
No t i f ica t ion  o f  se r ious  adve rse  even ts
A  s e r i o u s  a d v e r s e  e v e n t  (SAE )  i s  any  e v en t  wh i ch  i s  f a t a l  o r  l i f e - t h r e a t e n i n g ,  w h i c h  r equ i r e s  
o r  p r o l o n g s  ho sp i t a l i z a t ion ,  w h i c h  i s  s i g n i f i c a n t l y  o r  p e rm a n e n t ly  d i s a b l i n g  o r  in c ap a c i t a t ing ,  
w h i c h  c o n s t i t u t e s  a  c o n g e n i t a l  a n om a l y  o r  a  b i r th  d e f e c t ,  o r  w h i c h  i s  m ed i c a l ly s ig n i f i c an t ,  
m ay j e o p a r d i z e  t h e  s u b j e c t  a n d  m ay r e q u i r e  m e d i c a l  o r  s u r g i c a li n t e r v e n t i o n  to  p r e v e n t  o n e  o f  
t h e  o u t c om e s  l i s t e d  a b o v e .
Any  SAEo c cu r r ing  in  a  sub j e c t  f rom  con s en t  un t i l  3  mon th s  a f t e r  h i s /h e r  l a s t  do s e  o f  CFZ533
o r  2  mon th s  a f t e r  th e  end  o f  s tudy  v i s i t  fo r  p a t i en t s  o n  s t a n d a r d  o f  c a r e  t r e a tm e n t  mu s t  b e  
r e p o r t e d  e i t h e r  o n  t h e  p a p e r  SAE  r e p o r t  f o rm  o r  v i a  t h e  e l e c t r o n i c  SAE  f o rm  w i th in  th e  
c l i n i c a l  d a t a  c a p t u r e  s y s t em  (w h e r e  a v a i l a b l e ) .
Fo r  SAE s  r epo r t ed  u s ing  th e  p ap e r  SAE  r epo r t  fo rm ,  th e  I n v e s t i g a t o r  w i l l  en su r e  th a t  th e  fo rm  
i s  c om p l e t e d  a n d  f a x e d  by  t h e  I n v e s t i g a to r  to  t h e  l o c a l  N o v a r t i s  D r u g  S a f e ty  and  
Ep id em io logy D e p a r tm e n t  w i t h i n  2 4  h o u r s  o f  l e a r n i n g  o f  t h e  o c c u r r e n c e  o f  t h e  SAE  e v e n  i f  
t h e  SAE  d o e s  no t  a p p e a r  to  b e  d r u g- r e l a t e d .  Th e  o r i g i n a l  SAE  f o rm ,  t o g e t h e r  w i th  t h e  f ax  
c o n f i rm a t i o n  s h e e t ,  m u s t  b e  k e p t  w i t h  t h e  c a s e  r e p o r t  f o rm s  a t  t h e  s t u d y  s i t e .
F o r  SAE s  r e c o r d e d  e l e c t ron i ca l l yin  t h e  Nov a r t i s  c l i n i c a l  d a t a  c ap tu r e  sy s t em ,  in fo rm a t ion  
s h o u l d  b e  e n t e r e d ,  s av ed  a n d  e - s i g n e d  w i th in  2 4  h o u r s  o f  aw a r e n e s s  o f  t h e  SAE .  T h e s ed a t a  
w i l l  au tom a t i c a l ly  b e  subm i t t ed  to  N o v a r t i s  C h i e f  M e d i c a l  O f f i c e  a n d  P a t i e n t  S a f e t y  
D e p a r tm e n t.
M o r e  d e t a i l s  i n  S e c t i o n  7
Pe r sona l  Da tao f  t h i s  p r o t o c o l .
No va r t i s Con f iden t ia l Page  3
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Pe r sona l  Da ta
No va r t i s Con f iden t ia l Page  4
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Tab le  o f  con ten ts
N o t i f i c a t i o n  o f  s e r i o u s  a d v e r s e  e v e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
T a b l e  o f  c o n t e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
L i s t  o f  t a b l e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
L i s t  o f  f i g u r e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
L i s t  o f  a b b r e v i a t i o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
P h a rm a c o k i n e t i c  d e f i n i t i o n s  a n d  s ymbo l s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 4
G lo s s a ry o f  t e rm s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 5
P ro to co l  synop s i s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4
A s s e s sm e n t  s c h e d u l e  –P a r t  1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 8
A s s e s sm e n t  s c h e d u l e  –P a r t  2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 9
1 I n t r o d u c t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2
1 . 1 B a c k g r o u n d. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2
1 . 1 . 1 CD40 /CD40L c o - s t imu l a t ion :  a  t a rg e t  fo r  t r an sp l an t a t ion . . . . . . . . . . . . . . . . . . . . 3 3
1 . 1 . 2 CFZ 5 3 3 :  m e c h a n i sm  o f  a c t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
1 . 2 S tudy pu rpo s e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
2 S tudy o b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
2 . 1 S tudy P a r t  1 :  PK ,  PD  and  S a f e ty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
2 . 1 . 1 P r im a ry ob j e c t iv e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
2 . 1 . 2 S e cond a ry o b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
2 . 2 S tudy P a r t  2 :  CN I - f r e e  P roo f - o f - Con c ep t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
2 . 2 . 1 P r im a ry ob j e c t iv e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
2 . 2 . 2 S e cond a ry o b j e c t i v e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
3 I n v e s t i g a t i o n a l  p l a n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7
3 . 1 S tudy d e s ign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7
3 . 1 . 1 G e n e r a l  o v e r v i ew. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7
3 . 1 . 2 A l l  c o h o r t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 9
3 . 1 . 3 P a r t  1  –A rm  1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0
3 . 1 . 4 P a r t  2  –A rm s  2A- 2B. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1
3 . 2 R a t i o n a l e  f o r  s t u dy  d e s i g n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 2
3 . 3 R a t i o n a l e  f o r  d o s e / r e g im e n ,  d u r a t i o n  o f  t r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Co rpo ra te  Con f iden t ia l  In fo rma t ion
5 3Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  5
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
3 . 4  R a t i o n a l e  f o r  c h o i c e  o f  c om p a r a t o r . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 8
3 . 6 R i s k s  a n d  b e n e f i t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 8
3 . 6 . 1 CFZ 5 3 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9
3 . 6 . 2  A d j u n c t  imm u n o s u p p r e s s io n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6 1
3 . 6 . 3 R i s k  m i t i g a t i o n  s t r a t e g y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 1
4 Popu l a t ion. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 3
4 . 1 I n c l u s i o n  c r i t e r i a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 4
4 . 2 E x c l u s i o n  c r i t e r i a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
5 T r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 6
5 . 1  P r o t o c o l  r e q u e s t e d  t r e a tm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6 6
5 . 1 . 1 I n v e s t i g a t i o n a l  t r e a tm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 6
5 . 1 . 2 C o n t r o l  a n d  c o n c om i t a n t  d r u g s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 6
5 . 1 . 3 Add i t ion a l  s tudy t r e a tm en t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
5 . 2 T r e a tm e n t  a rm s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 6
5 . 3 T r e a tm e n t  a s s i g nm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7
5 . 4 T r e a tm e n t  b l i n d i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7
5 . 5 T r e a t i n g  t h e  s u b j e c t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7
5 . 5 . 1 S u b j e c t  n um b e r i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7
5 . 5 . 2 D i s p e n s i n g  t h e  s t u dy  t r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 8
5 . 5 . 3 H and l ing  o f  s tudy t r e a tm en t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 8
5 . 5 . 4 I n s t r u c t i o n s  f o r  p r e s c r i b i n g  a n d  t a k i n g  s t u d y  t r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . 6 9
5 . 5 . 5 P e rm i t t e d  d o s e  a d j u s tm e n t s  a n d  i n t e r r u p t i o n s  o f  s t u d y t r e a tm e n t. . . . . . . . 7 2
5 . 5 . 6 R e c omm e n d e d  t r e a tm e n t  o f  a d v e r s e  e v e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4
5 . 5 . 7  R e s c u e  m e d i c a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7 4
5 . 5 . 8 C o n c om i t a n t  t r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
5 . 5 . 9 P r o h i b i t e d  t r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 5
5 . 5 . 1 0 D i s con t inu a t ion  o f  s tudy t r e a tm e n t  a n d  p r em a t u r e  s u b j e c t  
w i t h d r aw a l. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 5
5 . 5 . 1 1 W i t h d r aw a l  o f  c o n s e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 8
5 . 5 . 1 2 L o s s  t o  f o l l ow- u p . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 8
5 . 5 . 1 3 R e p l a c em e n t  o f  e a r ly  w i t h d r aw a l s  o r  d i s c o n t i n u a t i o n s. . . . . . . . . . . . . . . . . . . . . . . . 7 8
5 . 5 . 1 4 Em e rg en cy u n b l i n d i n g  o f  t r e a tm e n t  a s s i g nm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 8
5 . 5 . 1 5 S tudy comp l e t ion  and  po s t - s tudy  t r e a tm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 8
5 . 5 . 1 6 E a r ly  s t u d y  t e rm i n a t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 9
6  V i s i t  a s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Co rpo ra te  Con f iden t ia l  In fo rma t ion
7 9
No va r t i s Con f iden t ia l Page  6
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
6 . 1 D i e t a ry,  f l u i d  a n d  o t h e r  r e s t r i c t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 9
6 . 2 I n f o rm a t i o n  t o  b e  c o l l e c t e d  o n  s c r e e n i n g  f a i l u r e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 0
6 . 3  S u b j e c t  d em o g r a p h i c s / o t h e r  b a s e l i n e  ch a r a c t e r i s t i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 0
6 . 4 T r e a tm e n t  e x p o s u r e  a n d  c om p l i a n c e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 0
6 . 5 E f f i c a cy  /  P h a rm a c o dy nam i c  a s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 1
6 . 5 . 1 E f f i c a cy a s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 1
6 . 5 . 2 P h a rm a c o dy n am i c  a s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 2
6 . 6 S a f e ty a s s e s sm en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3
6 . 6 . 1 Phys i c a l  ex am i n a t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3
6 . 6 . 2 V i t a l  s i g n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3
6 . 6 . 3 H e i g h t  a n d  w e i g h t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 4
6 . 6 . 4 L abo r a to ry e v a l u a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 4
6 . 6 . 5 E l e c t r o c a r d i o g r am  (ECG ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 6
6 . 6 . 6 P r egn an cy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 7
6 . 6 . 7 T u b e r c u l o s i s  s u r v e i l l a n c e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 7
6 . 7 P h a rm a c o k i n e t i c  a s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 7
6 . 7 . 1 PK  B l o o d  c o l l e c t i o n  a n d  p r o c e s s i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 7
6 . 7 . 2 P h a rm a c o k i n e t i c  a n a ly t i c a l  m e thod s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 7
6 . 7 . 3 P h a rm a c o k i n e t i c  p a r am e t e r s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 7
6 . 8 O t h e r  a s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 8
7 S a f e ty mon i to r ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 9
7 . 1 A d v e r s e  e v e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 9
7 . 2 S e r i o u s  a d v e r s e  e v e n t  r e p o r t i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 1
7 . 3 P r egn an cy r epo r t ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 2
7 . 4 E a r ly  p h a s e  s a f e ty  m o n i t o r i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 2
8 D a t a  r e v i ew  a n d  d a t a b a s e  m a n a g em en t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 3
8 . 1 S i t e  mon i to r ing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 3
8 . 2  D a t a  c o l l e c t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9 3
8 . 3 D a t ab a s e  m an ag em en t  and  qu a l i ty c o n t r o l . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 4
8 . 4 D a t a  M o n i t o r i n gComm i t t e e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 4
8 . 5 A d j u d i c a t i o n  C omm i t t e e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 5
9 D a t a  an a lys i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 5
9 . 1 An a lys i s  s e t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Co rpo ra te  Con f iden t ia l  In fo rma t ion
9 5
No va r t i s Con f iden t ia l Page  7
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
9 . 2  S u b j e c t  d em o g r a p h i c s  a n d  o t h e r  b a s e l i n e  c h a r a c t e r i s t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9 5
9 . 3 T r e a tm e n t s  ( s t u dy  d r u g ,  r e s c u e  m e d i c a t i o n ,  o t h e r  c o n c om i t a n t  t h e r a p i e s ,  
c om p l i a n c e ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 6
9 . 3 . 1 S tudy m ed i c a t ion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 6
9 . 3 . 2 C o n c om i t a n t  imm u n o s u p p r e s s a n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 6
9 . 3 . 3 O t h e r  c o- m ed i c a t ion s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 6
9 . 4 An a lys i s  o f  th e  p r im a ry  v a r i ab l e ( s ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 6
9 . 4 . 1 V a r i a b l e ( s ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 6
9 . 4 . 2 S t a t i s t i c a l  mod e l ,  hyp o t h e s i s ,  a n d  m e th o d  o f  a n a ly s i s. . . . . . . . . . . . . . . . . . . . . . . . . . 9 7
9 . 4 . 3 S u p p o r t i v e  a n a l ys e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 8
9 . 5 An a lys i s  o f  s e cond a ry  and  exp lo r a to ry  v a r i a b l e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 8
9 . 5 . 1 E f f i c a cy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 8
9 . 5 . 2 P h a rm a c o dy n am i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 8
9 . 5 . 3 S a f e ty. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 9
9 . 5 . 4 M o d e l  b a s e d  d o s e- e x p o s u r e  r e s p o n s e  a n a l y s i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 2
9 . 5 . 5 P h a rm a c o k i n e t i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 2
9 . 5 . 6 P h a rm a c o k i n e t i c  /  p h a rm a c o dy n am i c  i n t e r a c t i o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 2
9 . 6  S am p l e  s i z e  c a l c u l a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 0 4
9 . 7 P ow e r  f o r  a n a ly s i s  o f  k ey  s e cond a ry  v a r i a b l e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 7
1 0E t h i c a l  c o n s i d e r a t i o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 8
1 0 . 1 R egu l a to ry  and  e th i c a l  comp l i an c e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 8
1 0 . 2 I n f o rm e d  c o n s e n t  p r o c e d u r e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 8
1 0 . 3 R e s p o n s i b i l i t i e s  o f  t h e  i n v e s t i g a t o r  a n d  IRB /IEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 9
1 0 . 4 Pub l i c a t ion  o f  s tudy  p r o t o c o l  an d  r e s u l t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 9
1 1P r o t o c o l  a d h e r e n c e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 0
1 1 . 1 P r o t o c o l  Am e n dm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 0
1 2R e f e r e n c e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 1
1 3App end ix  1 :  S amp l eL og  t a b l e  –a l l  m a t r i c e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 14
1 4A p p e n d i x  2 :  US- S p e c i f i c  C e l lC e p t (R )  P r e g n a n c y a n d  S a f e t y  I n f o rm a t i o n. . . . . . . . . . . . . . . . . . . . 1 1 8
1 5A p p e n d i x  3 :  S t o p p i n g  r u l e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 2 0
1 6A p p e n d i x  4 :  G u i d e l i n e s  f o r  MMF  d o s e  r e d u c t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2 1
1 7A p p e n d i x  5 :  T a c r o l im u s  d r u g - d r u g  i n t e r a c t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1 2 2
1 8A p p e n d i x  6 :  B l i n d i n g  a n d  u n b l i n d i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Co rpo ra te  Con f iden t ia l  In fo rma t ion
1 2 5Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  8
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
1 9App end ix  7 :  C l in i c a l ly no t ab l e  l abo r a to ry  v a lu e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 6
2 0A p p e n d i x  8 :  B a n f f  ’ 0 9  M e e t i n g  R e p o r t :  A n t i b o d y M e d i a t e d  G r a f t  D e t e r i o r a t i o n  a n d  
Im p l em e n t a t i o n  o f  B a n f f  W o r k i n g  G r o u p s  1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2 7
L is t  o f  tab les
T a b l e  5- 1 S tudy s t o p p i n g  r u l e s  f o r  tBPAR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 6
T a b l e  9- 1 Summ a ry o f  h i s to r i c a l  con t ro ld a t a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 6
T a b l e  9- 2 Tw o- s id ed  80  and  95  p e r c en t  ex amp l e  C I s  f o r  b e tw e e n - t r e a tm en t  
d i f f e r e n c e  (CFZ 5 3 3-C o n t r o l  r e g im e n )  o f  c a l c u l a t e d  eGFR  
(MDRD ) ,  a s s um i n g  d r o p o u t  r a t e  =  3 0  p e r c e n t  ( n  =  5 3 / g r o u p ). . . . . . . . . . . 1 0 7
T a b l e  1 4- 1 A c c e p t a b l e  C o n t r a c e p t i o n  M e t h o d s  f o r  F em a l e s  o f  R e p r o d u c t i v e  
Po t en t i a l*. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 9
T a b l e  1 8- 1 B l i n d i n g  l e v e l s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2 5
L is t  o f  f igu res
F i g u r e  1- 1  R o l e s  o f  CD 4 0 - CD 1 5 4s i g n a l i n g  i n  t h e  T  a n d  B  c e l l. . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
F i g u r e  3- 1 CFZ533X2201  S tudy d e s i g n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 8
F i g u r e  3- 2 P a r t  1  D e s i g n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0
F i g u r e  9- 1 P rob ab i l i ty o f  s t o p p i n g  a  c o h o r t  f o r  v a r i o u s  t r u e  tBPAR  r a t e s . . . . . . . . . . . 1 0 4
F i g u r e  9- 2 P rob ab i l i ty o f  p r o g r e s s i n g  f o r  d i f f e r e n t  t r u e  v a l u e s  o f  tBPAR  f o r  
CFZ 5 3 3  a n d  c o n t r o l. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 5
F i g u r e  9- 3 R e su l t s  o f  B aye s i an  m e t a - a n a l y s i s  p r e d i c t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Co rpo ra te  Con f iden t ia l  In fo rma t ion
1 0 6Co r
o ra t
e  
Con f
iden t
ia l  
In fo r
ma t i
onCo rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis Confidential Page 9
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
List of abbreviations
AC Adjudication Committee
ADCC antibody -dependent cell -mediated cy totoxicity
AE adverse event
AESI adverse event of special interest
ALT alanine aminotransferase
ALP alkaline phosphatase
ANCOVA analysis of covariance
APC antigen presenting cell
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
ATC American Transplant Congress
b.i.d. twice a day
BMI Body Mass Index
BPAR biopsy -proven acute rejection
BUN blood urea nitrogen
CDC complement -dependent ly mphocy totoxic
CD-ROM compact disc –read onl y memory
CFR Code of F ederal Regulation
CKD Chronic Kidney  Disease
CKD -EPI Chronic Kidney  Disease Epidemiology  Collaboration Equation
CI confidence interval
CIT cold ischemic time
CK creatinine kinase
CMO&PS Chief Medical Office & Patient Safety
CMV cytomegalovirus
CNI calcine urin inhibitor
CO 2 carbon dioxide
CPO Country  Pharma Organization
CRF Case Report/Record Form
CRO Contract Research Organization
Novartis Confidential Page 10
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
CV coefficient of variation
CYP3A4 cytochrome P450 3A4
DBL database lock
DGF delay ed graft function
DMC Data Monitoring Committee
DS&E Drug Safet y & Epidemiology
DSA Donor specific antibodies
EBV Epstein- Barr virus
EC Ethics committee
ECG Electrocardiogram
eCRF Electronic Case Report Form
EDC Electronic Data Capture
eGFR estimated GFR
ELISA Enzy me-linked immunosorbent assay
EOS end of study
EOT end of treatment
FAS full analy sis set
FDA Food and Drug Administration
GC Germinal center
GCP Good Clinical Practice
GFR glomerular filtration rate
GI gastrointestinal
γ-GT Gamma -glutam yl transferase
h hour
HbA1c glycosylated hemoglobin
hCG human chorionic gonadotropin
HCV hepatitis C virus
HIGM Hyper-Immunoglobulin M Sy ndrome
HIV human immunodeficiency virus
HLA human leukocy te antigen
NHP non human primates
HR heart rate
Novartis Confidential Page 11
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
HUVEC Human umbilical vein endothelial cells
IA Interim Anal ysis
IB Investigator Brochure
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
INN International Nonproprietary  Name 
IRB Institutional Review Bo ard
IRT Interactive Response Technology
IS immunosuppressant
ITT intent -to-treat
IV intravenous
KLH keyhole limpet hemocy anin
LDH lactate deh ydrogenase
LLQ lower limit of quantification
LLN lower limit of normal
MABEL minimal anticipated biological effect level
MDRD Modification of Diet in Renal Disease
MedDRA Medical Dictionary  for Regulatory  Activities
mg milligram(s)
ml milliliter(s)
MMF mycophenolate mofetil
MPA mycophenolic acid
NHP Non human primate
NI non-inferiorit y
NOAEL no observed adverse effect level
NODAT new onset diabetes mellitus after transplantation
o.d. once a day
PA posteroanterior
PAD pharmacologically  active dose
PBMC peripheral blood mononuclear cells
PCP Pneumocy stis jiroveci pneumonia
Novartis Confidential Page 12
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
PCR polymerase chain reaction
PD pharmacod ynamic (s)
PI package insert
PK pharmacokinetic(s)
p.o. oral
PoC Proof of Concept
PP per-protocol
PRA panel reactive antibodies
PTLD post-transplant ly mphoproliferative disease
RA Rheumatoid eArthritis
RBC red blood cell(s)
RDC remote data capture
REB Research Ethics Board
RO receptor occupancy
SA surface area (1.73 square meters)
SAE serious adverse event
SC subcutaneous
SCD standard criteria donor
SD single -dose
sCD40 soluble CD40
sCD40L soluble CD40 ligand (or soluble CD154)
SD standard deviation
SMQ standardized MedDRA query
SoC standard of care
SOC system organ class
Tac tacrolimus 
TBL total bilirubin
TDAR Tcell dependent antibody response
tBPAR treated biops y-proven acute rejections
TPDI Therapeutic Protein Drug I nteractions
UCL upper confidence l imit
ULN upper limit of normal
Novartis Confidential Page 13
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
ULQ upper limit of quantification
WBC white blood cell(s)
Novartis Confidential Page 14
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Pharmacokinetic definitions and sy mbols
AUC0 -t The area under the plasma concentration -time curve from time zero to time 
‘t’ where t is a defined time point after admi nistration [µg*day /mL]
AUCinf The area under the plasma concentration -time curve from time zero to 
infinity  [µg*day /mL]
AUClast The area under the plasma concentration -time curve from time zero to the 
time of the last quantifiable concentration [µg*day /mL]
AUCtau The area under the plasma concentration -time curve from time zero to the 
end of the dosing interval tau [µg*day /mL]
AUCtau,ss The area under the plasma concentration -time curve from time zero to the 
end of the dosing interval tau at stead y state [µg*day /mL]
Cav,ss The average stead y state plasma concentration during multiple dosing
Cmax The observed maximum plasma concentration following drug administration 
[µg/mL ]
Cmax,ss The observed maximum plasma concentration following drug administration 
at stead y state [µg/mL ]
Cmin,ss The lowest plasma concentration observed during a dosing interval at steady 
state [µg/mL ]
CL The systemic clearance from plasma following intravenous administration 
[mL/day]
CL/F The apparent systemic clearance from plasma (orserum or blood) following 
extravascular administration [mL /day]
F Bioavailability  of a compound. Fabs is the absolute bioavailability , i.e., the 
fraction (or percentage) of the administered extravascular dose systemically  
available. 
T1/2 The terminal eli mination half -life [day ]
Tmax The time to reach the maximum concentration after drug administration [day ]
Vz The volume of distribution during the terminal elimination phase following 
intravenous administration [mL ]
Vz/F The apparent volume of distribution during the terminal elimination phase 
following extravascular administration [mL ]
Vss The volume of distribution at steady  state following intravenous 
administration [mL ]
Novartis Confidential Page 15
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Glossary  of terms
Assessment A procedure used to generate data required b y the study .
Control drug A study  drug used as a comparator to reduce assessment bias, 
preserve blinding of investigational drug, assess internal 
study  validit y, and/or evaluate comparative effects of the 
investigational drug.
Enrollment Point/time of subject entry into the study ; the point at which 
informed consent must be obtained (i.e., prior to starting any 
of the procedures described in the protocol).
Investigational drug The study  drug whose properties are being tested in the study ; 
this definition is consist ent with US CFR 21 Section 312.3 
and is synony mous with “investigational new drug” or 
“investigational medicinal product”.
Investigational treatment All investigational drug(s) whose properties are being tested 
in the study  as well as their associated tre atment controls.
This includes any placebos, any active controls, as well as 
approved drugs used outside of their indication/approved 
dosage or tested in a fixed combination.
Investigational treatment generall y does not include other 
treatments administere d as concomitant background therap y 
required or allowed by the protocol when used within 
approved indication/dosage. 
Medication number A unique identifier on the label of each study  drug package in 
studies that dispense study  drug using an I RT sy stem.
Subject number A number assigned to each subject who enrolls in the study . 
When combined with the center number, a unique identifier is 
created for each subject in the study .
Period A minor subdivision of the study  timeline; divides phases into 
smaller functional segments such as screening, baseline, 
titration, washout, etc.
Premature subject 
withdrawalPoint/time when the subject exits from the study  prior to the 
planned completion of all study  assessments.
Randomization number A unique identifier assigned to each randomized subject, 
corresponding to a specific treatment arm assignment.
Stage A major subdivision of the study  timeline; begins and ends 
with major study  m ilestones such as enrollment, 
randomization, completion of treatment, etc.
Study  completion Point/time at which the subject came in for a final evaluation 
Novartis Confidential Page 16
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
visit.
Study  drug/treatment Any drug (or combination of drugs) administered to the 
subject as part of the required study  procedures; includes 
investigational drug, active drug run-ins or background 
therap y: CFZ533 + tacrolimus andCFZ533 + mycophenolate 
mofetil
Study  drug discontinuation Point/time when subject permanentl y stops taking study  drug 
(any component of the regimen) for an y reason.
Subject An individual who has consented to participate in this study . 
The term Subject may be used to describe either a healthy 
volunteer or a patient.
Variable Information used in the data analysis; derived directly  or 
indirectly  from data collected using specified assessments at 
specified tim e-points.
No va r t i s Con f iden t ia l Page  17
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  18
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  19
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  20
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  21
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  22
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  23
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis Confidential Page 24
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Protocol sy nopsis
Protocol number CCFZ533X2201
Title A 12-month randomized, multiple dose, open -label, study evaluating safety , 
tolerability, pharmacokinetics/pharmacody namics (PK/PD) and efficacy of an 
anti-CD40 monoclonal antibody, CFZ533, in combination with m ycophenolate 
mofetil (MMF) and corticosteroids (CS), with and without tacrolimus (Tac), in 
de novo renal transplant recipients
Brief title Efficacy  and safety study of CFZ533 in kidney transplant patients 
Sponsor and Clinical 
PhaseNovartis
Phase II
Investigation type Drug (biologic)
Study type Interventional 
Purpose and 
rationaleThe purpose of this adaptive, two-part study is to investigate the potential for 
CFZ533 to replace calcineurin inhibitors (CNI), while providing a similar rate 
of acute rejection prophy laxis and better renal function in a de novo renal 
transplant population receiving an allograft from standard criteria donors.. 
Part 1 of this trial will focus on profiling the multiple dose pharmacokinetics 
(PK), pharmacody namics (PD) and tolerability for both IV and SC CFZ533 
administration in the setting of standard -of-care, CNI-based 
immunosuppression. 
Part 2 will evaluate the safety  and efficacy  of CFZ533 in the absence of a 
CNI in combination with adjunct MMF and basiliximab induction therapy for 
up to 12 months.
Overall, results of this study  will be used to inform the CFZ533 dose and 
regimen selection for investigation in thenext phase of clinical development.
Primary Objectives Part 1: PK, PD and Safety
To assess the safety , tolerability and pharmacokinetics of multiple IV 
and SC doses of CFZ533 in combination with MMF, CS, and Tac 
(standard exposure) in de novo renal transplant patients over the 
treatment and follow -up period
Part 2: CNI -free Proof -of-Concept
To assess the potential for CFZ533 to act as the primary 
immunosuppressant in a CNI -free regimen with MMF in de novo
renal transplant patients as assessed by tBPAR at Month 3 post -
transplantation
Secondary 
ObjectivesPart 1: PK, PD and Safety
To quantify the magnitude and duration of peripheral blood CD40 
occupancy (free CD40 and total CD40 on B cells) 
To quantify the change from baseline and recovery of peripheral 
blood total soluble CD40 and total soluble CD154 
To evaluate the immunogenicit y of CFZ533 via the quantitative 
analysis of anti- CFZ533 antibodies
Part 2: CNI -free Proof -of-Concept
To assess the safety  and tolerability of CFZ533 administered 
chronically in combination with MMF and CS up to 3 months against 
No va r t i s Con f iden t ia l Page  25
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
a  con t ro l
 To  assess  the  pharmacok ine t ics  o f  mu l t ip le   IV    doses  o f  CFZ533  
du r ing  the  12- mon th  t rea tmen t  pe r iod
 To  quan t i fy  the  magn i tude  and  du ra t ion  o f  pe r iphe ra l  b lood  CD40  
occupancy  ( f ree  CD40  and  to ta l  CD40  on  B  ce l ls )  du r ing  the  
t rea tmen t  pe r iod  fo l low ing  mu l t ip le  IV  doses  o f  CFZ533
 To  compa re  rena l  func t ion  in  CFZ533  t rea tmen t  a rms  to  con t ro l  a t  
Mon th  3  pos t- t ransp lan ta t ion  as  assessed  by :
 Es t ima ted  GFR  us ing  MDRD
 P ropo r t ion  o f  pa t ien ts  w i th  eGFR  <60  mL /m in /1 .73m2  
 P ropo r t ion  o f  pa t ien ts  w i th  nega t ive  eGFR  s lope   
 To  eva lua tethe  immunogen ic i ty  o f  mu l t ip le  IV  doses  o f  CFZ533  v ia  
the  quan t i ta t ive  ana ly s is  o f  an t i- CFZ533  an t ibod ies
 To  quan t i fy  the  change  f rom  base l ine  and  recove ry  o f  pe r iphe ra l  
b lood  to ta l  so lub le  CD40  du r ing  the  t rea tmen t  pe r iod  fo l low ing  
mul t ip le  IV  doses  o f  CFZ533
S tudy  des ign A  random ized ,  two - pa r t ,  6 -o r  12- mon th ,  sequen t ia l ,  adap t ive ,  con t ro l led ,  
open- labe l ,  mul t i cen te r ,  c l in ica l  p roo f- o f- concep t  s tud y  to  eva lua te  the  
e f f icacy,  sa fe ty ,  to le rab i l i ty ,  PK  and  PD  o f  CFZ533  +  MMF  +  CS ,  w i th  
s tanda rd  exposu re  ( Pa r t  1 )  o r  no  tac ro l imus  (Pa r t  2 , ) ,  fo r  in i t ia l  and  
main tenan ce  p rophy lax is  o f  o rgan  re jec t ion  in  adu l t  de  novorena l  t ransp lan t  
rec ip ien ts  as  compa red  to  s tanda rd  o f  ca re .
Pa r t  1  (PK ,  PD  and  Sa fe t y ):  Fo r  A rm  1 ,  6  pa t ien t s  to ta l  w i l l  be  en ro l led  to  
re ce i v e  IV  induc t ion  (Day  1 )  and  SC  adm in is t ra t ion  on  Days  15 ,  29 ,  43  and  
71  o f  3  mg/ k g  CFZ533  w i th  s tanda rd- exposu re  tac ro l imus  (who le  b lood  
t rough  concen t ra t ion  4 - 11  ng /mL ) ,  MMF  and  CS .
A l l  pa t ien ts  en ro l led  in to  Pa r t  1  w i l l  rema in  on  SoC  un t i l  Mon th  6  (EOS ) .
Pa r t  2  (CN I - f ree  PoC ):  Fo l low ing  2 :1  random iza t ion ,  45  pa t ien ts  w i l l  be  
en ro l led  in  A rms  2A  and  2B  in  a  pa ra l le l  manne r .  A rm  2A  w i l l  rece ivemul t ip le  
in t ravenous  CFZ533  10  mg /kg  doses  w i th  bas i l ix imab  induc t ion ,  MMF  and  
CS ;  A rm  2B  (con t ro l )  w i l l  rece ive  s tanda rd- exposu re  tac ro l imus  (who le  b lood  
t rough  concen t ra t ion  4 - 11  ng /mL )  w i th  bas i l ix imab  induc t ion ,  MMF  and  CS .
Popu la t ion de  novoadu l t  rena l  t ransp lan t  pa t ien ts
Inc lus ion  c r i te r ia
(key ) W ri t ten  in fo rmed  consen t
 Ma le  o r  fema lepa t ien ts  ≥  18  yea rs  o ld
 Rec ip ien ts  o f  a  t ransp lan t  f rom  a  hea r t- bea t ing  deceased ,  l iv ing  un re la ted  
o r  non- human  leukocy te  an t igen  (HLA )  iden t ica l  l iv ing  re la ted  dono r
 Rec ip ien ts  o f  a  k idney  w i th  a  co ld  ischem ia  t ime  (C IT )  <  30  hou rsCo rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis Confidential Page 26
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Exclusion criteria 
(key)Multi -organ transplant recipients
Recipient of an organ from a non -heart beating donor 
ABO incompatible allograft or complement -dependent ly mphocy totoxic 
(CDC) cross -match positive transplant
Receipt of a second kidney allograft, unless the first allo graft was lost due 
to surgical complication
High immunological risk for rejection as determined by local practice for 
assessment of anti- donor reactivity (e.g., high panel reactive antibodies 
(PRA) > 20%, presence of pre -existing donor -specific antibodies (DSA))
At risk for tuberculosis (TB)
Anti-HIV positive, HBsAg -positive or anti -HCV positive
EBV negative (in Part 1 only)
History of coagulopathy or medical condition requiring long -term 
anticoagulation which would preclude renal biops y after transplantation
Active infection
Pregnant or nursing (lactating) women
Women of child- bearing potential, defined as all women physiologically 
capable of becoming pregnant, unless they are using highly effective 
methods of contraception during dosing and fo r 12 weeks after the study 
medications have been stopped
Investigational and 
reference therapyPart 1
Arm 1 , n=6: CFZ533 at 3.0 mg/kg SC (5 doses; first dose is IV, SC on 
Days 15, 29, 43 and 71) + tacrolimus (4 -11 ng/mL) + MMF 1.0 g BID + CS
Part 2 
Arm 2A, n=30: Basiliximab 20 mg (Days 1, 4) + CFZ533 at 10 mg/kg IV 
(17 doses) + MMF 1.0 g BID + CS
Arm 2B Control/Standard of Care , n=15: Basiliximab 20 mg (Days 1, 4) 
+ tacrolimus (4 -11 ng/mL) + MMF 1.0 g BID + CS
Concomitant treatments
CMV, PCP, HBV & BK virus prophylaxis
Oral Candida treatment
Efficacy 
assessmentsTreated biopsy proven acute rejection (tBPAR), graft loss, death, estimated 
GFR 
No va r t i s Con f iden t ia l Page  27
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Sa fe ty  assessmen ts Rena l  func t ion
 Adve rse  and  se r ious  adve rse  even ts
 In fec t ions  
 Cytok ines
 Dono r  spec i f ic  an t ibod ies  
 NODAT
 EBV ,  CMV  and  BK  v i rus  and  tube rcu los is  su rve i l lance
 V i ra l  se ro logy
 Immunogen ic i ty
 ECG
 V i ta l  s ign s
 C l in ica l  labs
O the r  assessmen ts Pha rmacok ine t ics :  
 Free  CFZ533  in  p lasma
 Tac  t rough  leve ls
 MPA  t rough  leve ls
 So lub le  CD40  and  so lub le  CD154  in  p lasma
 G ra f t  su rv iva l
 Pa t ien t  su rv iva l
 Lymph  node  /  t issue  b iopsy
Da ta  ana lys is Pa r t  1
Pos te r io r  p robab i l i t ies  o f  the  tBPAR  ra tes  fo r  the  t rea tmen t  reg imen  abo ve  
va r ious  th resho lds  such  as  10% ,  15% ,  20% ,  25%  w i l l  be  p resen ted  as :  
P r  ( θCFZ533≥  T  | da ta )  fo r  T=0 .1 ,  0 .15 ,  0 .2 ,  0 .25 .  
assum inga  non- in fo rma t ive  neu t ra l  p r io r  o f  Be ta (1 /3 ,  1 /3 ) .
Pa r t  2
The  e f f icacy a na lys is  fo r  the  f i rs t  3  mon th s  o f  Pa r t  2  cons ide rs  whe the r  the  
CFZ533  t rea tmen t  a rm  mee ts  the  p re- de f ined  c r i te r ia  fo rPoC  dec la ra t ion:  P r  
( θCFZ 5 3 3 1–θS oC<0 .20  |  d a t a )  >  60%
The  requ i red  pos te r io r  p robab i l i t ies  w i l l  be  es t ima ted  f rom  s imu la t ion s  o f  the  
pos te r io r  d is t r ibu t ions  o f  θ CFZ533–θSoCand  compa red  to  the  th resho lds  fo r  the  
leve ls  o f  p roo f .
Key  wo rds Sa fe ty ,  e f f icacy,  pha rmacok ine t ics ,  pha rmacodynam ics ,  CFZ533 ,  de  novo
rena l  t ransp lan t  pa t ien tsCN I- f ree  immunosupp ress ion ,  CD40 ,B  ce l l sCo rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  28
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Assessmen t  schedu le  –Pa r t  1
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  29
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Assessmen t  schedu le  –Pa r t  2  
Co rpo ra te  Con f iden t ia l  In fo rma t ionCo rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  30
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Assessmen t  schedu le  –Foo tno tes  and  Legend
X  =  a s se s smen t  fo r  a l l  sub je c t s  in  s tud y  rega rd le s s  o f  on-o r  o f f-random i zed  s tud y  reg imen ,  to  be  re co rded  in  c l in i ca l  da taba se .
A  =  a s se s smen t  ONLY  fo r  sub je c t s  ma in ta in ing  the i r  random i zed  s tud y  reg imen ,  to  be  re co rded  in  c l in i ca l  da taba se .
S  =  a s se s smen t  to  be  re co rded  on  sou r ce  do cumen ta t ion .
m=  m inu te ;  h  =   hou r ;  d  =  da y;   EOT  =  End  o f  T rea tmen t ;  S tud y  Mon th  =  28  da y s ;
#  =  on l y  need  to  be  pe r fo rmed  on ce  in  a  12-hou r  pe r iod  i f  S c reen ing ,  Ba se l ine  and  Da y  1  o c cu r  in  c lo se  p ro x im i t y .  
(1 )  In fo rmed  con sen t  shou ld  be  ob ta ined  p r io r  to  pe r fo rm ing  an y  s tud y - re la ted  p ro cedu re s .
(2 )  On l y  fo r  fema les  o f  ch i ld- bea r ing  po ten t ia l .  Pregnan c y  te s t s  shou ld  be  ca r r ied  ou t  a c co rd ing  to  lo ca l  p ra c t i ce .  Lo ca l  re su l t  mu s t  be  a va i lab le  and  nega t ive  p r io r  to  
random iza t ion /en ro l lmen t .   
(3 )  S c reen ing  may  e x tend  up  to  4  wee k s  p r io r  to  t ran sp lan t  (e .g . ,  fo r  s chedu led  l i v ing  dono r  t ran sp lan t s )  and  ends  when  the  sub jec t  i s  e i the r  random i zed  o r  be come s  a  
sc reen ing  fa i lu re .  Fo r  e ve r y  con sen ted  sub je c t ,  the  S c reen ing  Pe r iod  D i spo s i t ion  CRF  page  mus t  be  comp le ted  to  ind i c ia tewhe the r  the  sub je c t  wa s  random i zed  o r  
cons ide red  a  sc reen ing  fa i lu re .
(4 )  Ba se l ine  co ve r s  the  t ran sp lan t  pe r iod  f rom  up  to  24  hou r s  p r io r  to  su rge r y  un t i l  random i za t ion /en ro l lmen t  o r  i t s  fa i lu re .Random i za t ion /En ro l lmen t  shou ld  occu r  w i th in  
24hou r s  o f  the  s ta r t  o f  the  t ran sp lan t  su rge r y .
(5 )  V i ra l  se ro logy  in c lude s  HCV ,  H IV ,  HBV  su r face  an t igen ,  CMV ,  EBV  and  BK  v i rus .  Fo r  the  in i t ia l  a s se s smen t ,  measu remen ts  made  w i th in  the  la s t  6  mon th s  w i l l  be  
a c cep ted .  O the rw i se ,  the  in i t ia l  te s t s  shou ld  be  pe r fo rmed  w i th in  one  wee k  o f  random i za t ion /en ro l lmen t .  
(6 )  F i rs t  dose  o f  CFZ533  w i l l  be  adm in is te red  in t ravenous ly  p re -o r  in t ra- ope ra t ive ly  and  mus t  be  comp le ted  by  the  t ime  o f  unc lamp ing  o r  up  to  6  hou rs  p r io r  to  the  t ime  o f  
un c lamp ing .  O the r  s tud y  d rug s  (e .g . ,  Ta c ,  MMF ,  CS )  shou ld  be  s ta r ted  w i thin  24  hou rs  pos t - t ransp lan ta t iono r  a c co rd ing  to  lo ca l  p rac t i ce.  
(7 )  F i rs t  do se  o f  ba s i l i x imabinduc t ion  shou ld  be  g i ven  w i th in  2  hou r s  p r io r  to  t ran sp lan t  su rge r y ,  o r  a c co rd ing  to  lo ca l  p ra c t i ce .  The  se cond  dose  shou ld  be  g iven  on  Da y  
4 ,  o r  a c co rd ing  to  lo ca l  p ra c t i ce .
(8 )  Lo ca l  labo ra to r y  te s t s  in c lude :  hema to log y ,  u r ina l y s i s ,  se rum  chem i s t r ie s ,rena l  fun c t ion ,  and  coagu la t ion  pa rame te r s .
(9 )  Ob ta ined  e ve r y  15  m in s  fo r  2  h r s  a f te r  the  s ta r t  o f  the  f i r s t  CFZ533  IV  in fu s ion  o r  t ime  o f  SC  in je c t ion .
(10 )  Nega t i ve  te s t  re su l t  mu s t  be  a va i lab le  p r io r  to  random i za t ion /en ro l lmen t .  
(11 )  B lood  co l lec t ions  and  sa fe t y  a s se s smen t s  shou ld  be  ta ken  p re -do se  i f  the  samp l ing  fa l l s  on  a  do s ing  da y .
(12 )  B lood  d raw s  fo r  t rough  con cen t ra t ion s  shou ld  be  pe r fo rmed  be fo re  the  ne x t  do se  i s  g i ven .  In  add i t ion ,  the y  shou ld  be  pe r fo rmed  lo ca l l y  a s  shown  and  add i t iona l l y  5±2  
da y s  fo l low ing  ea ch  c l in i c  v i s i t  in  wh i ch  do se s  a re  changed .
(1 4)  A l l  se r iou s  ad ve r se  even ts ,  se r ious  in fe c t ion s  and  p regnanc ies  mus t  be  repo r ted  f rom  in fo rmed  con sen t  un t i l  3  mon ths  a f te r  h is /her  las t  dose  o f  CFZ533o r  2  mon ths  Co rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis Confidential Page 31
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
after EoS visit for patients on SoC treatment .
(15) Induction therapy (e.g., basiliximab) and pre-transplant immunosuppression (if used) should be recorded on the Concomitant Medications CRF page under the 
Immunosuppressive category.
(16) Prophylaxis for CMV, PCP, HBV, BK and oral candida to be considered per protocol Section 5.5.8, and recorded on the Concomitant Medications CRF page if administered.
(17) All patients are expected to continue in the study to Month 6 or 12 and complete the Month 6 or 12 Completion page, regardl ess of whether they are on or off study 
medication. If subject s discontinue study treatment, he/she should continue in the study on SOC per local practice and attend study visits to Month 6 or 12.  Any 
permanent discontinuation of the randomized study regimen should be recorded on the appropriate DAR CRF pages. After disconti nuation of study regim en, the 
immunosuppressive regimen prescribed should be recorded on the Concomitant Medications CRF under the Immunosuppressive catego ry. 
(18) EOI = End of Infusion (IV) or End of Injection (SC). Blood samples obtained immediately after infusion for IV -administered CFZ533 or immediately after injection for 
SC-administered CFZ533.
(19) Timepoint calculated from start of infusion for patients on CFZ533 treatment and from Start of Transplant surgery for TAC treatment
Novartis Confidential Page 32
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
1 Introduction
1.1 Background
Over the past decades, organ allotransplantation has become a common medical procedure 
with considerable impact on extending and improving the quality  of life of patients with end 
stage renal, cardiac, hepatic or pulmonary  failure. To maximize efficacy  and minimize 
adverse effects, current immunosuppres sant (IS) regimens use combinations of IS drugs. 
Care is taken to achieve synergy  or additive immunosuppressive effects via the administration 
of submaximal doses of individual agents with different mechanism of actions while avoiding 
overlapping toxicitie s. Most treatment regimens today  include two or more primary  and 
adjunct immunosuppressants with or without an induction agent. Induction agents are 
administered during the first hours to days post transplantation to suppress the recipient’s 
immune system and priming of an immune response to the allograft while the other IS agents 
are reaching effective concentrations. Induction agents include the anti-CD25 mAb 
basiliximab (Simulect®, Novartis) or polyclonal anti-T cell globulin (Thymoglobulin®, rabbit 
ATG, rATG, Genzy me). In highly sensitized patients, induction with an anti-CD52 mAb, 
alemtuzumab (Campath®, Sanofi- Aventis SA) which leads to long -term lymphocy te depletion 
has been used. Within 1-2 days following transplant, the maintenance treatment regimen is 
initiated with two or more of the following agents: a calcineurin inhibitor (CNI ) such as 
cyclosporine (CsA, Neoral®, Novartis) or tacrolimus (Tac, FK506, Prograf®, Astellas), 
together with a lymphocy te proliferation inhibitor such as mycophenolic acid (MPA; 
Myfortic®, Novartis) or mycophenolate mofetil (MMF; CellCept®, Roche) or proliferation 
signal inhibitor such as everolimus (Zortress®, Certican®, Novartis) or sirolimus (Rapamune®, 
Pfizer). More recentl y, the Tcell co-stimulation blocker belatacept (Nulojix®, BMS), a fusion 
protein, demonstrated the potential of a biologic agent to replace CNIs in a calcineurin -free 
treatment regimen with MPA. 
Although the current standard -of-care regimens provide excellent short -term efficacy  with 
very low acute rejection rates, there is still an opportunity  to increase long-term graft and 
patient survival. The current rate of renal allograft graft survival in the first year and 5 years 
post-transplant is 95% and 68% (Matas et al 2013), respectivel y, with a rapid decline 
thereafter. The estimated glomerular filtration rateat 12 months has been strongl y associated 
with subsequent graft failure 
(Kasiske et al 2011). As such, kidney  all ograft function is also 
an important predictor of graft survival. Other factors, such as donor age, acute rejection and 
vascular remodeling may also play a role in overall graft survival, but the nephrotoxic effects 
of calcineurin inhibitors are directly  associated with irreversible renal function deterioration 
(Naesens et al 2009). By eliminating CNIs from the treatment regimen, mechanism -based side 
effects, such as nephrotoxicity , hypertension, dyslipidemia, neurotoxicity , gastrointestinal and 
hematological toxicity , and/or diabetogenic effects may be minimized or eliminated. In the 
search for novel therapeutics, there has been 
an increasing interest in the role B cells, plasma 
cells and antibodies play in the immune response to an allograft, specifically  acute cellular 
rejection and chronic humoral or antibody  mediated rejection (Clatworthy 2011). 
Bydeveloping a specific treatment that decreases the priming of T and B cells and subsequent 
production of donor specific antibodies and eliminating CNIs, it is hypothesized that chronic 
Novartis Confidential Page 33
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
rejecti on can be minimized and long-term graft survival may be increased. Hence, there is a 
significant need for new immunosuppressant agents.
1.1.1 CD40/CD40L co -stimulation: a target for transplantation
CD40 is a transmembrane glycoprotein constitutively  expressed onB cells and antigen -
presenting cells (APCs) such as monocy tes, macrophages, and dendritic cells (DC). CD40 is 
also expressed on platelets, and under specific conditions can be expressed oneosinophils and 
activated parenchy mal cells. Ligation 
of CD40 on B cells results in downstream signaling 
leading to enhanced Bcell survival and important effector functions, including clonal 
expansion, cytokine secretion, differentiation, germinal center formation, development of 
memory  Bcells, affinity  maturation, immunoglobulin (Ig) isoty pe switching, antibody 
production and prolongation of antigen presentation. CD154 -mediated activation of the 
antigen -presenting cell (APC) also leads to induction of cytokine secretion and expression of 
surface activation molecules including CD69, CD54, CD80, and CD86 that are involved in 
the regulation of CD4+ T helper cell and CD8+ T cell cross -priming and activation.
CD154 exists in two forms –membrane -bound and soluble. Membrane -bound CD154 is a 
transmembrane glycoprotein expresse d on activated CD4+, CD8+, and T-lymphocy tes, 
mast cells, monocy tes, basophils, eosinophils, natural killer (NK) cells, activated platelets and 
has been reported on B cells. It may also be expressed at low levels on vascular endothelial 
cells and up-regulated during local inflammation. SolubleCD154 (sCD154) is formed after 
proteoly sis of membrane -bound CD154 and is shed from ly mphocy tes and platelets following 
cell activation. Once shed, sCD154 remains functional and retains its ability  to bind to the 
CD40 receptor. 
Figure 1 -1 Roles of CD40- CD154 signaling in the T and B cell
Targeting CD40 -154 interactions in transplantation and autoimmune disease. CD40 -CD154 
interacti ons are essential for APC activation, T cell priming in the context of APC -T cell interactions 
and T cell dependent humoral responses. 
NOTE: mCD154=membrane bound CD154; sCD154=soluble CD154

No va r t i s Con f iden t ia l Page  34
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
T h e  c r i t i c a l  r o l e  o f  CD40 /CD154  i n t e r a c t i o n s  in  v i v o  a r e  b e s t  i l l u s t r a t e d  by  p a t i e n t s  su f f e r ing  
f r omHy pe r - Immunog lobu l in  M  (H IGM )a s  a  r e su l t  o f  lo s s  o f  fun c t ion  mu t a t ion s  in  CD 4 0  o r  
i t sl i g a n d .  P a t i en t s  w i th  H IGM  p r e s en t  w i th  a  s ev e r e  imp a i rm en t  o f  Tc e l l  d e p e n d e n t  an t ibody  
r e s p o n s e s ,  l a c k  o f  Bc e l l  m emo ry,a n d  l i t t l e  to  no  c i r cu l a t ing  I gG ,  I gA  o r  I gE .  I n  p a t i en t s  w i th  
mu t a t ion s  in  CD40  s ign a l ing,  a  s im i l a r  p h e n o ty p e  and  d i s e a s e  p r e s en t a t ion  h a s  b e en  d e s c r ib ed
( v a nK o o t e nandB a n c h e r e a u  2 0 0 0) .
 
 
U s i n g  mono c lon a l  
a n t i b o d i e s  to  t a r g e t  CD15 4  h a s  b e e n  h am p e r e d  by  t h e  o c c u r r e n c e  o f  t h r om b o em b o l i c  
c om p l i c a t i o n s  ( K aw a ie ta l2 0 0 0 )  s o  a n  a l t e r n a t i v e  a p p r o a c h  i s  t o  t a r g e t  t h e  r e c e p t o r ,  CD 4 0 .  
1 .1 .2 CFZ533 :  mechan ism  o f  ac t ionCo rpo ra te  Con f iden t ia l  In fo rma t ion
CFZ 5 3 3  i s  a  fu l ly  h um an ,  F c- s i l e n t ,  b l o c k i n g  I gG 1  a n t i - CD 4 0  a n t i b o d y  t h a t  b ind s  to  th e  
CD154  b ind ing  s i t e  on  CD40,p r e v e n tingCD 1 5 4b i n d i n g  a n dt h e  a c t iv a t ion  o f  CD 4 0p a thw ay  
s i g n a l i n g  and  down s t r e am  e f f e c t o r  f u n c t i o n s  o n  mu l t ip l e  c e l l  ty p e s  e x p r e s s i n g  t h e  r e c e p t o r .  
CFZ 5 3 3  h a r b o u r sa  mu t a t ion  r e n d e r i n g  i t  un ab l e  to  b ind  F cγr e c e p t o r s  o r  m e d i a t ean t ibody -
d e p e n d e n t  c e l l - m ed i a t ed  cyto tox i c i ty  (ADCC )  o r  c om p l em e n t  d e p e n d e n t  c y to tox i c i ty  (CDC ) .
C
o
r
p
o
r
a
t
e  
C
o
n
f
i
d
e
n
t
i
a
l  
I
n
f
o
r
m
a
t
i
o
nCo rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  35
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  36
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  37
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  38
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  39
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  40
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  41
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
CFZ533 :  Pa t ien ts  w i th  rheuma to id  a r th r i t is  (10  and  30  mg /kg  IV )
S i n g l e  d o s e s  o f  CFZ 5 3 3  a t  1 0  m g / k g  in  RA  p a t i e n t s  h a v e  b e e n  w e l l- t o l e r a t e d .  T h e r e  h av e  
b e e n  n od e a t h s ,s u s p e c t e dSAE s  o r  d i s c o n t i nu a t i o n s  d u e  to  AEs .   
Da ta  f romASKP1240c l in ica l  t r ia ls  (FIH  and  k idney  t ransp lan ta t ion )
ASKP1240  i s  a  mono c lon a l  an t ibody b lo ck ing  CD40  ( O k im u r ae ta l2 0 1 4 )  w i th  PK  p rop e r t i e s  
s im i l a r  to  t h o s e  o f  CFZ533  b a s e d  o n  d a t a  f r om  NHP  ( M a  e t  a l  2 0 1 4 )  a n d  h e a l thy  v o l u n t e e r s
( G o l dw a t e re ta l2 0 1 3 ) .  A t  ATC  2 0 1 5 ,  t h e  p r e l im i n a r y  d a t a  o f  a  Ph  I I  c l i n i c a l  t r i a l  w a s  
p r e s e n t e d  ( H a r l a n de ta l2 0 1 5 ) .  T h e  s t udy  f a i l ed  in  t h e  CN I- f r e e  a rm ,  i . e .  t h e r e  w e r e  mo r e  
r e j e c t i o n s  w i th  ASKP 1 2 4 0  t h a n  w i th  SoC .   
 
 
 I n  f a c t ,  m a ny  ind iv idu a l s  lo s t  t a r g e t  s a tu r a t ion  in  p e r i p h e r a l  
b l o o d ,  i . e .  ASKP 1 2 4 0  c o n c e n t r a t i o n  < 1 5  µg /mL  ( G o l dw a t e re ta l2 0 1 3Co rpo ra te  Con f iden t ia l  In fo rma t ion
) .  Th e  c l e a r a n c e  o f  
ASKP 1 2 4 0  w a s  m a rk ed ly h ig h e r  d u r i n g  t h e  f i r s t  mon th  a f t e r  t r a n s p l a n t a t i o nr e f l e c t i n g  an  C
o
r
p
o
r
a
t
e  
C
o
n
f i
d
e
n
t i
a
l  
I
n
f
o
r
m
a
t i
o
nCo rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  42
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
e n h a n c e de x p r e s s i o n  o f  CD 4 0  r e c e p t o r s  p o s t- t r a n s p l a n t a t i o n .  T h e  a n t i - CD 4 0  mA b  l ev e l s  
r e q u i r e d  fo r  fu l l  RO  in  t a rg e t  t i s su e s  du r ing  th e  f i r s t  tw omon thsa r el ik e ly  to  b e  60 - 8 0µ g /mL , 
w h i c h  i s  in  a c c o r d a n c e  w i th  o b s e r v a t i o n s  in  NHP  s t u d i e s  ( M ae ta l2 0 1 4 ) .   
 
 
 
Compa ra to r  and  backg round  med ica t ion
I n  a d u l t  d e  no vok idn ey  t r a n s p l a n t  r e c ip i en t s ,  t h e  u s e  o f  T a c ,  MMF ,  a n d  CS  i s  an  
a p p r o v e dr eg im en  ( e . g .  P r o g r a f®P I2 0 1 3 )  a n d  i s  t h e  c u r r e n t  s t a n d a r d  o f  c a r e  u s e d  in  mo r e  
t h a n  8 0%  o f  k idn ey  t r an sp l an t s  g l o b a l l y .  Wh en  T a c  i s  c om b i n e d  w i th  a n  MPA- b a s e d  r eg im en  
a n d  w i th  i n d u c t i o n  u s i n g  a n  IL - 2  a n t a g o n i s t ,  t h e  l a b e l e d  t r o u g h  con c en t r a t ion  r a n g e  f o r  T a ci s  
4 - 1 1  n g /mL  ( e . g .  P rog r a f®P I2 0 1 3) ,  a n d  t h i s  r a n g e  w i l l  b e  em p l o y ed  in  th i s  c l in i c a l  s tudy .
CFZ 5 3 3  w i l l  b e  t e s t e d  in  P a r t  1  o n  t o p  o f  T a c ,  MMF  a n d  CS ,  a n d  in  P a r t  2  in  a  T a c /CN I- f r e e  
r e g im e n  w i t h  MMFand  indu c t ion  th e r apy .  A l l  con com i t an t  m ed i c a t ion  w i l l  b e  u s ed  a c co rd ing  
t o  l a b e l .
Tac ro l imus  (Tac )
T a c  i s  a  c a l c i n e u r i n  inh ib i to r  t h a t  b l o c k s  Tce l l  a c t i v a t i o na n d  IL - 2  t r a n s c r i p t i o n .  
T a c( e . g .P r o g r a f®)  i s  ind i c a t ed  f o r  t h e  p r o p hy lax i s  o f  o r g a n  r e j e c t i o n  in  p a t i e n t s  r e c e i v i n g  
a l l o g e n e i c  k idn ey  t r an sp l an t s .  I t  i s  r e c omm e n d e d  t h a t  T a c  b e  u s e d  con com i t an t ly  w i th  
a z a t h i o p r i n e  o r  myc o p h e n o l a t e  m o f e t i l  ( MMF )  and  a d r e n a l  c o r t i c o s t e r o i d s .  T h e r a p e u t i cd r ug  
m o n i t o r i n g  i s  r e comm end ed  fo r  a l l  p a t i en t s  r e c e i v i n g  T a c .  I n  k idn ey  t r a n s p l a n t  p a t i e n t s ,  th e  
in i t i a l  do s e  o f  T a c  ( e .g .  P rog r a f®)  m ay  b e  adm in i s t e r ed  w i th in  24  hou r s  o f  t r an sp l an t a t ion ,  bu t  
shou ld  b e  d e l ay e d  un t i l  r en a l  fun c t ion  h a s  r e cov e r ed .  In  comb in a t ion  w i th  MMF / IL - 2  r e c ep to r  
a n t a g o n i s t  a  s t a r t i n g  d o s e  o f  0 . 1  mg /kg /d ay a n d  a  t a r g e t  t r o u g h  con c en t r a t ion  d u r i n g  t h e  f i r s t  
1 2  mon th s  o f  4 - 1 1  n g /mL  i s  r e c omm e n d e d .  T h e  mo s t  c omm o n  a d v e r s e  r e a c t i o n s  ( ≥  30% )  in  
k idn ey  t r a n s p l a n t  p a t i en t s  w e r e  i n f e c t i o n ,  t r em o r ,  hy p e r t e n s i o n ,  abno rm a l  r e n a l  fun c t ion ,  
c o n s t i p a t i o n ,  d i a r r h e a ,  h e a d a c h e ,  a b d om i n a l  p a in ,  i n s om n i a ,  n a u s e a ,  hy p om a g n e s em i a ,  
u r in a ry  t r a c t  in f e c t ion ,  h y p o p h o s p h a t em i a ,  p e r i p h e r a l  e d em a ,  a s t h e n i a ,  p a in ,  hy p e r l ip id em i a ,  
hy p e r k a l em i a ,  a n em i a .  F o r  m o r e  i n f o rm a t i o n  o n  T a c ,  p l e a s e  r e f e r  to  t h e  lo c a l  p a c k a g e  in s e r t  
( e . g .  P rog r a f®P I2 0 1 3)
Mycopheno la te  mo fe t i l  (MMF )
MMF  ( e . g . C e l lC e p t®)i s  a  p r o d r ug  o f  mycoph eno l i c  a c i d  (MPA ) ,  a  r ev e r s ib l e  inh ib i to r  o f  
i n o s i n e  m o n o p h o s p h a t e  d ehy d rog en a s e  ( I MPDH )  in  p u r i n e  ( g u a n i n e )  b io sy n t h e s i s  w h i c h  i s  
n e c e s s a ry  f o r  t h e  g r ow t h  o f  T  c e l l s  a n d  B  c e l l s .  O t h e r  c e l l s  a r e  a b l e  to  r e c o v e r  p u r i n e s  v i a  a  
s ep a r a t e  s a lv ag e  p a thw ay  and  a r e  thu s  ab l e  to  e s c ap e  th e  e f f e c t  thu s  MMF  h a s  po t en t  cy to s t a t i c  
e f f e c t s  o n  ly mpho cyt e s .  MMFi s  ind i c a t ed  f o r  th e  p rophy l ax i s  o f  o rg an  r e j e c t ion  in  p a t i e n t s  
r e c e i v i n g  a l l o g e n e i c  r e n a l ,  c a r d i a c  o r  h e p a t i c  t r a n s p l a n t s .  MMF s h o u l d  b e  u s e d  c o n c om i t a n t ly  
w i th  cy c l o s p o r i n e  a n d  c o r t i c o s t e r o i d s .  A  do s e  o f  1  g  a dm i n i s t e r e d  o r a l ly  t w i c e  a  d ay  
(d a i lydo s e  o f  2  g )  i s  r e c omm e n d e d  fo r  u s e  in  r en a l  t r an sp l an t  p a t i en t s .  MMF  ( e .g .  C e l lC e p t®Co rpo ra te  Con f iden t ia l  In fo rma t ion
)  
c a r r i e s  a  w a r n i n g  fo r  f em a l e  p a t i e n t s  w h o  m ay  b e c om e  p r e g n a n t .  Som e  m a n uf a c t u r e r s  o f  
MMF  r e c omm e n d  m a l e  c o n t r a c e p t i o n  ( condom ) .  U s e  d u r i n g  p r egn an cy  i s  a s s o c i a t e d  w i t h  
No va r t i s Con f iden t ia l Page  43
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
i n c r e a s e d  r i s k s  o f  f i r s t  t r im e s t e r  p r egn an cy  l o s s  a n d  c o n g e n i t a l  m a l fo rm a t ion s .  F em a l e s  o f  
r e p r o d u c t i v e  p o t e n t i a l  (FRP )  mu s t  b e  coun s e l ed  r e g a r d i n g  p r egn an cy  p r ev en t ion  and  p l ann ing .  
D u e  to  t h e  r i s k s  r e l a t e d  to  t h e  d r u g ’ s  u s e  d u r i n g  p r egn an cy ,  a  R i sk  Ev a lu a t ion  a n d  M i t ig a t ion  
S t r a t egy ( REMS )  p rog r am  h a s  b e en  e s t a b l i s h e d  in  t h e  Un i t ed  S t a t e s  fo r  p rodu c t s  con t a in ing  
myc o p h e n o l a t e  a n d  d e t a i l s  p e r t a i n i n g  to  th i s  p rog r am  a r e  p rov id ed  in  A p p e n d i x2 .  
O t h e rc omm o n  s id e  e f f e c t s  o f  MMFin c lud e  d i a r rh e a ,  vom i t ing ,  p a i n ,  s t om a c h  a r e a  p a in ,  
sw e l l i n g  o f  th e  low e r  l eg s ,  a n k l e s  a n d  f e e t ,  h igh  b lood  p r e s s u r e .  F o r  mo r e  i n f o rm a t i o n  p l e a s e  
r e f e r  t o  t h e  l o c a l  p a c k a g e  i n s e r t( e . g .C e l lC e p t®P I2 0 1 3 ) .
Bas i l ix imab
B a s i l ix im ab( e . g .  S im u l e c t®
Co rpo ra te  Con f iden t ia l  In fo rma t ion)  i s  a  c h im e r i c  CD25  m o n o c l o n a l  a n t ibody  o f  t h e  I gG 1  i so t y p e .  
I ta c t s  a s  an  an t agon i s t  a t  th e  i n t e r l e u k i n - 2( IL - 2 )  b ind ing  s i t e  o f  th e  p55  subun i t  (T a c  an t ig en )  
o f  t h e  h igh  a f f in i ty  I L -2  r e c e p t o r  (CD 2 5 )  on  th e  s u r f a c e  o f  t h e  a c t i v a t e d  T  ly mpho cyt e s .  
B a s i l ix im ab  i s  i n d i c a t e d  f o r  t h e  p rophy l ax i s  o f  a c u t e  o r g a n  r e j e c t i o n  in  p a t i e n t s  r e c e i v i n g  
r e n a l  t r a n s p l a n t a t i o n  wh en  u s e d  a s  p a r t  o f  a n  imm u n o s u p p r e s s i v e  r eg im en  t h a t  con t a in s  
cy c l o s p o r i n e  a n d  c o r t i c o s t e r o i d s .  B a s i l ix im abi s  f o r  c e n t r a l  o r  p e r iph e r a l  IVa dm i n i s t r a t i o n  
on ly .  R e c o n s t i t u t e d  b a s i l ix im abs h o u l d  b e  g i v e n  e i t h e r  a s  a  bo lu s  in j e c t ion  o r  d i lu t e d  to  a  
v o l um e  o f  2 5mL ( 1 0  mg v i a l )  o f  5 0  mL ( 2 0mg/ v i a l )  w i th  n o rm a l  s a l i n e  o r  d e x t r o s e  5%  and  
a dm i n i s t e r e d  a s  a n  IVi n f u s i o n  o v e r  2 0 - 3 0  m i n u t e s.  T h er e comm end ed  r e g im e n  fo r  a d u l t  
p a t i e n t s  i s  tw o  2 0  m g  d o s e s ;  t h e  f i r s t  d o s e  i s  s u g g e s t e d  to  b e  g i v e n  w i th in2  h o u r s  p r i o r  t o  
t r a n s p l a n t a t i o n  a n d  t h e  s e c o n d  d o s e  i s  sugg e s t ed  to  b e  g i v e n  4  d ay s  a f t e r  t r a n s p l a n t a t i o n .  
B o l u s  a dm i n i s t r a t i o n  m a y  b e  a s s o c i a t e d  w i th  n a u s e a ,  v om i t i n g  a n d  l o c a l  r e a c t i o n s  i n c l u d i n g  
p a i n .
No va r t i s Con f iden t ia l Page  44
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  45
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
1 .2 S tudy  pu rpose
T h e  p u r p o s e  o f  th i s  ad ap t iv e ,  tw o - p a r t  s tudy  i s  to  i n v e s t i g a t e  t h e  po t en t i a l  f o r  CFZ 5 3 3  to  
r e p l a c e  c a l c i n e u r i n  inh ib i to r s  (CN I ) ,  w h i l e  p r o v i d i n g  a  s im i l a r  r a t e  o f  a c u t e  r e j e c t i o n  
p rophy l ax i s  a n d  b e t t e r  r e n a l  f u n c t i o n  in  a  d e  no voCo rpo ra te  Con f iden t ia l  In fo rma t ion
r e n a l  t r a n s p l a n t  popu l a t ion  r e c e i v i n g  an  
a l l o g r a f t  f rom  s t and a rd  c r i t e r i a  d o n o r s .  P a r t  1  o f  th i s  t r i a l  w i l l  fo cu s  o n  p r o f i l i n g  t h e  
mu l t ip l e- d o s e  PK ,  PD  a n d  to l e r ab i l i ty  f o r  bo th  IV  a n d  SC  CFZ 5 3 3  adm in i s t r a t ion  i n  t h e  
Novartis Confidential Page 46
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
setting of standard -of-care, CNI -based immunosuppression. Part 2 will evaluate the safet y and 
efficacy  of CFZ533 in the absence of a CNI in combination with adjunct MMF and 
basiliximab induction therap y for up to 12 months.  
Overall, results of this study  will be used to inform the CFZ533 dose and regimen selection 
forinvestigation in the next phase of clinical development. 
2 Study  objectives
2.1 Stud y Part 1: PK, PD and Safety  
2.1.1 Primary  objective
To assess the safet y, tolerability and PK of multiple IV and SC doses of CFZ533 in 
combination with MMF, CS, and Tac (standard ex posure) in de novo renal transplant 
patients over the treatment and follow- up period
2.1.2 Secondary  objectives
To quantify  the magnitude and duration of peripheral blood CD40 occupancy  (free CD40 
and total CD40 on B cells) 
To quantify  the change from baseline and recovery  of peripheral blood total soluble CD40 
and total soluble CD154 
To evaluate the immunogenicity  of CFZ533 via the quantitative anal ysis of anti -CFZ533 
antibodies
2.2 Stud y Part 2: CNI -free Proof -of-Concept
2.2.1 Primary  objective
To assess the potential for CFZ533 to act as the primary  immunosuppressant in a CNI -free 
regimen with MMF in de novo renal transplant patients as assessed b y tBPAR at Month 3 
post-transplantation
2.2.2 Secondary  objectives
To assess the safety and tolerability of CFZ533 administered ch ronicall y in combination 
with MMF and CS up to 3 months against a control
To assess the pharmacokinetics of multiple  I V doses of CFZ533 during the 12 -month 
treatment period
To quantify  the magnitude and duration of peripheral blood CD40 occupancy  (free CD 40 
and total CD40 on B cells) during the treatment period following multiple IV doses of 
CFZ533
To compare renal function in CFZ533 treatment arm to control over 12 months
post-transplantation as assessed b y:
Estimated GFR using MDRD
Proportion of patients with eGFR <60 mL/min/1.73m2
Proportion of patients with negative eGFR slope 
No va r t i s Con f iden t ia l Page  47
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
T o  e v a l u a t e  t h e  imm u n o g e n i c i t y o f  m u l t i p l e  IV  d o s e so f  CFZ 5 3 3  v i a  t h e  q u a n t i t a t i v e  
a n a l y si s  o f  an t i - CFZ 5 3 3  a n t i b o d i e s
To  qu an t i fy t h e  c h a n g e  f r om  b a s e l i n e  and  r e cov e ry  o f  p e r iph e r a l  b lood  to t a l  so lub l e  CD40  
d u r i n g  t h e  t r e a tm e n t  p e r i o d  f o l l ow i n g  m u l t i p l e  IV  d o s e so f  CFZ 5 3 3
3 Inves t iga t iona l  p lan
3 .1 S tudy  des ign
3 .1 .1 Gene ra l  ove rv iew
S tudy C CFZ 5 3 3X 2 2 0 1  i s  a  r a n d om i z e d ,  tw o - p a r t ,  6 -o r  1 2 - mon th ,  s equ en t i a l ,  ad ap t iv e ,  
c o n t r o l l e d ,  o p e n - l ab e l ,  m u l t i c e n t e r ,  c l i n i c a l  p roo f - o f -c o n c e p t  s tudy  t o  e v a l u a t e  t h e  e f f i c a cy ,  
s a f e t y ,  to l e r ab i l i ty ,  PK  and  PD  o f  CFZ 5 3 3  +  MMF  +  CS ,  w i th  s t a n d a r d  e x p o s u r e  (P a r t  1 )  o r  
n o  T a c(P a r t  2 ) ,  fo r  in i t i a l  a n d  m a in t en an c e  p rophy l ax i s  o f  o rg an  r e j e c t ion  in  a d u l t  d en o v o
r e n a l  t r a n s p l a n t  r e c i p i e n t s  a s  c om p a r e d  t o  s t a n d a r d  o f  c a r e .
A s  i l l u s t r a t e d  in  F i g u r e  3 - 1Co rpo ra te  Con f iden t ia l  In fo rma t ion
,  e a c h  s tudy  p a r t  w i l l  ev a l u a t e  a  s e t  o f  CFZ 5 3 3  d o s e s  o r  t r e a tm e n t  
r e g im e n s  i n  a  p a r a l l e l  a rm  m a n n e r .  
No va r t i s Con f iden t ia l Page  48
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
F igu re  3 -1 CFZ533X2201  S tudy des ign
S tudy P a r t  1  o f  th i s  t r i a l  w i l l  f o c u s  o n  m e a s u r i n g  t h e  mu l t ip l e- d o s e  s a f e t y ,  to l e r ab i l i ty  P K  a n d  
PD  o f  CFZ 5 3 3  wh en  a dm i n i s t e r e d  w i th  t h e  con t empo r a ry  s t a n d a r d  o f  c a r e  (S oC )  t r e a tm en t  
r e g im e n .  T h e  SoC  con s i s t s  o f  c o n c e n t r a t i o n - con t ro l l ed  T a c ,  a  c a l c i n e u r i n  inh ib i to r  (CN I ) ,  
c om b i n e d  w i th  myc o p h e n o l a t e  mo f e t i l  (M MF )  a n d  c o r t i c o s t e r o i d s  (CS ) .  A rm1  w i l l  
i n v e s t i g a t e  CFZ533  3mg/kg  a dm i n i s t e r e d  IV  on  D ay 1 ,  fo l low ed  by  s u b c u t a n e o u s  (SC )  
a dm i n i s t r a t i o n  o n  D ays  15 ,  2 9 ,  4 3  a n d  7 1 .   w i l l  b e  m e a s u r e d  o n  a n  ongo ing  
b a s i s  du r ing  th i s  po r t ion  o f  th e  t r i a l  to  con f i rm  t h e  expo su r e - PD  r e spon s e   
.  A f t e r  t h e  l a s t  d o s e ,  p a t i e n t s  e n r o l l e d  in  P a r t  1  w i l l  
r em a i n  o n  th e i r  b a ckg round  SoC  t r e a tm e n t  r e g im e n ,  to  b e  m an aged  p e r  lo c a l  p r a c t i c e .  
P a t i e n t si n  P a r t  1  w i l ln o t  b e  c a r r i e d  o v e r  t o  P a r t  2 .  
S tudy P a r t  2  w i l l  c o n t i n u e  t h e  i n v e s t i g a t i o n  o f  e f f i c a cy ,  s a f e t y ,  to l e r ab i l i ty ,  PK  a n d  PD  w i th  
t h e  a d d i t i o n  o f  i n d u c t i o n  t h e r a p y  a n d  a v o i d a n c e  o f  T a c .   
 
Any s ig n i f i c an t  
d e v i a t i o n s  in  PK  o r  PD  e f f e c t s  wh i ch  m ay r e q u i r e  a  r ev i s ion  in  t h e  d o s i n g  s ch em e  
( d o s e ,f r equ en cy  o r  rou t e  o fa dm i n i s t r a t i o n )  w i l l  b e  a d d r e s s e d  v i a  a n  am endm en t  p r i o r  to  
i n i t i a t i n g  t h e  a f f e c t e d  d o s e ( s )  in  P a r t  2 .   
 
 Co rpo ra te  Con f iden t ia l  
In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis Confidential Page 49
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
3.1.2 All cohorts
Before any study -related evaluations are performed, the patient must give written informed 
consent. Once consent isobtained, pre-transplant screening and baseline assessments will 
occur to determine the patient’s eligibility  to participate in the study  starting up to 28 days 
prior to transplantation. If the screening, baseline and study  Day 1  v isits occur in close 
proximity  of each other (i.e., within a 12 hour timespan), certain repeated assessments may  be 
omitted, as noted in the Assessment schedule . Data collection from assessments performed at 
the clinical site as part of medical standard of care but prior ICF sign -off is acceptable in order 
to confirm patient eligibility for patients receiving an organ from a deceased donor, if 
assessed shortl y before transplantation (i.e within 24h– matching the baseline window of Day 
-1 to Day  1)and in -line with inclusion and exclusion criteria.
Day 1  is defined as the day of randomization/enrollment and transplantation. This protocol 
defines 7 days to a week and 4 weeks (or 28 days) to a Study  Month. For example, Week 2 is 
considered to start on Day 8 and Study  Month 2 is considere d to start on Week 5/Day  29. 
Randomization/enrollment should occur within 24 hours pre-transplant and drug 
administration will begin after randomization/enrollment. If CFZ533 is to be administered, t he 
first dose of CFZ533 will be administered IVpre-transplant or intra-operatively , and must be 
completed by  the time of unclamping. Other study drugs must be started within 24 hours post -
transplant or according to local practice . 
Patients who are random ized/enrolled but not transplanted will be replaced. 
Allrandomized/enrolled subjects are expected to continue in the study  up to Month 6 (Part 1) 
or Month 12 (Part 2) regardless of being on or off randomized/assigned treatment. 
Allsubjects will be follow ed-up for safet y (e.g., SAEs) for approximately three months after 
their last dose of CFZ533 or 2 months after the EoS visit for patients on SoC treatment .
Any treatment arm in which the rejection rate fulfills the a priori defined stopping rules 
(seeSection 5.5.10 )will be immediately  discontinued at any  time during the study . 
The transition from one arm to the next including Parts 1 to 2 will be based on a priori
defined rules as described in Section 9.4 . Any changes in dosing or clinical conduct of the 
study  will be implemented via an amendment, approved by the ethics committee responsible 
for approval of this study, and by the local heath authori ty when mandated by  local regulations.
Safety  assessments will include physical examinations, ECGs, vital signs, standard clinical 
laboratory  evaluations (hematology , blood chemistry , urinal ysis) AEand SAE monitoring as 
well as special assessments as out lined in Section 6.5 .
No va r t i s Con f iden t ia l Page  50
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
3 .1 .3 Pa r t  1  –A rm  1
F igu re  3 -2 Pa r t  1  Des ign
App rox im a t e ly 6  p a t i e n t s  w h o  m e e t  th e  in c lu s ion  c r i t e r i a  w i l l  b e  e n r o l l e d  w i th in  a p p r o x .  
1 2h o u r s  p r e- t r an sp l an t  to  r e c e i v e  IV  a n d  SC  CFZ 5 3 3  a t  3  mg/ k g  o n  D ay s  1  ( IV ) ,  1 5 ,  2 9 ,  43  
a n d  7 1 )  w i th  s t a n d a r d - e x p o s u r e  T a c(w h o l e  b l o o d  t r o u g h  con c en t r a t ion  4 - 1 1  n g /mL) ,  
myc o p h e n o l a t e  m o f e t i l  1 . 0 g  B ID  a n d  CS( F i g u r e3 - 2) .  
Th e  f i r s t  d o s e  o f  CFZ 5 3 3w i l l  b e  a dm i n i s t e r e d  IVp r e - t r an sp l an t  o r  i n t r a - op e r a t i v e l y .  
D ruga dm i n i s t r a t i o n  w i l l  b e g i n  a f t e r  en ro l lm en t  a n d  mu s t  be  comp l e t ed  by  t h e  t im e  o f  
u n c l am p i n g .  Sub s equ en t  d o s e s  o f  CFZ 5 3 3  w i l l  b e  a dm i n i s t e r e d  SC  f o r  a  p e r i o d  o f  
app rox im a t e ly  3  mon th s .  
O th e r  s tud y  d ru g sm u s t  b e  s t a r t e d  w i t h i n  2 4  h o u r s  p o s t -t r a n s p l a n t .  
T h e  d ay  o f  e n r o l lm e n t  a n d  t r an s p l an t  w i l l  b e  c o n s i d e r e d  to  b e  s tudy  D ay  1 .  Th e r e a f t e r ,  
p o s t- t r a n s p l a n t  ho sp i t a l i z a t ion  w i l l  o c c u r  a n d  th en  p a t i e n t s  w i l l  m a k e  w e e k ly  s tudy  v i s i t s  
d u r i n g  Mon th s  1 - 3  ( u p  to  app rox im a t e ly  D ay  7 1 ) ,  t h e n  app rox im a t e ly  e v e ry  o t h e r  w e ek  fo r  
Mon th s4 - 6  (up  to  app rox im a t e ly  D ay  1 5 5 ) .
Cumu la t i v e  e f f i c a c y  a n d  s a f e t y  d a t a  w i l l  b e  c o l l e c t e d  o n  a n  o n g o i n g  b a s i s  d u r i n g  t h e  condu c t  
o f  th e  s tudy .
PK ,  PD  a n d  tBPAR s  w i l l  b e  r e v i ew e d  o n  a n  o n g o i n g  b a s i s  by  t h e  c l i n i c a l  t r i a l  t e am .  I f  a t  a n y  
t im e  t h e  o b s e r v e d  n um b e r  o f  tBPAR s  e x c e e d s  th ea  p r io r i- d e f i ned  s t o p p i n g  c r i t e r i a  
( s e eS e c t i o n  5 . 5 . 1 0)  th e  s tudy  w i l l  b e  s t o p p e d .Co rpo ra te  Con f iden t ia l  
In fo rma t ionCo rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  51
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
3 .1 .4 Pa r t  2  –A rms  2A- 2B
F igu re  3 -3 Pa r t  2  Des ign
App rox im a t e ly 45  p a t i en t s  who  m e e t  th e  in c lu s ion  c r i t e r i a  w i l l  b e  r andom i z ed  in  a  2 :1  f a sh ion  
w i th in  2 4  h o u r s  p r e- t r an sp l a n t  t o  r e c e i v e  o n e  o f  t h e  2  t r e a tm e n t  a rm s  (F i g u r e  3- 3 ) :
1 .A rm  2A ,n=30 :  B a s i l ix im ab20  mg  (D ay s  1 ,  4 )  +  CFZ 5 3 3  a t  1 0  m g /k g  IV  ( 1 7d o s e s )+  
MMF  1 . 0 g  B ID  +  CS
2 .A rm  2B  C on t r o l /S oC,  n=15 :  B a s i l ix im ab2 0  m g  (D a y s  1 ,  4 )  +  T a c( 4 - 1 1n g /mL )  +  MMF  
1 . 0  g  B ID  +  CSCo rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  
In fo rma t ion
No va r t i s Con f iden t ia l Page  52
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Indu c t ion  th e r ap ym u s t  b e  s t a r t e d  w i th in  2  h o u r s  p r i o r  to  t r a n s p l a n t a t i o n ,  o r  a c c o r d i n g  to  
l o c a l  p r a c t i c e .  
Th e  f i r s t  d o s e  o f  CFZ 5 3 3w i l l  b e  a dm i n i s t e r e d  IVp r e - t r an sp l a n t  o r  i n t r a - o p e r a t i v e l y .  
D r uga dm i n i s t r a t i o n  w i l l  b e g i n  a f t e r  r a n d om i z a t i o n  a n d  mu s t  b e  comp l e t ed  by  t h e  t im e  o f  
un c l amp ing .  Sub s equ en t  do s e s  o f  CFZ533  w i l l  b e  adm in i s t e r ed  IV(A rm2A ) ,  o v e r  a  p e r iod  o f  
12  mon th s .  
O th e r  s tudy  d rug s( a p a r t  f r om  B a s i l i x im a b )  s h o u l d  b e  s t a r t e d  w i t h i n  24  h o u r s  p o s t- t r an sp l an t .  
T h e  s e c o n d  d o s e  o f  b a s i l i x im a b  w i l l  b e  a dm i n i s t e r e d  o n  D a y 4 ,  o r  a c c o r d i n g  t o  l o c a l  p r a c t i c e .
T h e  d ay  o f  r a n d om i z a t i o n  a n d  t r a n s p l a n t  w i l l  b e  c o n s i d e r e d  to  b e  s tudy  D ay  1 .  
F u r t h e rt r e a tm e n t  w i l l  b e  g iv en  on  s tudy D ay s3 ,  7 ,  15 ,  29 ,43 ,  57  and  th en  mon th ly  th e r e a f t e r  
un t i l  Mon th s  12  (upto  app rox im a t e ly  D ay  3 3 7 ) .  Sub j e c t s  w i l l  th en  und e rgo  S tudy  Comp l e t ion  
e v a l u a t i o n s .
T h e  p r im a ry  e ndpo in t  o f  P a r t  2  w i l l  b e  a s s e s s e d  to  d e t e rm i n e  w h e th e r  t h e  s u c c e s s  c r i t e r i a  
( s a f e t y  and  tBPAR )  h av e  b e en  m e t   
 
 
 I f  no t ab l eAEs  o r  s a f e t y  c o n c e r n s  m e e t i n g  th e  ap r io r i- d e f i n e d  s topp ing  
c r i t e r i a  ( s e e  S e c t i o n  5 .5 .10)  o n e  o f  t h e  p l ann ed  do s e  l e v e l s  m ay b e  c h a n g e d  o r  d i s con t inu ed  
v i a  am e n dm e n t .  
Sub j e c t s  w i l l  und e rgo  S tudy C om p l e t i o n  e v a l u a t i o n s  a t  t h e  e n d  o f  t h e  t r i a l .
3 .2 Ra t iona le  fo r  s tudy  des ign
T h e  o p e n- l ab e l ,  a d a p t i v e  d e s i g n  s e l e c t e d  f o r  P a r t  1  o f  th i s  p r o s p e c t i v e ,  mu l t i c en t e r  s tudy  w i l l  
a l l ow  f o r  a  c a u t i o u s  c om p a r i s o n  a n d  e v a l u a t i o n  o f  t h e  mu l t ip l e  d o s e  CFZ 5 3 3  s a f e ty ,  
to l e r ab i l i ty ,  PK  and  PD  a s  add ed  to  MMF +  T a c  and  CS  fo r  3  mon th s .  P a r t  2  exp andsu p o n  t h e  
k n ow l e d g e  g a in ed  in  P a r t  1  to  a s s e s s  th e  c l in i c a l  a c t iv i ty  and  expo su r e - r e spon s e  o f  CFZ533  in  
a  w e l l  p ow e r e d  CN I- f r e e  t r e a tm e n t  r e g im e n  w i th  b a s i l i x im a b  i n d u c t i o n  +  MMF  a n d  CS  f o r  
in i t i a l  a n d  m a i n t e n a n c e  p rophy l ax i s  o f  o r g a n  r e j e c t i o n  in  a du l t  d e  n o v o  Co rpo ra te  Con f iden t ia l  In fo rma t ion
r e n a l  t r an sp l an t  
r e c ip i en t s .  
 
 
A l t h o u g h  t h e  i d e a l  s tudy  w ou ld  emp loy  a  d oub l e- b l ind ,  d o u b l e- dummy  m e thodo logy  t o  
m i n im i z e  b i a s ,  in  c o n s i d e r a t i o n  o f  t h e  inh e r en t  comp l ex i ty  o f  th i s  a d a p t i v e  s tudy  
(mu l t ip l ea rm s ,  f r e q u e n t  v i s i t s ,  i n t e r im  an a ly s i s  a n d  e x t e n s i v e  i n v e s t i g a t i o n s ) ,  i t  h a s  b e en  
d e c i d e d  to  u t i l i z e  a n  op en- l a b e l  d e s i g n .  Th i s  op en- l a b e l  d e s i g n  w i l l  no t  on ly  m in im i z e  t h e  
r i s k s  f o r  p a t i e n t s  du r ing  th e  in i t i a l  i n v e s t i g a t i o n  o f  CFZ533  s h o u l d  t h e  n e ed  f o r  r a p i d  
i n t e r v e n t i o n  a r i s e ,  s u c h  a s  em e r g e n t  SAE s ,  bu t  i t  a l s o  avo id s  t h e  a d d i t i o n a l  d i f f i c u l t i e s  a n d  Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis Confidential Page 53
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
errors associated with sham -dose adjustments for a Tac placebo in CFZ533 arms and placebo 
injections/infusions in the control group. It is recognized that Investigator bias can affect the 
management of patients receivi ng investigational treatment; especially  in an open -label study 
setting. In general, such scrutiny  biases the study  in favor of the control arm. As such, efforts 
to minimize bias for or against the CFZ533 treatment arms will be managed through the use 
of alimited number of high-qualit y transplant centers with a similar standard of care and 
patient management. In order to overcome any bias introduced by the open -label design , in 
Part 2, a blinded external independent adjudication committee (AC) has been formed to
centrall y evaluate all biopsies taken for suspected rejection reactions and other kidney  disease 
related events in an unbiased, standardized and blinded manner .Adjudicat ion outcome will be 
entered into the eCRF and additional outputs provided.
This first-in-transplant study  will enroll a de novo patient population who receive a kidney 
from donor sper the inclusion and exclusion criteria outlined in the clinical study  protocol (see 
Section 4 ). This population was selected since they typically present the lowest risk of post-
transplant complications, including delay ed graft function and provide a fair assessment of 
clinical activity  while not requiring the highest level of immunosuppression. Safety  risks will 
be reviewed on a regular basis by  an external DMC (see Section 8.4 ), with particular attention 
given to serious infections and malignan cies associated to those (e.g., PTLD), as well as 
thromboembolic events . 
Appropriateness of efficacy  assessments 
The efficacy  endpoints of treated BPAR and GFR are consistent with recent HA guidance 
(CHMP/EWP/263148/06 2009 ) and discussions (FDA Workshop 2012 ) on including an 
assessment of graft function as well as the traditional efficacy endpoints (e.g., tBPAR , BPAR) 
with or without clinical outcomes (i.e., Death and Graft loss). 
The composite of tBPAR, graft loss or death has been used as an endpoint in many  previous 
studies in the kidney  transplantation indication and has been widely  accepted by health 
authorities for registration purposes in this indication.
Overall, this design is consistent with well-established precedents by global health authorities 
for clinical development of immunosuppressive regimens in kidney  transplantation.
3.3 Rationale for dose/regimen, duration of treatment
The initial CFZ533 dose to be administered to de novo renal transplant patients via both IV 
and SC route is 3 mg/kg CFZ533 (Part 1).. For all CFZ533 treatment regimens, the first dose 
of CFZ533 will be administered IV prior to or during transplant surgery  to ensure full CD40 
target occupancy  on Bcells in the periphery  at the time of unclamping and revascularization 
of the transplanted organ; the timing avoids initiation of an immune reaction in the initial 
presence of the foreign antigens. The SC route is preferred for patient convenience and ease of 
adminis tration while the IV route is reserved for high doses and administration of the initial 
dose during surgery . 
The following section discusses the overall CFZ533 dose rationale and specifics for Parts 1
and2 in turn:
No va r t i s Con f iden t ia l Page  54
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
D o s e  s e l e c t i on  fo r  P a r t  1 :  I n  h e a l thy  v o l u n t e e r s ,  3m g / k g  IV  o r  SC  l e d  to  f u l l  (> 9 0% )  CD40  
s a t u r a t i o n  o n  B  c e l l s  fo r  a b o u t  4  w e e k s .  N e v e r t h e l e s s ,  i t  i s  r e c o g n i z e d  t h a t  d i f f e r e n c e s  in  
e x p r e s s i o nl e v e l  a n d / o r  t u r n o v e r  o f  m em b r a n e  b o u n d  (L ow ee ta l2 0 1 0)  a n d  s o l u b l e  t a r g e t s  
(S c hw a b ee ta l  1 9 9 9,  Con t ine ta l  2 0 0 3,  K om u r ae ta l2 0 0 7)  m ay h a v e  a n  im p a c t  o n  th e  
PK /PD  p r o f i l e  o f  t h e r a p e u t i c  a n t i b o d i e s .  T o  p r o f i l e  t h e  mu l t ip l e- d o s e  CFZ 5 3 3  PK  a n d  PD  i n  
d e  n o v or e n a l  t r an sp l an t  p a t i e n t s ,  bo th  IV  a nd  SC  d o s e s  o f  3  m g / k g  CFZ 5 3 3  w i l l  b e  
i n v e s t i g a t e d  ov e r  a b o u t  2  1 /2  mon th s  in  P a r t  1  o f  th i s  s tudy .  I n  a d d i t i o n ,  to  b e t t e r  c o n t r o l  fo r  
i n t e r - p a t i e n t  v a r i a b i l i t y  a n d  m i n im i z e  t h e  n um b e r  o f  p a t i e n t s  e x p o s e d  to  q u a d r u p l e  
i mm u n o s u p p r e s s i o n ,  i t  i s  p l a n n e d  to  ev a lu a t e  bo th  IV  a n d  b iw e ek ly  a n d  mon th ly S C  
a dm i n i s t r a t i o n  w i th in  t h e  s am e  6  p a t i e n t s .  A  s imu l a t ion  o f  t h e  e x p e c t e d  CFZ 5 3 3  PK  and  
CD 4 0  r e c e p t o r  o c c u p a n c y  p l a n n e d  f o r  P a r t  1  i s  p r e s e n t e d  i n  
Co rpo ra te  Con f iden t ia l  In fo rma t ionF i g u r e  3- 4 .
No va r t i s Con f iden t ia l Page  55
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Th i s  CFZ533  r eg im en  i s  exp e c t ed  to  r e su l t  in  comp l e t e  CD40  supp r e s s ion  in  p e r iph e r a l  who l e  
b l o o d  o v e r  t h e  t r e a tm e n t  i n t e r v a l .   
 
 R e su l t s  f r om  P a r t  1  w i l l  
p r o v i d e  PK  a n d  PD  d a t a  t h a t  w i l l  b e  u s e d  to  b e t t e r  i n f o rm  m o d e l i n g  a n d  s e l e c t i o n  o f  IV  and  
SC  d o s i n g  r e g im e n s  t o  b e  i n v e s t i g a t e d  i n  P a r t  2  o f  t h i s  t r i a l .
T o  f u r t h e r  m in im i z e  t h e  r i sk  f o r  o v e r  immuno sup p r e s s i o n ,  no  b a s i l i x im a b  i n d u c t i o n  t h e r a p y  
w i l l  b e  a dm i n i s t e r e d  to  p a t i e n t s  p a r t i c i p a t i n g  in  th i s  p a r t  o f  t h e  t r i a l .  P a t i e n t s  w i l l  a l s o  r e c e i v e  
p rophy l ax i s  f o r  CMV  and  PCP  a n d  r e c i p i e n t s  w i th  n e g a t i v e  EBV  s e ro logy  w i l l  b e  ex c lud ed .  
U p o n  c om p l e t i o n  o f  t h e  f i n a l  CFZ 5 3 3  d o s e  adm in i s t r a t ion ,  p a t i e n t s  w i l l  r em a i n  o n  SoC  t o  b e  
m a n a g e d  b a s ed  o n  d e f in ed  l o c a l  p r a c t i c e s  a n d  w i l l  b e  m o n i t o r e d  th rough  Mon th  6  p e r  th e  
s tudy  p r o t o c o l .
D o s e  s e l e c t i on  fo r  P a r t  2 :  I n  P a r t  2  o f  th i s  t r i al ,  CFZ 5 3 3  w i l l  b e  inv e s t ig a t ed  a t  10  mg/kg  IV
( a  l o a d i n g  r e g im e nc o n s i s t i n g  o f  7  d o s e si s  b e i n g  u s e d  in  t h e  f i r s t  2mon th s ,  t h e n  mon th ly 
( q 4w )  d o s i n g  s t a r t i n g  on  s tudy  D ay  5 7 ) .   
 
PK  a n d  PD  d a t a  o f  ASKP 1 2 4 0  h a s  b e en  pub l i sh ed  fo r  NHP  ( M a  e t  a l  2014)  and  fo r  h e a l t hy  
v o l u n t e e r s  ( G o l dw a t e r  e t  a l  2 0 1 3)  a n d  s om e  d a t a  h a v e  b e en  r e v e a l e d  fo r  a  P h a s e  2  c l i n i c a l  
t r i a l  in  k idn ey  t r an sp l an t  ( H a r l and  e t  a l  2015) .   
 
 
 
 
 
 
 
 
 Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ionCo rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  56
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  57
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
D a t a  f r om  ASKP1240,  a  m on o c l on a l  an t ib od y  b l o ck in g  CD 4 0Co rpo ra te  Con f iden t ia l  In fo rma t ion
:  At  t h e  Am er i c a n  
Tr a n s p l a n t  Co n g r e s s2015 ,  p r e l im i n a r y  d a t a  f roma  Ph  I I  t r i a l  in  k idn ey  t r a n s p l a n t a t i o n
(H a r l a n d  e t  a l  Ab s t r a c t  ATC  2 0 1 5 ) ,sugg e s t ed  e f f i c i e n t  t a rg e t  m ed i a t ed  c l e a r a n c e  o f  
ASKP 1 2 4 0  d u r i n g  th e  f i r s t  tw o  mon th s  p o s t- t r a n s p l a n t a t i o n ,   
 
 
 
 
P a r t  1  PK /PD  d a t a  in  t r a n s p l a n t e d  p a t i e n t s  w i l l  b e  an a ly z ed  p r i o r  to  s t a r t  P a r t  2 .  A nyr e l ev an t  
d e v i a t i o n s  in  t h e  CFZ 5 3 3  PK  o r  CD 4 0  o c cup an cy  p ro f i l e  f o r  3mg/kg  IV / SC  m e a s u r e d  in  
P a r t1  o f  th i st r i a l   w i l l  b e  mod e l ed  to  f u r t h e r  suppo r t  
t h e  1 0m g / k g  IV  r eg im en  p r i o r  to  t h e  in i t i a t ion  o fP a r t  2 .  A ny  f u r t h e r  d o s e  o r  r eg im en  
a d j u s tm e n t s  w i l l  b e  im p l em e n t e d  v i a  am e n dm e n t .  Co rpo ra te  Con f iden t ia l  In fo rma t ionCo rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  58
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
3 .4 Ra t iona le  fo r  cho ice  o f  compa ra to r
I n  a d u l t  d e  no vok idn ey  t r a n s p l a n t  r e c ip i en t s ,  t h e  u s e  o f  T a c ,  MMF ,  a n d  CS  i s  an  
a p p r o v e dr eg im en  ( e . g .  P r o g r a f®P I2 0 1 3)  a n d  i s  t h e  c u r r e n t  s t a n d a r d  o f  c a r e  u s e d  in  mo r e  
t h a n  8 0%  o f  k idn ey  t r an sp l an t s  g l o b a l l y .  Wh en  T ac  i s  c om b i n e d  w i th  a n  MPA- b a s e d  r eg im en  
a n d  w i th  i n d u c t i o n  u s i n g  a n  IL -2  a n t a g o n i s t ,  t h e  l a b e l e d  t r o u g h  con c en t r a t ion  r a n g e  f o r  T a ci s  
4 - 1 1  n g /mL  ( e . g .  P rog r a f®P I2 0 1 3) ,  a n d  th i s  r a n g e  w i l l  b e  emp loy e d  in  th i s  c l i n i c a l  s tudy .  
O v e rt h e  p a s t  d e c a d e ,  th e  c l i n i c a l  u s e  o f  c a l c in eu r in  inh ib i to r s ,  i n c l u d i n g  T a c ,  h a s  f o c u s e d  on  
m in im i z a t ion  o f  t h e  CN I  to  m i t i g a t e  m any o f  th e  a s s o c i a t e d  a d v e r s e  e f f e c t s .  C u r r e n t  c l in i c a l  
u s e  o f  Ta c  w i th  a n  MPA- b a s e d  r e g im e n  r e s u l t s  in  e x c e l l e n t  g r a f t  a n d  p a t i en t  s u r v i v a l  a s  w e l l  
a s  l ow  r a t e s  o f  a c u t e  r e j e c t i o n .  
3 .6 R isks  and  bene f i ts
I n  t h i s  tw o  p a r t  t r i a l ,  t h e r e  i s  n o  b ene f i t  exp e c t ed  f o r  p a t i e n t s  p a r t i c i p a t i n g  in  P a r t  1  o f  th i s  
s tudy .  Th e  r i sk  (p a r t i cu l a r ly  o f  in c r e a s ed  in f e c t ion s )  to  p a t i en t s  in  P a r t  1  w i l l  b e  m in im i z ed  by  
a d h e r e n c e  to  t h e  in c lu s ion / ex c lu s ion  c r i t e r i a ,  c l o s e  c l i n i c a l  m o n i t o r i n g  and  m in im i z a t ion  o f  
th e  ov e r a l l  expo su r e  to  CFZ533   du r ing  t r e a tm en t  p e r iod .In  P a r t  2 ,  th e  b en e f i t  
o f  a  CN I- f r e e  r eg im en  c a r r i e st h e  exp e c t a t ion  o f  im p r o v e d  r e n a l  f u n c t i o n  and  
v a s c u l a r /m e t a b o l i c  p ro f i l e  ( V in c en t ie ta l2 0 1 0) .  Th e  r i s k s  o f  i n s u f f i c i e n t  e f f i c a cy  ( h igh e r  r a t e  
o f  a c u t e  r e j e c t i o n - tBPAR  t h a n  s t a n d a r d  o f  c a r e )  w i l l  b e  m i n im i z e d  by  f r e q u e n t  m o n i t o r i n g  o f  
c l i n i c a l  l a b s  a n d  s ign s  and  sy mp tom s  s u g g e s t i n g  tBPAR  and  t h e  e a r l y  d i s con t inu a t ion  o f  a n y  
t r e a tm e n t  a rm  t h a t  i s  in e f f e c t i v e  a c co rd ing  to  t h e  S to p p i n g  R u l e s  ( s e e  d e t a i l s  in  
S e c t i o n5 . 5 . 1 0Co rpo ra te  Con f iden t ia l  In fo rma t ion
) .  
T h e  be l ow  s e c t ion s  l i s t  t h e  r i s k s  r e l a t e d  to  CFZ533  t r e a tm e n t .  F o r  f u r t h e r  d e t a i l s  pl e a s es e e  Co rpo ra te  Con f iden t ia l  
In fo rma t ion
No va r t i s Con f iden t ia l Page  59
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
S e c t ion  7o f  th e  cu r r en t  I n v e s t i g a to r ’ s  B r o c h u r e .  In f o rm a t i o na n d  g u i d a n c e  f o r  th e  s t and a rd  o f  
c a r e  t r e a tm e n t  u s e d  in  t h i s  s tudy  i s  p r o v i d e d  int h e  l o c a l  l a b e l l in gin fo rm a t iona n d  s h o u l d  b e  
s t r i c t ly  f o l l ow e d .
3 .6 .1 CFZ533
R i sk s  o f  CFZ 5 3 3  a dm i n i s t r a t i o n  i n c l u d e  t h o s e  g e n e r a l ly  a s s o c i a t e d  w i th  a dm in i s t r a t ion  o f  a  
m o n o c l o n a l  an t ibody  i n  h um a n s .  T h e s e  in c lud e  th e  po s s ib i l i ty  o f  a  hy p e r s en s i t iv i ty  r e a c t i o n  
c h a r a c t e r i z e d  by  a c u t e  o r  d e l ay ed  a l l e r g i c  r e a c t ion ,  a n a p h y l ax i s ,  u r t i c a r i a ,  r a sh ,  dy spn e a ,  
hy p o t e n s i o n ,  f e v e r ,  ch i l l s  a n d  imm u n o g e n i c i t y .  A  s e r i o u s  in f u s i o n  r e a c t i o n  t h a t  r e s u l t s  in  
a n a p h y l ax i s  i s  a  r a r e  ev en t  in  m o n o c l o n a l  a n t i b o d y  t h e r a py .  CFZ 5 3 3  i s  a  fu l ly  h um a n i z e d  
m o n o c l o n a l  an t ibody  o f  t h e  I gG 1  c l a s s .  Th i s  c l a s s  o f  an t ibody  i s  no rm a l ly  a b u n d a n t  in  
h um a n s .  T h e r e f o r e ,  th e  an t ibody  i t s e l f  i s  expe c t e d  to  b e  l e s s  imm u n o g e n i c  in  hum an s  
c om p a r e d  to  c h im e r i c  o r  o t h e r  h um a n i z ed  a n t i b o d i e s .  A s s ays  to  d e t e c t  a  p u t a t i v e  an t ibody  
r e s p o n s e  t o  CFZ 5 3 3  a r e  i n c l u d e d  i n  t h e  s t u d y  d e s i g n .
I n  c on s id e r a t ion  o f  t h e  P h a s e  1  s tudy  r e s u l t s  and  n o n - c l i n i c a ltox i co logy  s tudy  r e s u l t s  fo r  
CFZ 5 3 3  a s  w e l l  a s  c l i n i c a l  s t u d i e s  w i th  a n t i b o d i e s  t h a t  t a r g e t  CD 4 0  a n d  CD 1 5 4  (CD 4 0L ) ,  th e  
p o t e n t i a l  r i s k s  o f  CFZ 5 3 3  i n  h um a n s  m a y  in c lud e :
1 .I n fu s ion  r e a c t ion s ,  sy s t em i c  i n f l amm a t i o n  a n d  c y t o k i n e  r e l e a s e
2 .Imm u n o s u p p r e s s i o n  a n d  i n f e c t i o n s
3 .L ymp h o p r o l i f e r a t i v e  d i s o r d e r s
4 .O t h e r  hy p o t h e t i c a l  r i s k s
T h e s e  r i s k s  a n d  a n  o v e r a l l  r i s k  m i t i g a t i o n  s t r a t e g y a r e  d i s c u s s e d  i n  t u r n  b e l ow .  
3 .6 .1 .1 In fus ion  reac t ions ,  sys tem ic  in f lamma t ion  and  cy tok ine  re lease
In fus ion  reac t ions  and  cy tok ine  re lease
CFZ 5 3 3  i s  a  hum an ,  n o n - a g o n i s t i c ,  F c  s i l e n t ,  I gG 1Co rpo ra te  Con f iden t ia l  
In fo rma t ionan t ibody .  
 
 
c l i n i c a l  r e s u l t s  w i th  CFZ 5 3 3  h av e  no t  d em o n s t r a t e d  s i g n s  o r  sy mp tom s  o f  cy t o k in e  r e l e a s e  
sy n d r om eo r  e l ev a t ion  o f  cy tok in e s  a s  d e t e rm in ed  by  mu l t ip l ex  cy tok in e  a s s ay s .
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  60
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
3 .6 .1 .2 Immunosupp ress ionand  in fec t ions
CFZ 5 3 3  i s  b e i n g  d e v e l o p e d  f o r  i t s  e x p e c t e d  imm u n o s u p p r e s s i v e  a c t i v i t y .  CD 4 0  l ig a t ion  i s  
l i n k e d  to  t h e  f u n c t i o n a l  a c t iv i ty  o f  a n ti g e n  p r e s e n t a t i o n ,  a s  w e l l  a s  Tc e l l  p r im i n g ,  Bc e l l  
d i f f e r e n t i a t i o n ,  an t ibody  p r o d u c t i o n  a n d  imm u n e  m emo ry.A dm i n i s t r a t i on  o f  CFZ 5 3 3  i s  
e x p e c t e d  to  r e s u l t  in  g e n e r a l  immuno supp r e s s ion  w i th  a  d e c r e a s e d  c ap a c i ty  t o  moun t  a  
r e s p o n s e  to  n o v e l  imm u n o g e n s ,  i n c l u d i n g  t h o s e  o f  b a c t e r i a l ,  v i r a l ,  fung a l  a n d  p a r a s i t i c  o r i g i n  
 h a s  b e e n  a c h i e v e d .P a t i e n t s  r e c e i v i n g  CFZ533  m ay b e  imm u n e  
s u p p r e s s e d  f r om  w e ek s to  mon th s  d e p e n d i n g  o n  t h e  d o s e.  D u r i n g  th i s  t im e  o f  
imm u n o s u p p r e s s i o n  s u b j e c t s  m a y  b e  a t  a  h i g h e r  r i s k  f o r  i n f e c t i o n .
I t  h a s  b e en  shown  th a t  p a t i e n t s  w i th  an  X -l ink ed  g e n e t i c  dy s fun c t ion  in  CD 4 0- CD 1 5 4  
s i g n a l i n g ,  hy p e r- I gM  (H I GM )  sy n d r om e ,  a r e  a t  a n  i n c r e a s e d  r i s k  fo r  r e c u r r e n t  b a c t e r i a l  
i n f e c t i o n s  a n d  in f e c t ion  w i th  i n t r a c e l l u l a r  p a thog en s  s u c h  a s  C r yp to spo r id iumand  
P n e um o c y s t i s  j i r o v e c ip n e um o n i a  (PCP )  ( v a n  K o o t e n  a n d  B a n c h e r e a u  2 0 0 0) .  
 
 
 
C o n s i d e r i n g  t h e  ph a rm a co logy  o f  CFZ 5 3 3 ,  indu c t ion  o f  a  t r a n s i e n t  H IGM– l i k e  ph eno ty p e  in  
p a t i e n t s  r e c e i v i n g  CFZ533  i sp o s s i b l e ,  l im i t i n g  t h e i r  ab i l i ty  t o  moun t  a n  imm u n e  r e s p o n s e  t o  
n ew  i n f e c t i o u s  p a t h o g e n s  a n d  i n d u c t i o n  o f  l o n g- l a s t ing  immun e  m emo ry  t o  n ew  imm u n o g e n s .
 
A l t h o u g h  t h e  ab i l i ty  t o  moun t  a  p r im a ry  i mm u n e  r e spon s e  
w i l l  b e  a f f e c t e d  by  C FZ 5 3 3 ,  t h e  m emo ry Bc e l l  r e p e r t o i r e  a n d  imm u n e  r e c a l l  r e s p o n s e  shou ld  
r em a i n  in t a c t  and  p r o t e c t i v e .  I n  a d d i t i o n ,  sub j e c t s  wi l l  h av e  ad equ a t e  p r e f o rm e d  an t ibody  t o  
m a i n t a i n  p r o t e c t i v e  h um o r a l  r e s p o n s e  f o r  e x te n d e d  p e r i o d s  o f  t im e  (mo n t h s ) .
 
 
S im i l a r ly,  cy to tox i c  T  ly mpho cyt e  (CTL )  r e s p o n s e  to  v i r a l  in f e c t ion s  m ay 
b e  r e d u c e d  d u e  to  im p a i rm e n t  o f  a n t i g e n  p r e s e n t a t i o n ,  bu t  a r e  e x p e c t e d  to  r em a i n  i n t a c t .
 
I n  p a t i en t s  r e c e iv ing  w e ek ly  t o  b i - mon th ly adm in i s t r a t ion  o f  th e  p a r en t  an t ibody  lu c a tumum ab ,  
t h e  r a t e  o f  in f e c t ion  w a s  v e ry  l ow  a n d  s im i l a r  t o  c o n t r o l ,  s u p p o r t i n g  t h e s e  a b o v e  h y po th e se s .
3 .6 .1 .3 Lymphop ro l i fe ra t ive  d iso rde rs
 
 
I t  h a s  b e en  shown  
p r e - c l in i c a l ly  t h a t  t h e  E p s t e i n -B a r r  v i r u s  u t i l i z e s  t h e  CD 4 0  s i g n a l i n g  p a thw ay  t o  i n f e c t  Bc e l l s  
a n d  i n d u c e  long  t e rm  s u r v i v a l  ( L o u g a r i s  e t  a l  2 0 0 5Co rpo ra te  Con f iden t ia l  In fo rma t ion
) .  T h e r e f o r e  EBV  r e a c t i v a t i o n  i s  no t  
e x p e c t e d .T o  m in im i z e  t h e  r i s kin  P a r t  1  o f  th i s  t r i a l ,  p a t i e n t s  w h o  a r e  EBV- n e g a t i v e  w i l l  b e  
e x c l u d e d .  F o r  p a t i e n t s  i n  P a r t  2 ,  t h e  imm u n o s u p p r e s s i v e  b u r d e n  i s  l ow e r  in  t h e  c o n t e x t  o fa  Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  61
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
CN I- f r e e  t r e a tm e n t  r e g im e n ,  a n d  r e c i p i e n t s  w i th  a  n e g a t i v e  o r  po s i t iv e  EBV  s t a t u s  w i l l  b e  
e l i g i b l e .  Du r ing  t h e  t r i a l  a l l  p a t i e n t s  w i l l  b e  m o n i t o r e d  w i th  r e g u l a r  a s s e s sm e n t s  o f  
h em a to logy ,  EBV- s t a tu s  a s  p e r  lo c a l  p r a c t i c eand  c l in i c a l  s ign s  a n d  sy mp tom s  
( s e eA s s e s sm e n ts ch edu l e ) .
3 .6 .1 .4 Th rombos is
T h e r e  i s  a  hy po th e t i c a l  r i s k  fo r  th rombo embo l i c  c om p l i c a t i o n s  w h e n  t a rg e t ing  th e  
CD 4 0- CD 1 5 4  c o - s t imu l a to ry  p a thw ay .Th i s  r i sk  i s  b a s e d  o n  c l i n i c a l  r e su l t s  f r om  p r e v i o u s  
c om p o u n d s  w h i c h  h a v e  t a r g e t e d  CD 1 5 4  a n d  r e su l t ed  in  a  f a t a l  hy p e r c o a g u l a b l e  ph eno ty p e .
 
 
D u r i n g  th e  P h a s e  1  p r o g r am ,  a  fo cu s  on  c o a g u l a t i o n  w a s  
i n c l u d e d  i n  t h e  t r i a l ,  i n c l u d i n g  r e g u l a r  h em a t o l o g y ,  PT ,  aPTT  and  th rombo e l a s tog r aphy  (TEG ) .  
I n  a d d i t i o n ,  t h e r e  h av e  b e e n  n o  r e p o r t s  o f  th rombo embo l i c  c om p l i c at ion s  w i th  t h e  n o n - F c  
s i l en t  c om p e t i t o r  a n t i - CD 4 0  an t ibody  A SKP1240  (A s t e l l a s  P h a rm a;  G o l dw a t e re ta l2 0 1 3;  
Y ange ta l2 0 1 2) .
I n  P a r t  1o f  th i s  s tudy ,  o n e  p a t i e n t  s u f f e r e df rom  d e e p  v e i n  t h r om b o s i s(DVT ) ,  p u lm o n a r y  
embo l i sm  (PE )  a n d  dy spn e a .  V enou s  t h r om b o t i c  e v e n t s  a r e  k n ow n  to  o c cu r  in  p a t i e n t s  a f t e r  
r e n a l  t r a n s p l a n t a t i o n  w i th  p u b l i s h e d  l i t e r a t u r e  s u g g e s t i n g  a  r i sk  o f  u p  to  8 .3%  
( A n d r a s sye ta l2 0 0 4) .  I n  a dd i t ion ,  t h e  m ed i c a l  h i s to ry  o f  th i s  p a t i en t  in c lud ed  k idn ey  d i s e a s e ,  
sm o k i n g ,  d i a b e t e s ,  ob e s i ty ,  a  s ed en t a ry  l i f e s t y l e ,  a n d  t a c ro l imu s  u s e  a n d  a r e  a l l  l ik e ly  t o  b e  
con t r ibu to ry  f a c t o r s  to  t h e  t h r om b o em b o l i c  ev en t s  o b s e r v e d .  Th e r ef o r e ,  g i v e n  th e  av a i l ab l e  
i n f o rm a t i o n ,  t h e  c a u s a l  r e l a t i o n s h i p  b e tw e e n  CFZ 5 3 3  a dm i n i s t r a t i o n  a n d  th e s e  
t h r om b o em b o l i c  e v e n t s  r em a i n s  u n c l e a r ,  how ev e r ,  c a n n o t  b e  d e f in i t iv e ly  e x c lud ed ,  and  
t h e r e f o r e  t h e  i n c i d e n t  w a s  c l a s s i f i e d  a s  SUSAR.   
3 .6 .2 Adjunc t  immunosupp ress ion
T h e  c om b i n a t i o n  o f  CFZ 5 3 3  a n d  ad jun c t  imm u n o s u p p r e s s i o n  w i th  T a c
( e . g .P rog r a f®P I2 0 1 3) ,  MMF  ( e . g .  C e l lC ep t®  P I  2013) ,  b a s i l ix im ab  ( e .g .  S im u l e c t®P I 2011 )  
a n d  CSi s  n o t  k n ow n .  P l e a s e  r e f e r  to  t h e  l o c a l  l a b e l i n g  f o r  t h e  o t h e r  ag en t s  f o r  f u l l  d i s c l o s u r e  
o f  t h e  e x p e c t e d  r i s k s  a s s o c i a t e d  w i th  u s e  in  t h e  s e t t i n g  o f  d e  n o v or e n a l  t r a n sp l a n t a t i o n  f o r  t h e  
i n v e s t i g a t i o n a l  a rm s  a s  w e l l  a s  c o n t r o l .  
3 .6 .3 R isk  m i t iga t ion  s t ra tegyCo rpo ra te  Con f iden t ia l  In fo rma t ion
 
 
 Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  62
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
W i th  i n i t i a l  a dm i n i s t r a t i o n  o f  a  b i o l o g i c ,  t h e  f i r s t  4  ho u r s  o f  e x p o s u r e  a r e  mo s t  c r i t i c a l  w i t h  
mo s t  i n f u s i o n  r e a c t i o n s  ( i n c l u d i n g  hy p e r s en s i t iv i ty ,  cy t o k i n e  r e l e a s e ,  an aphy l ax i s )  o c c u r r i n g  
w i th in  t h e  f i r s t  2  h o u r s  o f  e x p o s u r e  ( T a b r i zi  a n d  Ro sko s  20 0 7) .   
Cytok in e  
r e l e a s e  o r  a n a p h y l ax i s  h a s  no t  b e e n  r e p o r t e d  w i th  s im i l a r  c om p o u n d s  t a r g e t i n g  th e  CD40  
r e c e p t o r .P a t i e n t s  w i l l  r e c e i v e  th e i r  f i r s t  do s e  o f  CFZ 5 3 3  in  t h e  p r e-to  i n t e r - o p e r a t i v e  t im e  
p e r i o d ,  a  t im e  w h e r e  p a t i en t s  a r e  u n d e r  t h e  c l o s e  s u p e r v i s i o n  o f  c l in i c a l  s t a f f  in  a  h o s p i t a l  
e n v i r o nm e n t .  A ny  in fu s ion  r e l a t e d  r e a c t i o n s  c an  b e  m a n a g e d  a t  t h a t  t im e  in  a cc o r d a n c e  w i th  
l o c a l  p r o t o c o l s .  
C o n s i d e r i n g  th e  e x p e c t e d  immuno supp r e s s iv e  n a t u r e  o f  t h e  c om p o u n da l o n e  and  in  
c om b i n a t i o n  w i th  i n d u c t i o n  a n d  a d j u n c t  imm u n o s u p p r e s s i v e  a g e n t s ,  p a t i en t s  w i l l  b e  s c r e e n e d  
f o r  a  h i s to ry  o f  TB .  A  n e g a t i v e  t e s t  r e s u l t  fo r  TB( PPD,Q u a n t iFe ron  t e s t  o r  ch e s t  X -r ay )  th a t  
h a s  b e en  p e r f o rm e d  w i th in  6  mon tho f  r andom i z a t ion  w i l l  b e  r e q u i r e d  p r i o r  to  en ro l lm en t .  
T e s t s  w i l l  b e  p e r fo rm ed  p e r i o d i c a l ly  d u r i n g  th e  t r i a l .  I f  t h e r e  i s  s u s p i c i o n  o f  TB ,  a  c h e s t  x - r ay  
m ayb e  p e r f o rm e d  in  a c c o r d a n c e  w i th  l o c a l  g u i d e l i n e s;  s u b j e c t s  w i th  a  p o s i t i v e  t e s t  w i l l  b e  
e x c l u d e d  f r om  p a r t i c ip a t ion.  P a t i e n t s  w i l l  b e  s c r e e n e d  fo rE p s t e i n -B a r r  v i r u s  and  i f  
s e r o - n eg a t iv e ,ex c lud ed  f r om  p a r t i c i p a t i o nin  P a r t  1  d u e  to  t h e  h igh  imm u n o s u p p r e s s i v e  
b u r d e n  e x p e c t e d  in  th i s  c o h o r t .  P rophyl ax i s  f o r  CMV  a n d  PCP  w i l l  b e  a dm i n i s t e r e d  to  a l l  
p a t i e n t s  d u r i n g  t h e  t r i a l  a c c o r d i n g  t o  l o c a l  p r a c t i c e .
P a t i e n t s  w i l l  h o s p i t a l i z e d  f o r  t h e  f i r s t  f ew  d ay s  p o s t- t r a n s p l a n t  a n d  w i l l  r e t u r n  to  t h e  c l i n i c  
f r e q u e n t l y  du r ing  t h e  f i r s t  mon th  w i tha  p rog r e s s iv e ly  i n c r e a s ing  v i s i t  w i n d ow  a s  t h e  s tudy  
p r o g r e s s e s  to  mon th ly v i s i t s  a t  M o n t h  6  t h r o u g h  1 2 .  D u r i n g  t h e s e  v i s i t s  s a f e t y ,  e f f i c a cy  a n d  
PK /PD  a s s e s sm e n t sw i l l  b e  c o l l e c t e d .  S t a n d a r d  s a f e t y  a s s e s sm e n t s  w i l l  i n c l u d e  v i t a l  s i g n s ,  
phy s i c a l  ex am in a t i o n s ,  ECG s ,  c l i n i c a l  l a b o r a t o r y  e v a l u a t i o n s  (h em a to logy ,  b l o o d  c h em i s t r y  
and  u r in a ly s i s ) ,  AEs  and  SAEs  mon i to r ing  a s  ou t l in ed  in  th e  A s s e s sm e n t  s c h e d u l eCo rpo ra te  Con f iden t ia l  
In fo rma t ion
.In  add i t ion  
to  s t a n d a r d  c l i n i c a l  l a b o r a t o r y  a s s e s sm e n t s ,  s u b j e c t s  w i l l  b e  m o n i t o r e d  r e g u l a r l y  f o r  s i g n s  and  
sy mp tom s  o f  in f e c t iou s ,  in f l amm a to ry,  h em a to log i c  o r  r en a l  tox i c i ty  a s  o u t l in e d  b e l ow .
P a t i e n t s  w i l l  b e  r e g u l a r ly  e v a l u a t e d  w h i l e  d om i c i l e d  a n d  u p o n  r e t u r n  t o  t h e  c l i n i c  f o r  s i g n s  a n d  
sy mp tom s  w h ic h  m i g h t  i n d i c a t e  a  s e v e r e  in f e c t ion ,  i . e . ,  f e v e r ,  n a u s e a ,  mya l g i a ,  h e ad a ch e ,  
a r t h r a l g i a ,  ch i l l s ,  d i a r rh e a ,  s t i f f  n e ck ,  and  m a l a i s e ,  and  t r e a t ed  a s  app rop r i a t e  p e r  lo c a l  p r a c t i c e  
d e p e n d i n g  o n  t h e  in f e c t iou s  a g e n t .  P a t i e n t s  w i l l  b e  i n f o rm e d  to  r e p o r t  a n y  o fth e  
a f o r em e n t i o n e d  sy mp tom s  to  t h e  c l i n i c a l  s t a f f  to  a s s u r e  p rop e r  a s s e s sm en t  a n d  c a r e  c an  b e  
a dm i n i s t e r e d  i n  a  t im e l y  m a n n e r .
V i r a l  r e a c t i v a t i o n  w i l l  b e  a s s e s s e d  fo r  EBV,  CMVa n d  BK  a c c o r d i n g  to  l o c a l  p r a c t i c e  o n  a  
r e g u l a r  b a s i s .
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  63
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
I n  a g r e em e n t  w i th  t h e  s e cond a ry  o b j e c t iv e s ,  ch a n g e s  in  r e n a l  f u n c t i o n  w i l l  b e  a s s e s s e d  v i a  
s e r um  c r e a t i n i n e  a n d  c a l c u l a t e d  c r e a t i n i n e  c l e a r a n c e  (MDRD ) .  
 
 
Hyp e r co agu l ab i l i ty  a nd  c o a g u l o p a t h y  w i l l  b e  a s s e s s e d  u s ing  s t a n d a r d  c o a g u l a t i o n  s t u d i e s ,  
i n c l u d i n g  p r o t h r omb in  t im e  (PT )a n d  a c t i v a t e d  p a r t i a l  t h r om b o p l a s t i n  t im e  ( aPTT )a c c o r d i n g  
t o  l o c a l  p r a c t i c e .
F in a l ly,k ey  s a f e t y  d a t a  w i l l  b e  r e v i ew e d  by  t h eS p o n s o r  in  a  b l i n d e d  m a n n e r  in  a n  o n g o i n g  
b a s i s .  A  DMC  w i l l  r ev i ew  u n - b l i n d e d  s tudy  d a t a  r e g u l a r l y  a n d  on  a n  ad  h o cb a s i s  to  a s s e s s  
w h e t h e r  t h e  b e n e f i t / r i s k  o f  e a c h  t r e a tm e n t  a rm  r em a in s  a c c e p t a b l e .  Ap r io r id e f i n e d  s topp ing  
c r i t e r i a  a n d  g u i d e l i n e s  ( S e c t i o n  5 . 5 . 1 0)  in  a d d i t i o n  to  t h e  c l i n i c a l  op in iono f  t h e  I n v e s t i g a t o r  
a n d  b iop sy  r e s u l t s  m a n a g e d  p e r  lo c a l  p r a c t i c e  w i l l  b e  u s e d  to  p ro t e c t  i n d iv i d u a l  p a t i e n t  s a f e t y  
d u r i n g  t h e  t r i a l .  
 
 
 
 
 
 C a s e s  o f  s e r i o u s  i n f e c t i o n s  
o r  n e o p l a sm s  w i l la l s o  b e  m o n i t o r e d  a n d  r e v i ew e d  o n  a n  o n g o i n g  b a s i s .  
B a s e d  o n  th e  in fo rm a t ion  o u t l i n ed  a b o v e ,  th e  r i sk  o f  a dm i n i s t e r i n g  CFZ533  in  comb in a t ion  
w i th  MMF ,  c o r t i c o s t e r o i d s ,  a n d  b a s i l i x im a b  a s  w e l l  a s  a d d  o n  to  a  T a c- b a s ed  s t a n d a r d  o f  c a r e  
r e g im e n  a p p e a r s  m an ag e a b l e  a n d  r e a s o n a b l e  to  i n v e s t i g a t i n g  t h e  c l i n i c a l  a c t iv i ty  o f  CFZ533  
i n  t h e  i n t e n d e d  p a t i e n t  p o p u l a t i o n .
4 Popu la t ion
P a r t s  1  a n d  2  ( in i t i a l  PoC  p h a s e )  o f  th i s  mu l t i c en t e r  s tudy  w i l l  b e  c o n d u c t e d  in  a p p r o x im a t e l y  
2 0  c e n t e r s  w o r l dw i d e .  Th e  s tudy  p opu l a t ion  o f  P a r t s  1  a n d  2  w i l l  c o n s i s t  o f  app rox im a t e ly  
5 1m a l e  a n d  f em a l e  d e  n o v o  a d u l t  r e n a l  t r a n sp l a n t  p a t i e n t s .
T h eI nv e s t ig a to r  mu s t  e n s u r e  t h a t  a l l  s u b j e c t s  b e i n g  c o n s i d e r ed  f o r  t h e  s tudy  m e e t  th e  
f o l l ow i n g  e l ig ib i l i ty  c r i t e r i a .  N o  a d d i t io n a l  c r i t e r i a  s h o u l d  b e  a p p l i e d  b y  th e  I nv e s t ig a to r ,  
ino r d e r  t h a t  t h e  s t u dy  p o p u l a t i o n  w i l l  b e  r e p r e s e n t a t i v e  o f  a l l  e l i g i b l e  s u b j e ct s .
S u b j e c t  s e l e c t i o n  i s  to  b e  e s t a b l i s h e d  by  c h e ck ing  t h r o u g h  a l l  in c lu s ion / ex c lu s ion  c r i t e r i a  a t  
s c r e e n i n g / b a s e l i n e .  A  r e l e v a n t  r e c o r d  ( e . g . ,  ch e ck l i s t )  o f  t h e  e l ig ib i l i ty  c r i t e r i a  mu s t  b e  s to r ed  
w i t h  t h e  s o u r c e  d o c um e n t a t i o n  a t  t h e  s t u d y s i t e .
D e v i a t i o nf r om  any  Co rpo ra te  Con f iden t ia l  
In fo rma t ion
en t ry  c r i t e r ion  ex c lud e s  a  sub j e c t  f rom  en ro l lm en t  in to  th e  s tudy .Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  64
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
4 .1 Inc lus ion  c r i te r ia
S u b j e c t s  e l i g i b l e  f o r  i n c l u s i o n  i n  t h i s  s t u d y  h a v e  t o  f u l f i l l  a l lo f  t h e  f o l l ow i n g  c r i t e r i a :
1 .W r i t t e n  i n f o rm e d  c o n s e n t  m u s t  b e  o b t a i n e d  b e f o r e  a n y a s s e s sm en t  i s  p e r fo rm ed .
2 .M a l e  o r  f em a l e  p a t i e n t s  ≥18  y e a r s  o l d .
3 .R e c i p i e n t s  o f  a  k i d n e y t r a n s p l a n t  f r om  a  h e a r t - b e a t i n g  d e c e a s e d ,  l i v i n g  u n r e l a t e d  o r  n o n -
hum an  l euko cy t e  a n t i g e n  (HLA )  i d e n t i c a l  l i v i n g  r e l a t e d  d o n o r .
4 .R e c i p i e n t s  o f  a  k i d n e y w i th  a  co ld  i s ch em i a  t im e  (C I T )<  3 0  h o u r s .
5 .A b l e  t o  c omm u n i c a t e  w e l l  w i t h  t h e  I n v e s t i g a t o r ,  t o  u n d e r s t a n d  a n d  com p l y  w i t h  t h e  
r e q u i r em e n t s  o f  t h e  s t u d y .
4 .2 Exc lus ion  c r i te r ia
S u b j e c t s  f u l f i l l i n g  anyo f  t h e  f o l l ow i n g  c r i t e r i a  a r e  n o t  e l i g i b l e  f o r  i n c l u s i o n  i n  t h i s  s t u d y :
1 . U s e  o f  o t h e r  i n v e s ti g a t i o n a l  d r u g s  a t  t h e  t im e  o f  e n r o l lm e n t ,  o r  w i t h i n  3 0  d a y s  o r  5  h a l f -
l i v e s  o f  e n r o l lm e n t ,  w h i c h e v e r  i s  l o n g e r .
2 . H i s t o r y o f  h y p e r s e n s i t i v i t y  t o  a n y  o f  t h e  s t u d y  d r u g s o r  t o  d r u g s  o f  s im i l a r  c h em i c a l  c l a s s e s .
4 . R e c i p i e n t s  of  a n  o r g an  f r om  a  n o n - h e a r t  b e a t i n g  d o n o r .
5 .  ABO  i n c om p a t i b l e  o r  c om p l em e n t - d e p e n d e n t  lym p h o c y t o to x i c  (CDC )  c r o s sm a t ch  
p o s i t i v e  t r a n s p l a n t  ( i s o l a t e d  p o s i t i v e  Bc e l l  c r o s sm a t c h e s  a r e  n o t  a n  e x c l u s i o n  c r i t e r i o n ) .
6 .  S u b j e c t sr e c e i v i n g  a  s e c o n d  k i d n e y  a l l o g r a f t ,  u n l e s sth e  f i r s t  a l l o g r a f t  w a s  l o s t  d u e  t o  
s u r g i c a l  c om p l i c a t i o n .
7 . S u b j e c t s  a t  h i g h  imm u n o l o g i c a l  r i s k  f o r  r e j e c t i o n  a s  d e t e rm i n e d  by  l o c a l  p r a c t i c e  f o r  
a s s e s sm e n t  o f  a n t i - d o n o r  r e a c t i v i ty  ( e . g . ,  h i g h  PRA  >  2 0% ,  p r e s e n c e  o f  p r e- e x i s t i n g  
1 0 .S u b j e c t s  a t  r i s k  f o r  t u b e r c u l o s i s  (TB ) ,  s p e c i f i c a l l y  s u b j e c t s  w h o :
H a v e  c u r r e n t  c l i n i c a l ,  r a d i o g r a p h i c  o r  l a b o r a t o r y e v i d e n c e  o f  a c t i v e  o r  l a t e n t  TB
H av e  a  h i s to ry o f  a c t iv e  TB
a .W i th in  th e  l a s t  2  ye a r s  e v e n  i f  i t  w a s  t r e a t e d
b .G r e a t e r  t h a n  2  y e a r s  a g o ,  u n l e s s  t h e r e  i s  d o c um e n t a t i o n  o f  a d e q u a t e  t r e a tm en t  
a c c o r d i n g  t o  l o c a l l y - a c c e p t e d  c l i n i c a l  p r a c t i c e
Co rpo ra te  Con f iden t ia l  In fo rma t ion
I n  t h e  o p i n i o n  o f  t h e  I n v e s t i g a t o r  a n d  b a s e d  u p o n  a n  a p p r o p r i a t e  e v a l u a t i o n ,  h a v e  a  
1 3 .S u b j e c t  w i t h  s e v e r e  sy s t em i c  i n f e c t i o n s ,  c u r r e n t  o r  w i t h i n  t h e  tw o  w e e k s  p r i o r  t o  
r a n d om i z a t i o n / e n r o l lm e n t .Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  65
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
1 6 .H i s to ry o f  m a l ign an cy  o f  anyo rg an  sy s t em  ( o t h e r  t h a n  l o c a l i z e d  b a s a l  c e l l  c a r c i n om a  o f  
t h e  s k i n ) ,  t r e a t e d  o r  u n t r e a t e d ,  w i t h i n  t h e  p a s t  5  y e a r s ,  r e g a r d l e s s  o f  w h e th e r  t h e r e  i s  
e v i d e n c e  o f  l o c a l  r e c u r r e n c e  o r  m e t a s t a s e s .
1 8 .P r e g n a n t  o r  n u r s i n g  ( l a c t a t i n g )  w om e n ,  w h e r e  p r e g n a n c y i s  d e f in e d  a s  t h e  s t a t e  o f  a  
f em a l e  a f t e r  c o n c e p t i o n  a n d  u n t i l  t h e  t e rm i n a t i o n  o f  g e s t a t i o n ,  c o n f i rm e d  b y  a  p o s i t i v e  
hCG  l abo r a to ry  t e s t .
1 9 .W om e n  o f  c h i l d- b e a r i n g  p ot e n t i a l ,  d e f i n e d  a s  a l l  w om e n  p h y s i o l o g i c a l l y  c a p a b l e  o f  
b e c om i n g  p r e g n a n t ,  u n l e s s  t h e y  a r e  u s ing  h igh ly  e f f e c t i v e  m e t h o d s  o f  c o n t r a c ep t i o n  
d u r i n g  d o s i n g  a n d  f o r  1 2  w e e k s  a f t e r  t h e  s t u dy  m e d i c a t i o n s  h a v e  b e e n  s t o p p e d .  H i g h ly  
e f f e c t i v e  c o n t r a c e p t i o n  m e t h o d si n c l u d e :
T o t a l  a b s t i n e n c e  (w h e n  t h i s i s  i n  l i n e  w i t h  t h e  p r e f e r r e d  a n d  u s u a l  l i f e s t y l e  o f  th e  
s u b j e c t .  P e r i o d i c  a b s t i n e n c e  ( e . g . ,  c a l e n d a r ,  o v u l a t i o n ,  s y mp to th e rm a l ,  po s t- ov u l a t i o n  
m e t h o d s )  a n d  w i t h d r aw a l  a r e  n o t  a c c e p t a b l e  m e t h o d s  o f  c o n t r a c e p t i o n .
F em a l e  s t e r i l i z a t i o n( h a v e  h a d  s u r g i c a l  b i l a t e r a l  o o p h o r e c t om y  w i t h  o r  w i t h o u t  
hy s t e r e c t om y )  o r  t u b a l  l i g a t i o n  a t  l e a s t  s i x  w e e k s  b e f o r e  t a k i n g  s t u dy  t r e a tm e n t .  I n  
c a s e  o f  o o p h o r e c t om y  a lon e ,  on ly  w h e n  t h e  r e p r o d u c t i v e  s t a t u s  o f  t h e  w om a n  h a s  
b e e n  c o n f i rm e d  by  f o l l ow  u p  h o rm o n e  l e v e l  a s s e s sm e n t .
M a l e  s t e r i l i z a t i o n  ( a t  l e a s t  6  m o n t h s  p r i o r  t o  s c r e e n i n g ) .  F o r  f em a l e  s u b j e c t s  o n  t h e  
s tudy ,  t h e  v a s e c t om i z e d  m a l e  p a r t n e r  s h o u l d  b e  t h e  s o l e  p a r t n e r  f o r  t h a t  s u b j e c t .
Comb in a t ion  o f  any tw o  o f  t h e  f o l l ow i n g  ( a+ b  o ra+ c ,  o r  b+ c ) :
a .U s e  o f  o r a l ,  i n j e c t e d  o r  im p l a n t e d  h o rm o n a l  m e t h o d s  o f  c o n t r a c e p t i o n  o r  o t h e r  
f o rm s  o f  h o rm o n a l  c o n t r a c e p t i o n  t h a t  h a v e  c om p a r a b l e  e f f i c a c y  ( f a i l u r e  r a t e  < 1% ) ,  
f o r  e x am p l e ,  h o rm o n e  v a g i n a l  r i n g  o r  t r a n s d e rm a l  h o rm o n e  c o n t r a c e p t i o n .Co rpo ra te  Con f iden t ia l  In fo rma t ion
b .P l a c em e n to f  a n  i n t r a u t e r i n e  d e v i c e  ( IUD )  o r  i n t r a u t e r i n e  sy s t em  ( IUS ) .
c .B a r r i e r  m e t h o d s  o f  c o n t r a c e p t i o n :  C o n d om  o r  O c c l u s i v e  c a p  ( d i a p h r a gm  o r  
c e r v i c a l / v a u l t  c a p s )  w i t h  s p e rm i c i d a l  f o am / g e l / f i lm / c r e am / v a g i n a l  s u p p o s i t o r y .
I n  c a s e  o f  u s e  o f  o r a l  c o n t r a c e p t i o n  w om e ns h o u l d  h a v e  b e e n  s t a b l e  o n  t h e  s am e  b r a n d  (o r  
g e n e r i c  e q u i v a l e n t )  f o r  a  m i n im um  o f  3  m o n t h s  b e f o r e  t a k i n g  s t u dy  t r e a tm e n t .
Wom en  a r e  c o n s i d e r e d  p o s t- m e n o p a u s a l  a n d  no t  o f  c h i l d  b e a r i n g  po t en t i a l  i f  th ey  h a v e  h ad  
1 2mon th s  o f  n a t u r a l  ( s p o n t a n e o u s )  am e n o r r h e a  w i th  a n  a p p r o p r i a t e  c l i n i c a l  p r o f i l e  ( e . g . ,  ag e  
a p p r o p r i a t e ,  h i s to ry  o f  v a somo to r  sy mp tom s )  o r  h a v e  h a d  s u r g i c a l  b i l a t e r a l  o o p ho r e c tom y  
(w i t h  o r  w i thou t  hy s t e r e c tomy )  o r  t u b a l  l ig a t ion  a t  l e a s t  s ix  w e e k s  a g o .  I n  th e  c a s e  o f  
o o p h o r e c t omy  a l o n e ,  on ly  w h e nt h e  r ep rodu c t iv e  s t a t u s  o f  th e  wom an  h a s  b e e n  c o n f i rm e d  by  C
o
r
p
o
r
a
t
e  
C
o
n
f
i
d
e
n
t
i
a
l  
I
n
f
o
r
m
a
t
i
o
nCo rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis Confidential Page 66
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
follow up hormone level assessment is she considered not of child bearing potential. 
20. Any additional contraindication to the use of Tacor my cophenolate mofetil according to 
the national labeling information of these products (see local product label).
No additional exclusions may be applied by the Investigator, in order to ensure that the study 
population will be representative of all eligible patients.
5 Treatmen t
5.1 Protocol requested treatment
5.1.1 Investigational treatment
The following drugs will be used in this study  and will be administered in accordance with 
this protocol and where applicable, current local labeling. Not all dosage forms listed are 
available in each country , dependent on local approval status and regulations. The treatment 
regimen to which subjects are randomized comprises of up to four components: MMF 
(allstudy  parts), CS (all study  parts), CFZ533 and/or Tac(both in Part 1; either one in Part 2 )
and basiliximab (Parts 2 only ).
CFZ533 isprovided as 150 mg/mL  lyophilized open -label bulk medication requiring 
reconstitution. CFZ533 150 mg/mL  concentrate for solution for infusion/ solution for 
injection (liquid in vial) will be introduced . Instructi ons for preparation and administration 
to be described in a separate pharmacy  manual. 
5.1.2 Control and concomitant drugs
Concomitant medication will be used according to label.
Tac(e.g. Prograf®or Generics ) as 0.5 mg, 1.0 mg or 5.0 mg capsules or tablets
Mycophenolate mofetil ( e.g. CellCept®or Generics ) 250 mg or 500 mg film- coated 
tablets, or 250 mg capsules, or 500 mg vial for IVadministration
Basiliximab as 20 mg ly ophilized vial for IVadministration following reconstitution with 
sterile water.
CSfor oral and IV administration, MMF, Tacand basiliximab will be supplied locally . 
5.1.3 Additional study treatment
No additional immunosuppressive agents may be used other than what is defined as per 
protocol. Concomitant therapies are as described below in Section 5.5.8 .
5.2 Treatment arms
In Part 1, s ubjects will be enrolled into Arm 1 .In Part 2, subjects will be randomized to one of 
the Arms 2A -2B. Study  treatments are defined as:
Part 1
Arm 1 ,n=6: CFZ533 at 3.0 mg/kg SC (5 doses; first dose IV) + Tac (4-11ng/mL) + MMF 
1.0g BID + CS
Part 2 
Novartis Confidential Page 67
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Arm 2A,n=30: Basiliximab 20 mg (Day s 1, 4) + CFZ533 at 10 mg/kg IV ( 17doses) + 
MMF 1.0 g BID + CS
Arm 2B Control/Standard of Care , n=15: Basiliximab 20 mg (Day s 1, 4) + Tac
(4-11 ng/mL) + MMF 1.0 g BID + CS
5.3 Treatment assignment
Randomization/Treatment numbers will be assigned to eligible subjects in Part 2 
(seeSection 5.5.1 for details) prior to surgery . If provided, the Investigator will enter the 
randomization/treatment number onto the Electronic Case report Form ( eCRF ).
Patients in Part 1 will be enrolled sequentially  across centers and will keep their screening/ 
subject number throughout the tr ial. Patients in Part 2 will be randomized 2:1 to Arms 2A:2B. 
The randomization/treatment numbers will be generated using the following procedure to 
ensure that treatment assignment is unbiased and concealed from subjects and Investigator 
staff, as applic able: 
For Part 1, the Investigator or his/her designee will contact the Sponsor at screening or 
baseline and confirm the subject fulfills the population criteria. 
For Part 2, IRT will be used .IRT is a validated s ystem that automates the random 
assignmen t of treatment arms to randomization numbers in the specified ratio. The 
Investigator or his/her designee will log into the IRT system at screening or baseline and 
confirm that the subject fulfills the population criteria. The IRT will assign a 
randomizati on number to the patient, which will be used to link the patient to a treatment 
arm. Detailed instructions on the use of the IRT can be found in the separate I RT manual. 
5.4 Treatment blinding
This is an open -label , exploratory study  and it is not planned to blind patients or site staff to 
treatment . In Part 1 since there is just one treatment arm, it will be known to the whole 
Clinical Trial Team that the subjects all received 3mg/kg CFZ533. In Part 2,core Clinical 
Trial Team members will be unblinded to continuously  review safet y and clinical data and 
evaluate the stopping rules. 
5.5 Treating the subject
5.5.1 Subject numbering
Subject number
Each subject is uniquely identified by a subject number assigned by Novartis or IRT system 
which is composed of a site number and a sequential number at each site. Once assigned, the 
Subject Number will not be re -used and will be the primary  identifier for the subject in the study .
For Part 1, upon signing the informed consent form, the subject is assigned the next sequential 
subject number as given by the Investigator using the next blank eCRF book available from 
the EDC sy stem. 
If the subject fails to be randomized or treated for any reason, the reason will be entered into 
Novartis Confidential Page 68
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
the Screening Disposition eCRF.
For Part 2, upon signing the informed consent form, the subject is assigned the next sequential 
subject number by the Investigator via Interactive Response Technology  (IRT). The 
Investigator or his/her staff will log into the IRT system and provide the requested identify ing 
information for the subject to register them into the IRT. The site should select the eCRF book 
with a matching Randomization Number from the EDC sy stem to enter data.
If the subject fails to be treated for any reason, the IRT should be updated within 2 days that 
the subject was not treated, the reason will be entered into the Screening Disposition eCRF.
Randomization/treatment number
In addition to the subject number primary  identifier, subjects in randomized studies will also 
be assigned a randomization/treatment number linked to treatment. Once the subject is 
deemed eligible for randomization/enrollment, the randomization/treatment number will be 
assigned. Once assigne d to a subject, the randomization/treatment number will not be reused.
Patients will keep the subject num ber throughout the trial.
5.5.2 Dispensing the study treatment
The investigational drug, CFZ533 will be prepared by Novartis and supplied to the 
Investigato rs as open -labeled bulk medication.
For preparation of the study  medication in Part 2, the unblinded pharmacist or designee at the 
Investigator’s sitewill need to log into the IRT system to receive the treatment code . In 
addition, theunblinded pharmacist or designee at the Investigator’s site will prepare the 
medication for administration to subjects based on a separate pharmacy  manual.
Appropriate documentation of the subject specific dispensing process must be maintained.
Bulk medication labels will be in the local language, will comply  with the legal requirements of 
each country , and will include storage conditions for the drug but no information about the subject.
Each patient will be supplied by the study  site with commercial drugs. Commercial Novarti s 
drugs and/or 3rdparty  drugs used for this trial will be locally  purchased and supplied either by  
the local CPO or by the clinical site per local regulations. In exceptional cases, central suppl y 
may be carried out.
5.5.3 Handling of study  treatment
5.5.3.1 Handling o f investigational treatment
Investigational treatment must be received at the study  site by a designated person, handled 
and stored safel y and properly , and kept in a secured location to which only the Investigator 
and designated staff have access. Upon receipt, the study  drugs should be stored according to 
the instructions specified on the labels.
Storage conditions must be adequatel y monitored and appropriate temperature logs 
maintained as Source data.
The Investigator must maintain an accurate record of the shipment and dispensing of study 
Novartis Confidential Page 69
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
drug in a drug accountability  ledger. Drug accountability  will be noted by the Monitor during 
site visits and/or at the completion of the trial.
All drug supplies are to be used only for this protocol and not for any other purpose. 
Unless specifically  instructed by Novartis, the Investigator must not destroy any drug labels, 
or an y partl y used or unused drug supply.
At the conclusion of the study , and, if allowed during the course of the study  (e.g., an open -
label study  or an unblinded monitor), the Investigator will provide a copy of the drug 
accountability  ledger to the monitor.
Only  after receiving a written authorization by Novartis, the Investigator/designee will send 
all the unused and partly used drug supplies as well as the empty  containers to the address 
provided at the time of authorization for destruction, or have the unused and partly used drug 
supplies as well as the empty  containers destro yed by the site’s pharmacist, providing a drug 
destruction certificate.
5.5.4 Instructions for prescribing and taking study treatment
The Investigator will dispense the appropriate amount of study  drugs to cover each visit and 
additional drug in case of loss, breakage, or scheduling problems. Drug accountability  will be 
performed to assess compliance. The Investigator should promote complianc e by instructing 
the patient to take the study  drug exactly  as prescribed and by stating that compliance is 
necessary  for the patient’s safet y and the validity  of the study . The patient should be 
instructed to contact the Investigator if he/she is unable for any reason to take the study  drugs 
as prescribed.
If MMF, Tacand/or CSare part of the assigned regimen, they will be taken concomitantly  as 
per standard of local practice. The study  drugs may be taken with or without food, but in a 
consistent fashion. Special attention must be taken to avoid concomitant administration of 
drugs, food or beverages which are known to be a strong indu cer or inhibitor of CYP3A4 
(seeAppendix 5 ).
All drug trough levels assessed in this study  (CFZ533, Tac, MPA) will be measured per the 
Assessment schedule or as per local practice (Tac/ MPA) .For all samples sent for central 
analysis, the exact time and the date of sampli ng, together with the exact time and date of the 
last study  medication dose prior to the sampling must be recorded on the central laboratory 
request form (refer to the separate Laboratory  Manual). CFZ533 and MPA will be measured 
in plasma and Tacwill be measured in whole blood samples. The patient will be instructed 
not to take his/her morning dose of immunosuppressant medications the day of a scheduled 
sampling, to record the medication dosage and time of last dose on the day prior to the blood 
sampling, and to bring all study  drugs to the visit so that a dose may be administered upon 
completion of blood sampling. 
All dosages of CFZ533 (all parts) , MMF and Tacand all dose changes during the study  must 
be recorded, with reason for administration, on the corresponding Dosage Administration 
Record eCRF. 
All immunosuppressive drugs used and dosages administered must be recorded during the 
study . All changes to the immunosuppressive medication dosing regimen should be recorded 
Novartis Confidential Page 70
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
in the appropriate eCRF, along w ith the reason for change and dates. 
Induction therapy , pre and post -transplant immunosuppression
For patients randomized to the control arm or where Tac, MMF and/or steroids are to be 
administered per protocol, they may be administered prior to transplant according to center 
practice but such practice must be applied consistently  to all subjects at a given center. 
Atrandomization/enrollment, all subjects must follow the assigned regimen. Pre-transplant 
immunosuppression, including induction therap y and any Tac or MMF should be recorded on 
the Concomitant medication eCRF under the Immunosuppressive category.
Basiliximab induction therapy
Subjects randomize d to receive induction therap y will receive 2 x 20 mg doses of basiliximab 
administered IV. The first dose should be given within 2 hours prior to transplant surgery , and 
the second dose should be administered on Day 4  p ost-transplant, or according to local 
practice. 
The 20 mg vial should be reconstituted with 5 mL sterile water. The resultant solution is 
isotonic and may be injected as an IV bolus. Alternativel y, the solution may be diluted to a 
volume of 50 mL with sterile saline and 5% dextrose and admi nistered as an infusion over 
30minutes. If venous irritation occurs following bolus administration, the next dose 
(ifappropriate) should be administered as a 30 minute infusion. There is no maintenance dose, 
and no other antibodies are permitted for induction therap y. All basiliximab doses and 
changes must be recorded in the Concomitant Medications eCRF under the 
Immunosuppressive category .
CFZ533 therapy
CFZ533 will be administered by IVinfusion or SCinjection to the patient by authorized 
Investigator staff at each visit specified in the Assessment schedule .
The first dose of CFZ533 will be administered IVpre-transplant or intra-operativel y. Drug 
administration will begin after randomiza tion/enrollment and must be completed up to 6 hours 
prior to or at the time of unclamping.
The study  medication preparation and administration guidelines are described in a separate 
pharmacy  manual. The subject will be weighed at the Baseline visit and thi s weight value will 
be used for the initial study  medication preparation and the calculation of the dose. 
Most actual weight will serve as basis for further dose calculations.
All dosages prescribed and dispensed to the subject and all dose changes during the study 
must be recorded on the CFZ533 Dose Administration Record eCRF. Patients can be released 
after each treatment if deemed appropriate b y the Investigator.
MMF administration
Mycophenolate mofetil will be 2 tablets of 500 mg or 4 capsules of 250 mg b.i.d. (2 g/day ). 
For patients who remain intubated >24 hours post-transplant and/or whom are otherwise 
unable to swallow oral medication, IVMMF may be substituted until oral conversion is 
Novartis Confidential Page 71
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
possible.
The first dose of MMF will be administered immediately  after randomization/enrollment and 
no later than 24 hours after graft reperfusion of the allograft or according to local practice . 
Dose adjustment/interruption guidance for MMF is provided in Appendix 4. All MMF doses 
and changes must be recorded on the MMF Dose Administration Record eCRF (Part 1) and 
Concomitant Medications eCRF under the Immunosuppressive category (Part 2) . 
Tacrolimus administration
Tac will be administered as PO capsules b.i.d. and adjusted to maintain within the target 
ranges of 4-11 ng/mL . Tac should be initiated as soon as possible and no later than 24 hours 
after reperfusion of the graft. The lowest permitted dosing of Tacin this study  is 0.5 mg b.i.d. 
If Tacis discontinued for more than 21 consecutive days, and the study  regimen cannot be 
maintained, the patient must be discontinued from the randomized treatment and managed per 
local practice. Subjects who discontinue their study  regimen are expected to remain in the 
study  on standard of care to Month 6 in Part 1 or Month 12 in Part 2. 
Tacdosing will be modified by Investigators as needed and recorded on the Tacrolimus 
Dosage Administration Record (Part 1) and Concomitant Medication (Part 2)eCRF at each 
visit. In the event of Tac intolerance (e.g., nephrotoxicity , neurotoxicity ) dose reduction of 
Tacmay be necessary . If it occurs that the Tactrough level is outside the required target level, 
then the Investigator will be asked to confirm the intended Tactrough level, to reco rd the start 
date and reason for dose reduction on the Tacrolimus Dosage Administration Record (Part 1) 
and Concomitant Medication (Part 2 ) eCRF.
The co-administration of drugs known to interfere with Tac metabolism (seeAppendix 5) 
should be avoided if possible. If these drugs are required, the Investigator should carefull y 
monitor Tactrough levels. 
The patient will be instructed to record the time of the last dose on the day prior to the blood 
draw and to bring the morning dose to the visit so it may be administered after the blood 
sampling is completed.
Corticosteroids
CS will be administered according to local standard practice in a way that is consistent in all 
patients enrolled at each site. Dosi ng of CS should be recorded in the Concomitant 
Medications eCRF under the I mmunosuppressive category .
Novartis Confidential Page 72
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
5.5.5 Permitted dose adjustments and interruptions of study  treatment
In general, symptomatic treatment should be considered first to treat patients who have 
difficulties to tolerate their immunosuppressive regimen. However, for patients who are still 
unable to tolerate the protocol -specified study  treatment, dose adjustments and interruptions 
of study  drugs are permitted in order to keep the patient on study  treatment as follows below. 
MMF / MPA
Dose adjustment/interruption guidance for MMF is provided in Appendix 4. All MMF doses 
and changes should be recorded on the MMF Dose Administration Record eCRF (Part 1) and 
Concomitant Medications eCRF under the Immunosuppressive category (Part 2) .
MMF (e.g. Cellcept) is known to cause significant gastrointestinal side effects in some 
patients. In case of acute intolerance of MMF, other medications (e.g. Myfortic ) can be given 
to reach target mycophenolate trough levels when used according to drug label and as per 
local practice at the clinical sites. Each case should be discussed individually  with the Sponsor.
At clinical sites where mycophenolates other than MMF (e.g. M yfortic) are being used as SoC,
these drugs can be c onsidered instead of MMF after 
discussion with the Sponsor. 
Tacrolimus
Tac dosing will be modified by Investigators as needed and recorded on the Tacrolimus 
Dosage Administration (Part 1)and Tacrolimus Concomitant Medication (Part 2)eCRF at 
each visit. 
CFZ533
No dose adjustments beyond changes based on the patient’s weight are permitted to the 
CFZ533 dose during the study . 
In case of notable AEs, SAEs including loss of efficacy  and/or associat ed PK/PD data 
collected during the study , changes to the next planned dose level may be considered and 
implemented via an amendment. 
Treatment of A cute Rejection Episodes
In all suspected acute rejection episodes, regardless of initiation of anti -rejectio n treatment, an 
allograft biops y must be performed within 48 hours. Handling of biopsies is addressed in 
Section 6.5.1 .
All episodes of acute rejection must be entered on the corresponding eCRF (e.g., Acute 
Rejection eCRF, Kidney Allograft Biops y eCRF) preferabl y within 24 hours. Sites should 
complete a SAE form for all confirmed acute rejection events in Part 1 and 2 and inform 
Sponsor within 24h.
Acute rejections should be treated with bolus methy lpred nisolone (other CSare acceptable at 
an equivalent dose) according to local practice. Recommended treatment is with at least 3 
boluses of IV methylprednisolone with a minimal dose of 250 mg/bolus or at least 2 boluses 
of IV meth ylprednisolone with a minima l total dose of 750 mg.
Novartis Confidential Page 73
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Patients who experience steroid -resistant rejections, vascular rejections or rejections with a 
Banff grade ≥ 2B (Appendix 8) should be discontinued from study  treatment, converte d to 
local SoC and may  be treated with other anti- rejection therapies (i.e., antibody  therapy ).
All medications used for the treatment of suspected or confirmed acute rejections must be 
recorded on the Concomitant Medications eCRF under the Immunosuppressi ve category .
Management of signs of over-immunosuppression
CFZ533 was highly  effective in preventing renal transplant rejection in NHP when used as
monotherap y. Combining CFZ533 with MPA and CS after basiliximab induction may 
increase the risk for over-immunosuppression (e.g. BK viremia) . For CFZ533 to be effective ,
full inhibition of CD40 signaling is required . Reducing the CFZ533 dose is not advisable ,
since under -dosing of CFZ533 may trigger loss of immunosupp ression . In case of suspected 
over-immunosuppression clinical sites should first consider reducing the MPA level by 50 % 
or more (if MPA is completely stopped, CS may be slightly  increased) with a follow up 
within the next weeks as per local practice. If t here still are signs of over -immunosuppression, 
they should consider removing MPA and/or reduce CS. If there still are signs of over-
immunosuppression, or if the symptoms are severe, patient should be discontinued from 
CFZ533 and be switched to SoC.
Manag ement of BK viremia
In case of diagnosed BK virus inurine, MPA level s should be reduced as a first measure as 
described in the Section above “Management of signs of over-immunosuppression” .
Patients are considered to have significant BK viremia when their plasma PCR results report 
≥10,000 copies/mL  of BK virus ( Sood et al 2012 ). 
If a pati
ent is found to have BK viremia that reaches ≥10,000 copies/mL in plasma ,reducing/ 
stopping of MPA should be considered as a first measure . Ifpatient s have biopsy -proven BK 
nephropath ythey should be discontinued from their randomized treatment and be switched to 
standard -of-care treatment as per local center practice. 
Management of Patients with Delay ed Graft Function (DGF)
DGF for this trial is defined as:
A dialy sis performed within 7 day s of transplant
excluding up to two dialysis sessions to correct electrol yte abnormalities (e.g., 
hyperkalemia) in the post -transplant time period
In case a patient experiences DGF, the DGF is by definition starting at reperfusion after the 
transplantation procedure. If the graft dysfunction is starting later according to the 
Investigator, then this condition is considered secondary  graft dy sfunction. 
DGF must be reported as an AE for patie nts who experience DGF without requiring dialysis. 
In case DGF is reported as an AE and dialy sis is also reported, the end of DGF is considered 
the day  the last dial ysis session ends.
In case of DGF, treatment will be according to local practice. DGF treat ments must maintain 
Novartis Confidential Page 74
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
sufficient immunological coverage for the graft and may include maintaining, interrupting or 
reducing the dose of study  drug and the use of anti-thymocy te globulin. If a polyclonal 
antibody  or anti -thymocyte globulin is used, the study  treatment must be discontinued and the 
subject will be placed on standard of care per local practice. 
Primary  graft non-function (PGNF) is defined as dialy sis started 7 days after transplantation 
with a continuous record of post-transplant dialy sis until either transplantectomy  or death. 
PGNF should be reported on the Graft Loss eCRF.
If a subject is placed on permanent dialysis (or retransplanted), study  treatment must be 
discontinued, the Graft Loss and Adverse Event eCRFs should be completed, and an SAE 
report of graft loss submitted. Dialy sis treatments should be recorded on the Dialysis eCRF. 
Retransplantation should be recorded on the Surgical and Medical Procedures eCRF. 
5.5.6 Recommended treatment of adverse events
Medicat ion used to treat AEs must be recorded on the Concomitant medications/Significant 
non-drug therapies eCRF.
5.5.7 Rescue medication
Not applicable.
5.5.8 Concomitant treatment
The Investigator should instruct the subject to notify  the study  site about any  new medicatio ns 
he/she takes after the subject was enrolled into the study . All medications, procedures and 
significant non-drug therapies (including physical therapy  and blood transfusions) 
administered after the subject was enrolled into the study  will be recorded on the Concomitant 
Medications eCRF or the Surgical and Medical Procedures eCRF respectively .
CMV prophylaxis
Cytomegalovirus (CMV) prophy laxis, with i.v. ganciclovir or oral valganciclovir, will be used 
in patients (CMV positive and CMV negative) as per loc al medical practice. Prophy laxis 
should be recorded on the Concomitant Medications eCRF. 
Pneumocystis jirovecii (Pneumocystis carinii ) pneumonia (PCP) prophy laxis
All patients will be started on trimethoprim- sulfamethoxazole, starting when oral medication
can be tolerated and continued throughout the study . The same regimen should be 
administered to all patients at a given study  center. Aerosolized pentamidine or dapsone may 
be administered to patients unable to tolerate trimethoprim- sulfamethoxazole. 
Prop hylaxis should be recorded on the Concomitant Medications eCRF. 
Hepatitis B (HBV) prophylaxis
Prophy laxis for recurrent hepatitis B during the course of this study  is allowed and will be 
administered at the discretion of the Investigator. Prophy laxis shou ld be recorded on the 
Concomitant Medications eCRF.
Novartis Confidential Page 75
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
BK virus
Patients with BK viremia or viruria should be treated according to local practice. If treatment 
is given it should be recorded on the Concomitant Medications eCRF.
Oral Candida treatment
For oral thrush (Candida), Nystatin may be used in a swish and swallow regimen; 
alternativel y, clotrimazole (My celex®) lozenges/troches may  be used. Routine use of sy stemic 
agents, e.g., itraconazole, voriconazole and fluconazole, will not be allowed in study  Part1 
unless patients are systemically  infected since azoles may increase blood concentrations of 
Tac. Systemic therapy  in Part 2 is to be based on center practice and at the Investigator’s 
discretion. Treatment should be recorded on the Concomitant Medicatio ns eCRF. 
5.5.9 Prohibited treatment
Immunosuppressants other than those specified in the protocol are NOT allowed after 
informed consent up to the end of study . If the use of any ofthese medications or other 
non-protocol immunosuppressants is discovered prior to randomization/enrollment, the 
subject must not be randomized and will be recorded as a screen failure. If discovered after 
randomization/enrollment, no further doses are to be given, and the subject should continue 
on the randomized/assigned treatment r egimen, noting the protocol deviation.
The exception is for the treatment of acute rejection not responding to corticosteroids.
5.5.10 Discontinuation of study treatment and premature subject withdrawal
Study “Stopping rules”
The following stopping rules based onpotential toxicities will serve as the basis for placing 
the study  on hold. Although the stopping criteria do not incorporate an absolute requirement 
for causality , the potential relationship between an AE and CFZ533 will be evaluated 
carefully  on a case-by-case basis between the Sponsor and the Investigator. Following a 
review of the AE(s), a decision to permanentl y discontinue enrollment or re-initiate dosing 
will be made b y the DMC. 
Two (2) or more patients presenting with PTL D or PML  
No va r t i s Con f iden t ia l Page  76
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ionI n  a d d i t i o n ,  s p e c i f i c  s topp ing  ru l e s  fo r  th e  in c id en c e  o f  tBPAR  w i l l  b e  app l i ed .  Th e s e  ru l e s  a r e  
d e s i g n e d  to  e n s u r e  t h a t  aCFZ 5 3 3  t r e a tm e n ta rm  w i l l  b e  s t o p p e d  i f  t h e r e  i s  h i g h  p r o b a b i l i t y  
(> 9 0% )  th a t  t h e  t r u e  tBPAR  r a t e  i s  g r e a t e r  t h a n  2 0% .   
 
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis Confidential Page 77
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
In addition to the automatic hold criteria and tBPAR criteria presented above, the DMC will 
review safet y data regularly  as outlined in their charter (see Section 8.4 ) during quarterly  and 
ad hoc meetings. The DMC can recommend stopping a specific study  arm(s) or the entire trial 
if significant changes or effects that, in their collective opinion, are deemed unsaf e or 
unethical to continue administering CFZ533.
Discontinuation of study regimen
The Dosage Administration Records for CFZ533 (all parts), MMF and Tac (Part 1 only)and 
Concomitant Medication eCRF forMMF and Tac(Part 2)will be used to record if a subje ct 
has permanently  discontinued study  treatment and why .
Possible reasons for study  treatment discontinuation are:
Adverse Event
Lack of Efficacy
Technical problem during transplant surgery
Subject/Guardian Decision
Lost to follow -up
Death
Graft Loss
The Investigator should discontinue a subject from their randomized treatment regimen if, on 
balance, he/she believes that continuation would be detrimental to the subject’s well -being.
Subjects who become pregnant while taking study  medication must be disconti nued from 
study  medication and from the study , such pregnancies should be reported as SAEs to 
Novartis DSE and entered as AEs in the eCRF, the reason for discontinuation of study  
medication should be recorded as AE and reason for discontinuation from study is pregnanc y 
(see next section below). 
Subjects who discontinue study  medication (CFZ533 or Tac) should remain in the study , if 
possible, and receive standard of care immunosuppression, according to local practice, until 
completing the study  at Month 6 (Part 1) or Month 12 (Part 2). Visits and assessments for 
such subjects are described in the Assessment schedule . All immunosuppressants after 
discontinuation of study regimen must be recorded on the Concomitant Medication eCRF 
under the Immunosuppressive category .
Novartis Confidential Page 78
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Subjects who discontinue their study treatment regimen should NOT be considered withdrawn 
from the study  UNLESS they  withdraw their consent to participating in all the elements of the 
study  (see Section 5.5.11 ). Information on treatment discontinuation needs to be captured on 
the end of treatment eCRF page. Such subjects should remain in the study , if possible, and 
receive standard of care immunosuppression, according to local practice, until completing the 
study  at Month 6 (Part 1) 
or Month 12 (Part 2).See the Assessment schedule for the required 
assessments of these subjects after discon tinuation of study  regimen. If they fail to return for 
these assessments for unknown reasons, every  effort should be made to contact them as 
specified in Section 5.5.12 .
5.5.11 Withdrawal of consent
Subjects m ay voluntarily  withdraw consent to participate in the study  for any  reason at any  time.
Withdrawal of consent occurs only when a subject does not want to participate in the study  
anymore and does not want any further visits or assessments and does not want any further 
study  related contacts and does not allow anal ysis of alread y obtained biologic material.
If a subject withdraws consent, the Investigator must make every  effort to determine the 
primary  reason for this decision and record this information in the eCRF. Study  treatment 
must be discontinued and no further assessments conducted. All biological material that has 
not been analyzed at the time of withdrawal must not be used. Further attempts to contact the 
subject are not allowed unless safet y findin gs require communicating or follow -
up.
5.5.12 Loss to follow -up
For subjects whose status is unclear because they  fail to appear for study  visits without stating 
an intention to withdraw, the Investigator should show "due diligence" by documenting in the 
source documents steps taken to contact the subject (e.g., dates of telephone calls, registered 
letters). A subject should not be considered lost to follow -up until his/her scheduled end of 
study  visit would have occurred.
5.5.13 Replacement of early withdrawals or disco ntinuations
The sponsor allows for over-recruitment of 2 patients in Part 1 and additional 10% in Part 2, 
to compensate for potential earl y withdrawals or discontinuations from the study.
5.5.14 Emergency  unblinding of treatment assignment
Not applicable.
5.5.15 Study completion and post -study treatment
Each subject will be required to complete the study  in its entirety  and thereafter no further 
study  treatment will be made available to them (as applicable based on local regulations). 
Subjects who are prematurely  withdrawn from the study  should be treated according to local 
standard of care per Investigator’s judgment. The study  will complete when the last subject 
completes their Study  Completion visit, and any repeat assessments associated with this visit 
have been documented and followed- up appropriately by the Investigator.
For Part 2: patients who completed the study on treatment with CFZ533 should be switched to
Novartis Confidential Page 79
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
tacrolimus (or other SoC treatment) not earlier than 28 days after having received their last 
CFZ533 dose in order to not cause over-immunosuppression .From Days 28 to 35after last 
dose, the concentration of tacrolimus should be at the lower recommended level before 
increasing it to the dose considered appropriate for the individual patient. Doses of MMF and 
CS may remain unchange dor be adapted accordingl y.
5.5.16 Early  study termination
The study  can be terminated at any  time for any  reason by  Novartis. Should this be necessary, 
the subject should be seen as soon as possible and treated as a prematurel y withdrawn subject. 
The Investigat or may be informed of additional procedures to be followed in order to ensure 
that adequate consideration is given to the protection of the subject’s interests. 
TheInvestigator will be responsible for informing IRBs and/or ECs of the early  termination of 
the trial.
6 Visit assessments
The full Assessment schedule is presented at the end of the synoptic section, above. “X” 
indicates assessments that are to be performed for all subjects. “A” indicates asses sments onl y 
to be performed for subjects maintaining the stud y regimen. 
All randomized subjects are expected to continue in the study  up to Month 6 (Part 1) or 
Month 12 (Part 2) regardless of being on or off randomized treatment. Subjects who 
discontinue their randomized study  treatment regimen should be treated according to standard 
of care immunosuppression and return for the assessments indicated by “X” in the 
Assessment schedule . If they refuse to return for these assessments or are unable to do so, 
every  effort should be made to contact them or a knowledgeable informant by telephone to 
determine the subject and graft status.
Subjects should be seen for all visits on the designated day with an allowe d visit window as 
specified in the Assessment schedule .
Every  effort will be made to take the PK sample at the protocol specified time. 
Other assessments (e.g., ECG, vital signs) will be taken prior to or after the PKsample . 
ECGs must be recorded after 5 minutes rest in the supine position to ensure a stable baseline. 
The preferred 
sequence of cardiovascular data collection during study  visits is: ECG 
collection first, followed by  vital signs, and blo od sampling . 
At a minimum, subjects will be contacted for safety  evaluations (e.g., SAEs) up to 3 months 
after his/her last dose of CFZ533 , and 2 months after End of Study  visit (EoS) for patients in 
the control arm for Part 2. Documentation of attempts to contact the subject should be 
recorded in the source documentation.
6.1 Dietary , fluid and other restrictions
Not applicable.
Novartis Confidential Page 80
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
6.2 Information to be collected on screening failures
All subjects who have signed informed consent but do not enter the next period 
(i.e.,Randomized treatment to Month 6 or Month 12) will have the Study Completion eCRF 
for the screening period, demographics (giving reason for screen failure), inclusion/exclusion 
and SAE data collected. AEs that are not SAEs will be followed by the Investigator and 
collected only in the source data. All consented subjects must be entered in the IRT system at 
screening for Part 2. For subjects who are not randomized, the Screening Disposition eCRF 
must both be updated to indicate screen failure.
Rescreenin g is only allowed for subjects who were screen failures on the initial Screening 
visit (e.g., due to lab values out of range). Rescreened subjects should be recorded as screen 
failures under their original Subject ID number and assigned a new Subject ID number in the 
database when consented for rescreening. 
All subjects who have signed informed consent and received study  treatment will have all 
AEs occurring after informed consent is signed recorded on the Adverse Event eCRF until 
they completed the study .
Investigators will have the discretion to record abnormal test findings on the Medical History 
eCRF whenever in their judgment, the test abnormality  occurred prior to the informed consent 
signature.
6.3 Subject demographics/other baseline characteristics
After informed consent has been signed and the subject’s eligibility  to participate in the study 
has been determined, baseline subject information will be obtained in accordance with local 
regulations, including date of birth, age, sex (with child bearing status for females), race and 
ethnicity . In addition, relevant medical history (including CKD and ESRD history ) and 
current medical conditions at screening, a full physical examination, vital signs and a 
pregnancy  test (for females of child -bearing potential) will also be performed. 
At Baseline/Transplantation, information on the renal transplant procedure, recipient and 
donor transplant background, recipient and donor viral serology  and recipient/donor HLA 
testing results will be recorded. For randomization/e nrollment of subjects in Part 1, the 
sponsor must be contacted and the sponsor will assign the treatment number. 
Forrandomization of subjects in Part 2, the I RT must be contacted and the IRT will assign the 
randomization number. For all subjects regardles s of randomization/enrollment status, the 
Enrollment (Part 1) or IRT (Part 2) and Screening Disposition eCRF must be completed to 
document all consented subjects as either randomized or as screen failures and the reason for 
screen failure recorded in the eCRF.
6.4 Treatment exposure and compliance
CFZ533 concentrations and PK parameters (measures of treatment exposure) will be 
determined in all subjects treated with study  treatment, as detailed in Section 6. 7.
All pre-transplant immunosuppression administered pre-randomization/enrollment, such as 
basiliximab, Tac, MMF and/or CS, will be recorded on the Concomitant Medications eCRF 
under the Immunosuppressive category .
Novartis Confidential Page 81
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
All post-randomization/enrollment doses of CFZ533 (all parts) , Tacand MMF (Part 1 onl y)
will be recorded on their respective Dose Administration Record eCRFs. For Part 2, Tac will 
be recorded on the Tac Concomitant Medications eCRF . Basiliximab (all parts) , MMF (Part 2)
and/or CS will be recorde d on the Concomitant Medications eCRF under the 
Immunosuppresive category .
For all these immunosuppressive drugs, the start date, total dose, stop date and reason for dose 
administration or dose change are to be provided. If study  drug is interrupted due to inability  
to tolerate oral medication and rescue therapy  via a NG tube isadministered, the non-study 
drug immunosuppressive should be recorded on the Concomitant Medications eCRF under 
the Immunosuppressive category .
Tac and MPA trough levels will be determined locally  and recorded on the relevant trough 
level eCRF. The local trough values will be used to adjust the Tac and MPA dosing as needed.
Post-discontinuation of study  regimen, for patients remaining in study  to Month 6 (Part 1) or 
Month 12 (Part 2), the trough levels should be recorded on the appropriate trough level eCR F.
Other drugs administered prior to and continuing at start of study  medication will be entered 
on the Concomitant Medications eCRF.
Compliance will be assessed by the Investigator and/or study  personnel at each visit and 
information provided by the pati ent. This information should be captured in the source 
document at each visit.
6.5 Efficacy  / Pharmacody namic assessments
6.5.1 Efficacy  assessments
Treated Biopsy  Proven A cute Rejection (tBPA R)
A treated BPAR is any condition where the subject received anti-rejection treatment and was 
histologically  diagnosed as acute rejection (according to the Banff 2009 criteria, Appendix 8
or the Banff 2013 criteria. Borderline histological findings are interpreted according to local 
medical practice and fulfill the criteria of tBPAR if anti-rejection treatment is given) .
Renal biopsies will be collected for all cases of suspected acute reje ction. 
Kidney  allograft biopsy
For all suspected rejection episodes, regardless of initiation of anti-rejection treatment, 
anallograft biopsy  must be performed according to local practice preferably  within 48 hrs . 
Biopsies will be read by the local patho logist according to the updated Banff 2009 criteria 
(Appendix 8, or the Banff 2013 criteria depending on the local practice). The results of the 
biopsy  read by the local pathologist will be listed on the Kidney  Allograft Biops y eCRF. 
Theresults will be used for subject management for acute rejection. The local pathologist will 
remain blinded to treatment. Any biopsies performed according to local practice (e.g., not for 
cause) should also be recorded. In Part 2, biopsies performed for suspected rejection and other 
kidney  disease related events will also be evaluated centrall y by an independent Adjudication 
Committee.
No va r t i s Con f iden t ia l Page  82
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
G ra f t  loss
T h e  a l l o g r a f t  w i l l  b e  p r e s um e d  to  b e  lo s t  o n  t h e  d ay  t h e  s u b j e c t  s t a r t s  d i a lys i s  a n d  i s  no t  ab l e  
to  sub s equ en t ly  b e  r emov ed  f r om  d i a ly s i s .  I f  t h e  s u b j e c t  u n d e r g o e s  a l l o g r a f t  n e p h r e c t omy  
p r i o r  to  s t a r t i n g  p e rm an en t  d i a ly s i s ,  t h e n  t h e  d ay  o f  n eph r e c tomy  i s  th e  d ay  o f  g r a f t  lo s s .  
T h er e a s o n  f o r  g r a f t  lo s s  w i l l  b e  r e c o r d e d  o n  th e  G r a f tL o s s  eCRF .  Th i s  w i l l  b e  r e p o r t e d  on  
t h e  S tudy C omp l e t ion  eCRF  a n d  T r e a tm e n t  Ph a s e  D i spo s i t ion  eCRF  w i th  G r a f t  L o s s  a s  th e  
r e a s o n  f o r  s tudy  d i s con t inu a t ion  a n d  on  t h e  a p p r o p r i a t e  D o s a g e  A dm i n i s t r a t i o n  R e c o r d  
eCRF ( s )  i f  d e a t h  o c cu r s  w h i l e  o n  r a n d om i z e d  t r e a tm e n t .  G r a f t  lo s s  i s  c o n s i d e r e d  a  SAEand  
s h o u l d  b e  r epo r t ed  o n  th e  Adv e r s e  E v e n t  eCRF  ( a ss e r i o u s )  a n d  th e  SAE  r e p o r t e d  to  th e  lo c a l  
N o v a r t i s  D r u g  S a f e ty  a n d  Ep id em io logy D e p a r tm e n t  l o c a l  Nov a r t i s  D r u g  S a f e ty a nd  
Ep id em io logy (DS&E )  D e p a r tm e n t  w i t h i n  2 4  h r s .
Dea th
I n  t h e  e v e n t  o f  sub j e c t  d e a th ,  th e  SAE  l e ad ing  to  d e a t h  s h o u l d  b e  r epo r t ed  to  Nov a r t i s  DS&E  
w i th in  2 4  h r s .  T h e  ev en t s  l e a d i n g  to  t h e  d e a th  shou ld  b e  e n t e r e d  o n  t h e  A d v e r s e  Ev en t  eCRF  
a n d  t h e  d e a th  s h o u l d  b e  i n d i c a t e d  o n  th e  app rop r i a t e  D o s a g e  A dmin i s t r a t ion  R e c o r d  eCRF ( s )  
( i f  d e a th  o c c u r s  w h i l e  on  r a n d om i z e d  t r e a tm en t ) ,  o n  th e  S tudy C omp l e t ion  eCRF  a n d  on  th e  
T r e a tm e n t  P h a s e  D i s p o s i t i o n  eCRF .
6 .5 .2 Pha rmacodynam ic  assessmen ts
So lub le  CD40  and  so lub le  CD154
P e r i p h e r a l  b l o o d  to t a l  s o l u b l e  CD 4 0  a n d  to t a l  s o l u b l e  CD 1 5 4  c o n c e n t r a t i o n s  w i l l  b e  
d e t e rm i n e d  in  P a r t  1 ,  b e f o r e ,  d u r i n g  a n d  a f t e r  adm in i s t r a t ion  o f  CFZ 5 3 3 .  On ly t o t a l  so lub l e  
CD 4 0  l e v e l s  w i l l  b e  d e t e rm i n e d  i n  P a r t  2 .
6 .5 .2 .1 Pha rmacodynam ic  samp le  co l lec t ion  and  p rocess ing
A l l  b l o o d  s am p l e s  w i l l  b e  t a k e n  by  e i th e r  d i r e c t  v e n i p u n c t u r e  o r  a n  i n dw e l l i n g  c annu l a  
i n s e r t e d  in  a  fo r e a rm  v e in .  A l l  s am p l e s  w i l l  b e  g i v e n  a  u n i q u e  s amp l e  numb e r  ( a s  l i s t ed  in  
A p p e n d i x1Co rpo ra te  Con f iden t ia l  In fo rma t ion
) .  T h e  d e t a i l s  o f  s am p l e  p r o c e s s i n g ,  h a n d l i n g ,  s t o r a g e ,  and  s h i pm e n t  w i l l  b e  
d e s c r i b e d  i n  a  s e p a r a t e  l a b o r a t o r y  m a n u a l .  Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  83
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
6 .5 .2 .2 Pha rmacodynam ic  ana lyt ica l  me thods
An a lyt i c a l  m e t h o d s  w i l l  b e  d e s c r i b e d  i n  a  s e p a r a t e  l a b o r a t o r y  m anu a l .
6 .5 .2 .3 Pha rmacodynam ic  pa rame te rs
To ta l  so lub le  CD40  and  to ta l  so lub le  CD154
P e r i p h e r a l  b l o o d  to t a l  s o l u b l e  CD 4 0  a n d  to t a l  s o l u b l e  CD 1 5 4  ( c o n c en t r a t i o n s  b e f o r e ,  du r ing  
o r  a f t e r  t r e a tm e n t ,  a s  a p p l ic a b l e )  w i l l  b e  a n a l y z e d ,  a s  a p p l i c a b l e .
6 .6 Sa fe ty  assessmen ts
6 .6 .1 Phys ica l  exam ina t ion
A  c om p l e t e  phy s i c a l  ex am in a t ion  shou ld  in c lud e  th e  ex am in a t ion  o f  g en e r a l  app e a r an c e ,  sk in ,  
n e c k  ( i n c l u d i n g  thy ro id ) ,  ey e s ,  e a r s ,  n o s e ,  th ro a t ,  l u n g s ,  h e a r t ,  a b d om e n ,  b a c k ,  ly mp h  nod e s ,  
ex t r em i t i e s ,  v a s c u l a r  and  n e u r o l o g i c a l  sy s t em s .  I f  i n d i c a t e d  b a s e d  on  m ed i c a l  h i s to ry  a nd /o r  
sy m p t om s ,  r e c t a l ,  e x t e r n a l  g e n i t a l i a ,  b r e a s t ,  a n d / o r  p e l v i c  e x am s  m a y b e  p e r f o rm e d .
I n fo rm a t ion  fo r  a l l  phy s i c a l  ex am in a t ion s  mu s t  b e  in c lud ed  in  th e  sou r c e  do cum en t a t ion  a t  th e  
s tudy  s i t e  a n d  w i l l  no t  b e  r e c o r d e d  o n  t h e  eCRF .  S i g n i f i c a n t  f i n d i n g s  th a t  a r e  p r e s e n t  p r i o r  to  
i n f o rm e d  c o n s e n t  a r e  i n c l u d e d  in  t h e  R e l e v a n t  M e d i c a l  H i s to ry e CRF .  S i g n i f i c a n t  f ind ing s  
o b s e r v e d  a f t e r  in fo rm ed  c o n s e n t  s i g n a t u r e  w h i ch  m e e t  t h e  d e f in i t ion  o f  a n  AEmu s t  b e  
a p p r o p r i a t e l y  r e c o r d e d  o n  t h e  A d v e r s e  E v e n t  eCRF .
6 .6 .2  V i ta l  s igns
V i t a l  s i g n s  ( r a d i a l  p u l s e  r a t e ,  b l o o d  p r e s s u r e  and  body  t em p e r a t u r e )  w i l l  b e  r e c o r d e d  a s  
i n d i c a t e d  in  th eA s s e s sm en t  s c h e d u l e .  B l o o d  p r e s s u r e  a n d  pu l s e  r a t e  w i l l  b e  a s s e s s e d  a t  th e  
s am e  a rm  e a c h  t im e  o f  d e t e rm i n a t i o n  and  a f t e r  th e  sub j e c t  h a s  r e s t e d  in  t h e  s i t t i n g  po s i t ion  
(m ay  b e  sup in e  i f  du r ing  ho sp i t a l i z a t ion )  fo r  a t  l e a s t  f iv e  m inu t e s .  Sy s to l i c  a n d  di a s to l i c  b lood  
p r e s s u r e  w i l l  b e  m e a s u r e d  t h r e e  t im e s  u s i n g  a n  a u t om a t e d  v a l i d a t e d  d e v i c e  ( e . g . ,  OMRON )  
w i th  a n  a p p r o p r i a t e l y  s i z ed  c u f f .  I n  c a s e  t h e  c u f f  s i z e s  a v a i l a b l e  a r e  no t  l a r g e  e n o u g h  fo r  th e  
s u b j e c t ' s  a rm  c i r c um f e r e n c e ,  a  sphy gm om a n om e t e r  w i th  a n  ap p r o p r i a t e ly  s i z ed  c u f f  m ay b e  
u s e d .  
T h e  r e p e a t  s i t t i n g  m e a s u r em e n t s  w i l l  b e  m a d e  a t  u p  to  5  m i n u t e  i n t e r v a l s  a n d  m e a su r em en t s  
w i l l  b e  r e c o r d e d  o n  th e  V i t a l  S i g n s  eCRF .  C l in i c a l ly n o t a b l e  v i t a l  s i g n s  a r e  d e f i n e d  in  
A p p e n d i x7Co rpo ra te  Con f iden t ia l  In fo rma t ion
.
Novartis Confidential Page 84
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Body temperature should be measured as per local practice –the same method tobe used 
consistently  for all patients at each site.
6.6.3 Height and weight
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram [kg] in indoor 
clothing, but without shoes) will be measured.
Body mass index (BMI) will be calculated using the following formula:
BMI = Bod y weight (kg) / [Height (m)]2
Results will be recorded in the Vital Signs eCRF.
6.6.4 Laboratory  evaluations
In the case where a laboratory  assessment that is listed in the inclusion/exclusion criteria is 
outside of a protocol -specified range at screening and/or at the initial baseline, the 
assessment may be repeated once prior to randomization/enrollment. If the repeat value 
remain s outside of protocol -specified ranges, the subject is excluded from the study .
Results from routine blood laboratory  evaluati on -directly  assessed before Transplantation
(i.e. within 24h prior to Tx) -can be used instead of further baseline laboratory  evaluation. No 
second assessment implying second drawing of venous blood needs to be done.
In the case where a laboratory  range is not specified by the protocol , but is outside the 
reference range for the laboratory  at screening and/or initial baseline, a decision regarding 
whether the result is of clinical significance or not shall be made by the Investigator and shall 
be based, in part, upon the nature and degree of the observed abnormality . The assessment 
may be repeated once prior to randomization/enroll ment.
In all cases, the Investigator must document in the source documents, the clinical 
considerations (i.e., result was/was not clinically  significant and/or medically  relevant) in 
allowing or disallowing the subject to continue in the study .
Clinically  relevant deviations of laboratory  test results occurring during or at completion of 
the study  must be reported and discussed with Novartis personnel. The results should be 
evaluated for criteria defining an AEand reported as such if the criteria are met. Repeated 
evaluations are mandatory  until normalization of the result(s) or until the change is no longer 
clinically  relevant. In case of doubt, Novartis personnel should again be contacted.
Clinically  notable laboratory  findings are defined in Appendix 7 .
6.6.4.1 Hematology
Platelets, hemoglobin, red blood cell (RBC), white blood cell (WBC) and differential count 
(e.g., neutrophils, basophils, eosinophils, monocy tes, ly mphocy tes) will be measured.
Novartis Confidential Page 85
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
6.6.4.2 Clinical chemistry
Albumin, alkaline phosphatase, total bilirubin, bicarbonate/CO2, calcium, cholesterol, 
chloride, creatinine, CK, gamma -GT, glucose, HbA1c, LDH, inorganic phosphorus, lipase, 
amylase, magnesium, potassium, total protein, AST, ALT, sodium, triglycerides, BUN and 
uric acid will be measured. At timepoints on 6h, 24h, 48h and 72h samples have to be taken 
only for Mg, K, c reatinine , Ca and glucose.
If the total bilirubin concentration is increased above 1.5 times the upper limit of normal, 
direct and indirect reacting bilirubin should be differentiated.
6.6.4.3 Urinaly sis
The following parameters will be measured: protein, creatinine, albumin, glucose; proteinuria 
and albuminuria per 24hr period will be estimated from spot protein/creatinine and 
albumin/cr eatinine ratios.
If the dipstick result is positive for protein, nitrite, leucocy tes and/or blood the sample will be
sent for microscopic analysis of WBC, RBC and casts according to local practice .
Local practice for transplant patients is that no microsco pic analysis of the urine is done for 
the first two weeks after transplantation. 
• Within the first two weeks after transplantation additional microscopic analy sis will only  
need to be performed if the dipstick result is 3+ (or more) positive for leucocy tes and/or 
blood (no WBC, RBC cast is expected to be seen with only  proteinuria). 
• From visit 108 (Study  Day  29) onwards a microscopic anal ysis should be performed, except 
if the dipstick is completely  negative. 
6.6.4.4 Special clinical laboratory  evaluations
The details of sample processing, handling, storage, shipment and analysis for the following 
assay s will be described in a separate laboratory  manual, as required.
6.6.4.5 Renal Function
Renal function will be assessed by  calculated eGFR using the MDRD formula .
6.6.4.6 Coag ulation studies
Coagulation studies will be performed, including prothrombin time (PT) and activated partial 
thromboplastin time ( aPTT). 
6.6.4.7 Cytokine assessment
Blood samples will be collected during the study  (see Assessment schedule ) for cytokine 
assessment via multiplex cytokine (or similar) platform (e.g., IL- 2, IL- 12, IFN-gamma, IL-4, 
IL-
5, IL-10, IL-13, IL-1b, IL-6, IL-8, TNF -alpha, IL2R) and analyzed centrally , triggered by 
safet y signals such as for example: 
hyper acute rejection or tBPAR associated with CFZ533 administration or in close 
proximity  to the administration of CFZ533 
No va r t i s Con f iden t ia l Page  86
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
 a  f e b r i l e  r e s p o n s e  a r o u n d  t h e  t im e  o f  CFZ 5 3 3  a dm i n i s t r a t i o n  a s  a n  i n d i c a t o r  o f  a n  
i n f l amm a t i o n  
6 .6 .4 .8 Dono r  spec i f ic  an t ibod ies(DSA )
B l o o d  s am p l e s  f o r  dono r  s p e c i f i c  a n t i b o d i e s  (a n t i b o d i e s  d i r e c t e d  ag a in s t  a n t i g e n s  exp r e s s ed  
o n  d o n o r  o r g a n s)  w i l l  b e  c o l l e c t e d  a n d  e v a l u a t e d  l o c a l l y .  
6 .6 .4 .9 Immunogen ic i ty
T h e  p r e s e n c e  o f  a n t i - CFZ 5 3 3  a n t i b o d i e s  w i l l  b e  d e t e rm i n e d  u s i n g  a  b r i d g i n g  EL ISA- b a s ed  
a s s ay .
6 .6 .4 .11V i ra l  tes ts  and  EBV /CMV /BK  v i rus  su rve i l lance
A l l  s u b j e c t s  w i l l  b e  s c r e e n e d /m o n i t o r e d  f o r  h ep a t i t i s  B ,  h e p a t i t i s  C ,  H IV ,  E p s t e in -B a r r  V i ru s  
(EBV ) ,  cy t om e g a l o v i r u s  (CMV )  a n d  BK  v i r u s  p e r  l o c a l  c e n t e r  p r a c t i c e .F o r  c e n t e r s  w h e r e  no  
p r o t o c o l  ex i s t s ,  d e t a i l s  o n  t h e  a s s e s sm en t  r e q u i r em e n t s  w i l l  b e  p rov id ed  in  t h e  l a b o r a t o r y  
m a n u a l .R e s u l t s  o f  t h e s e  a s s e s sm e n t s  a r e  t o  b e  t r a n s c r i b e d  i n t o  t h e  a p p r o p r i a t e  eCRFp ag e s.
6 .6 .5 E lec t roca rd iog ram  (ECG )Co rpo ra te  Con f iden t ia l  In fo rma t ion
T h e  F r i de r i c i a  QT  c o r r e c t i o n  f o rm u l a  (QT cF )  w i l l  b e  u s e d  f o r  c l i n i c a l  d e c i s i o n s .
S i n g l e  1 2  l e ad  ECG s  a r e  c o l l e c t e d .  Th e  o r i g i n a l  ECG s  o nn o n - h e a t- s e n s i t i v e  p ap e r,  
a p p r o p r i a t e l y  s i g n e d ,  s h o u l d  b e  c o l l e c t e d  a n d  a r c h i v e d  a t  t h e  s t u d y  s i t e .
E a c h  ECG  t r a c i n g  s h o u l d  b e  l a b e l e d  w i th  s tudy  n um b e r ,  s u b j e c t  in i t i a l s ,  s u b j e c t  n um b e r ,  d a t e  
a n d  t im e ,  b e  a p p r o p r i a t e l y  s i g n e d  a n d  d a t e d  to  c o n f i rm  r e v i ew  a n d  f i l e d  in  t h e  s tudy  s i t e  
s o u r c e  do cum en t s .  F o r  any  E CG s  w i th  s u b j e c t  s a f e ty  c o n c e r n s ,  tw o  add i t ion a l  ECG s  s h o u l d  
b e  p e r f o rm e dto  con f i rm  t h e  s a f e t y  f ind ing .  C l in i c a l ly s i g n i f i c a n t  ECG  f i n d i n g s  p r i o r  to  
d o s i n g  w i t h  i n v e s t i g a t i o n a l  t r e a tm e n t  m u s t  b e  d i s c u s s e d  w i t h  t h e  s p o n s o r .
C l in i c a l ly s i g n i f i c a n t  abno rm a l i t i e s  s h o u l d  b e  r e c o r d e d  o n  th e  r e l e v a n t  s e c t ion  o f  th e  M ed i c a l  
H i s to ry/Cu r r e n t  M e d i c a l  C o n d i t i o n s /AE  eCRF  p a g e  a s  a p p r o p r i a t e .
Novartis Confidential Page 87
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
6.6.6 Pregnancy
Pregnancy  tests will be required for all females of child -bearing potential at timepoints as 
designated in the Assessment Schedule, and defined below. 
Serum or urine pregnancy  tests should becarried out according to local practice. Local result 
must be available and negative prior to randomization /enrollment . 
6.6.7 Tuberculosis surveillance
Patients should have no history  of active tuberculosis (per their pre-transplant assessments). 
Atuberculosis (TB) test (e.g. QuantiFeron, PPD or chest X-ray) will be conducted durin g 
screening whenever local procedures will allow (e.g. for living donors). For patients enrolled 
in areas where TB is endemic or who are at higher risk of active or latent TB disease, local 
screening result should be available and negative prior to randomization/enrollment for 
recipients of transplants from living donors. For de ceased donor transplants a TB test showing 
negative results performed within 6 months prior to enrollment/ randomization is acceptable. 
Samples for a TB test will be collected at baseline and at various time points throughout the 
conduct of the study  as defined in the Assessment schedule . Chest X-ray to verify  or monitor 
TB status of the patients is acceptable depending on local regulations.  Whenever during the 
course of the study  a positive test for TBis being confirmed, the patient will be discontinued 
from study  treatment and returned to SoC.
6.7 Pharmacokinetic assessments
See Sample log tables ( Appendix 1 ).
6.7.1 PK Blood collection and processing
All blood samples will be taken by either direct venipuncture or an indwelling cannula 
inserted in a forearm vein. Details of sample processing, handling, storage and shipment will 
be described in a separate laboratory  manual. All samples will be given a unique sample 
number and a collection number (as listed in the blood log, Appendix 1). The actual sample 
collection date and time will be entered on the PK blood collection page of the eCRF . 
Sampling problems will be commented in the eCRFs.
6.7.2 Pharmacokinetic analytical methods
Analy tical methods will be described in a separate laboratory  manual.
6.7.3
Pharmacokinetic parameters
For standard PKabbreviations and definitions, see the list provided at the beginning of this 
protocol.
If data permit, typical exposure metrics and parameters could be determined using the actual 
recorded sampling times and non-compartmental method(s) with WinNonlin Pro or Phoenix, 
including (but not limited to): Cmax, Cmin, Ctrough , Tmax, , AUC t, from the plasma 
concentration -time data.
Concentrations below the LLQ will not be considered for PK parameter calculations. 
No va r t i s Con f iden t ia l Page  88
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
 
 
D e f i n i n gb io av a i l ab i l i ty  u s i n g  t h e  r a t i o  o f  d o s e- n o rm a l i z e d  AUC  a p p r o a c h ,  o r  t h e  r a t i o  o f  
d o s e s  t h a t  p r o v i d e  equ a l  AUC s  a p p r o a c h ,  cou ld  b e  m i s l e a d i n g  ( e v e n  i f  i d en t i c a l  d o s e s  a r e  
a dm i n i s t e r e d  IV  a n d  SC ) .  I n d e e d ,  a  n o n - comp a r tm e n t a l  a p p r o a c h ,  r e q u i r e s  l i n e a r  k in e t i c s  
e v e n  i f  t h e  s am e  IV  a n d  SC  d o s e s  a r e  u s e d .  F o r  mA b s ,s u b j e c t  to  t a r g e t  m e d i a t e d  d i s p o s i t i o n ,  
c l e a r a n c e  a n d  d i s t r ibu t ion  a r e  d o s e / c o n c e n t r a t i o n s- d e p e n d e n t.  A  d o s e - ind ep end en t ,  
mod e l- b a s e d  an a ly s i s  o f  IV  a n d  SC  d a t a  wou ld  b e  th e  b e s t  w ay to  d e t e rm in e  b io av a i l ab i l i ty  in  
th i s  s tudy .  S u c h  a n a ly s i s  m ay  b e  r e p o r t e d  i n  a  s e p a r a t e  s t a n d a l o n e  r e p o r t .Co rpo ra te  Con f iden t ia l  In fo rma t ion
6 .8 O the r  assessmen tsCo rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  89
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
7 Sa fe ty mon i to r ing
7 .1 Adve rse  even tsCo rpo ra te  Con f iden t ia l  In fo rma t ion
A n  AE  i s  a n y  un tow a rd  m e d i c a l  o c c u r r e n c e  ( i . e . ,  a n y  u n f a v o r a b l e  and  u n i n t e n d e d  s ign  
[ i n c l u d i n g  a b n o rm a l  l abo r a to ry  f ind ing s ] ,  s ymp tom  o r  d i s e a s e )  in  a  s u b j e c t  o r  c l in i c a l  
i n v e s t i g a t i o n  sub j e c t .  T h e r e f o r e ,  a n  AE  m ay o r  m ay n o t  b e  t em p o r a l l y  o r  c au s a l ly  a s so c i a t ed  
w i t h  t h e  u s e  o f  a  m e d i c i n a l  ( i n v e s t i g a t i o n a l )  p r o d u c t .
F o r  a l l  sub j e c t s  who  h av e  s ign ed  in fo rm ed  con s en t  and  a r e  en t e r edin to  th e  s tudy  w i l l  h av e  a l l  
a d v e r s e  e v e n t s  o c c u r r i n g  a f t e r  i n f o rm e d  c o n s e n t  i s  s i g n e d  r e c o r d e d  o n  t h e  A d v e r s e  E v e n t  eCRF .
P r e- e x i s t i n g  m e d i c a l  c o n d i t i o n s / d i s e a s e s  ( i . e . ,  M e d i c a l  H i s to ry( i e s ) )  a r e  c o n s i d e r e d  AE s  i f  
th ey  w o r s en  a f t e r  p r o v i d i n g  w r i t t en  i n f o rm ed  con s en t .  A b n o rm a l  l abo r a to ry  v a lu e s  o r  t e s t  
r e s u l t s  c o n s t i t u t e  AE s  on ly  i f  th ey  i n d u c e  c l i n i c a l  s ign s  o r  sy mp tom s ,  o r  a r e  con s id e r ed  
c l in i c a l ly  s ign i f i c an t ,  o r  th ey  r equ i r e  th e r apy .
T h e  o c c u r r e n c e  o f  AEs  shou ld  b e  s o u g h t  by  n o n -d i r e c t i v e  q u e s t i o n i n g  of  t h e  s u b j e c t  a t  e a ch  
v i s i t  d u r i n g  t h e  s tudy .  AE s  a l s o  m ay b e  d e t e c t ed  w h e n  th ey  a r e  v o l u n t e e r e d  by  t h e  sub j e c t  
d u r i n g  o r  b e tw e e n  v i s i t s  o r  t h r o u g h  p h y s i c a l  ex am in a t ion ,  l abo r a to ry  t e s t ,  o r  o t h e r  a s s e s sm e n t s .
AEs  mu s t  b e  r e c o r d e d  o n  t h e  A d v e r s e  E v e n t  eCRF  u n d e r  t h e  s i g n s ,  sy mp tom s  o r  d i a g n o s i s  
a s s o c i a t e d  w i t h  t h em ,  a n d  a c c om p a n i e d  b y  t h e  f o l l ow i n g  i n f o rm a t i o n :
Novartis Confidential Page 90
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
1.the severit y grade
mild:usually  transient in nature and generall y not interfering with normal activities
moderate: sufficiently  discomforting to int erfere with normal activities
severe: prevents normal activities
2.its relationship to the investigational treatment (no/y es), or other stud y treatment (non -
investigational) (no/ yes), or both or indistinguishable,
3.itsduration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved should be reported.
4.whether it constitutes a serious adverse event (SAE)
5.action taken regarding investigational/other stud ytreatment
6.whether other medicat ion or therapies have been taken (concomitant medication/non -drug 
therap y)
7.its outcome
An SAE is defined as any AE which meets an y one of the following criteria:
is fatal or life -threatening
results in persistent or significant disability /incapacity
consti tutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for:
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condi tion
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent form
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospital admission 
social reasons and respite care in the absence of any  deterioration in the subject’s 
general conditi on
is medically  significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above.
All malignant neoplasms will be assessed as serious under “medically  significan t” if other 
seriousness criteria are not met.
Unlike routine safety assessments, SAEs are monitored continuously and have special 
reporting requirements; see Section 7.2 .
Novartis Confidential Page 91
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
All AEs should be treated appro priatel y. Treatment may  include one or more of the following: 
no action taken (i.e., further observation only); study  drug dosage adjusted/temporaril y 
interrupted; study  drug permanentl y discontinued due to this AE; concomitant medication 
given; non-drug therap y given. The action taken to treat the AEshould be recorded on the 
Adverse Event eCRF.
Once an AEis detected, it should be followed until its resolution or until it is judged to be 
permanent, and assessment should be made at each visit (or more frequently , ifnecessary ) of 
any changes in severity, the suspected relationship to the study  drug, the interventions 
required to treat it, and the outcome.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator Brochure (IB) or will be communicated between IB updates in the 
form of Investigator Notifications. This information will be included in the informed consent 
and should be discussed with the subject during the study  as needed.
7.2 Serious adverse event reporting
To ensure subject safet y, every SAE, regardless of causality , occurring from after the subject 
has provided informed consent and until 3 months after his/her last dose of CFZ533 or 2 
months after the EoS visit for patients on SoC treatment must be reported to Novartis within 
24 hours of learning of its occurrence.
ASAE form for each confirmed acute rejection event should be completed since these are 
considered to be “medically  significant events” for this clinical trial requiring timely  and
detailed reporting. The SAE form should be completed as soon as the PI at the site confirms 
the event based on the histological report from the local pathologist together with a clinical 
assessment of the event.
Recurrent episodes, complications, or progr ession of the initial SAE must be reported as 
follow -up to the original episode, regardless of when the event occurs. This report must be 
submitted within 24 hours of the Investigator receiving the follow -up information. An SAE 
that is considered completely  unrelated to a previously  reported one should be reported 
separately  as a new event.
Information about all SAEs (either initial or follow up information) is collected and recorded 
on the paper Serious Adverse Event Report Form. The Investigator must assess the 
relationship to each specific component of study treatment (if study treatment consists of 
several drugs) complete the SAE Report Form in English, and send the completed, signed 
form by fax within 24 hours after awareness of the SAE to the local Novartis Drug Safet y and 
Epidemiology  Department. The telephone and fax number of the contact persons in the local 
department of Drug Safety  and Epidemiology , specific to the site, are listed in the Investigator 
folder provided to each site. The original copy  of the SAE Report Form and the fax 
confirmation sheet must be kept with the case report form documentation at the study  site.
Follow-up information should be provided using a new paper SAE Report Form stating that 
this is a follow -up to a previou sly reported SAE.
Novartis Confidential Page 92
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Follow- up information provided should describe whether the event has resolved or continues, 
if and how it was treated, whether the treatment code was broken or not and whether the 
subject continued or withdrew from study  participation. Each re-occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the investigational treatment, a Drug Safet y 
and Epidemiology  Department associate may urgentl y require further information from the 
Investigator for Health Authority  reporting. Novartis may need to issue an Investigator 
Notif ication (IN) to inform all Investigators involved in any study  with the same 
investigational treatment that this SAE has been reported. Suspected Unexpected Serious 
Adverse Reactions (SUSARs) will be collected and reported to the competent authorities and 
relevant ethics committees in accordance with EU Guidance 2011/C 172/01 or as per national 
regulatory  requirements in participating countries.
7.3 Pregnancy  reporting
To ensure patient safet y, each pregnancy  occurring while the patient is on study  treatment 
must be reported to Novartis within 24 hours of learning of its occurrence. The pregnancy 
should be followed up to determine outcome, including spontaneous or voluntary  termination, 
details of the birth, and the presence or absence of any  birth defects, cong enital abnormalities, 
or maternal and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by the 
Investigator to the local Novartis Drug Safet y and Epidemiology  Department. Pregnanc y 
follow -up should be recorded on the same form and should include an assessment of the 
possible relationship to the investigational treatment to pregnancy  outcome. Any SAE 
experienced during pregnancy  must be reported on the SAE Report Form.
Any SAE experienced during pregnancy  must be reported on the SAE Report Form. If a 
patient of a US study  center becomes pregnant, please also refer to the country -specific 
instructions in Appendix 2 .
7.4 Ea rly phase safety  monitoring
The Investigator will monitor AEs in an ongoing manner and inform the Sponsor of any 
clinically  relevant observations. Any required safet y reviews will be made jointly  between 
medically  qualified personnel representing the Spons or and Investigator. Such evaluations 
may occur verball y, but the outcome and key discussion points will be summarized in writing 
(e-mail) and made available to both Sponsor and all Investigator(s). Criteria pertaining to stopping 
the study /treatment or ad apting the study  design are presented above.
When two or more clinical site(s) are participating in the clinical study, the Sponsor will 
advise the Investigator(s) at all sites in writing (e-mail) (and by telephone if possible) of any 
new, clinically  relevant safet y information reported from another site during the conduct of 
the study  in a timel y manner.
Novartis Confidential Page 93
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
8 Data revie w and database management
8.1 Site monitoring
Before study  initiation, at a site initiation visit or at an Investigator’s meeting, a Novartis 
repres entative will review the protocol and eCRFs with the Investigators and their staff. 
During the study , the field monitor will visit the site regularl y to check the completeness of 
patient records, the accuracy  of entries on the eCRFs, the adherence to the protocol and to 
Good Clinical Practice, the progress of enrollment, and to ensure that study  drug is being 
stored, dispensed, and accounted for according to specifications. Key  study personnel must be 
available to assist the field monitor during these visit s.
The Investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on eCRFs must be traceable to these source documents in the 
subject's file. The Investigator must also keep the original informed consent form signed by 
the subject (a signed copy  is given to the subject).
The Investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the eCRF entries. Novartis monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/excl usion criteria, 
documentation of SAEs, and the recording of data that will be used for all primary  and safet y 
variables. Additional checks of the consistency of the source data with the eCRFs are 
performed according to the study -specific monitoring plan. No information in source 
documents about the identity  of the subjects will be disclosed.
8.2 Data collection
Designated Investigator staff will enter the data required by  the protocol into the eCRFs using 
fully validated software that conforms to 21 CFR P art 11 requirements. 
Designated Investigator site staff will not be given access to the EDC system until they have 
been trained. Automatic validation programs check for data discrepancies and, by generating 
appropriate error messages, allow the data to be confir med or corrected before transfer of the 
data to Novartis or the CRO working on behalf of Novartis. The Investigator must certify  that 
the data entered into the eCRF s are complete and accurate. After database lock, the 
Investigator will receive a CD-ROM or paper copies of the subject data for archiving at the 
investigational site.
All data captured for this study  will have an external originating source (either written or 
electronic); the eCRF is not considered as source.
No va r t i s Con f iden t ia l Page  94
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
8 .3 Da tabase  managemen t  and  qua l i ty con t ro l
A l l  d a t a  s h o u l d  b e  r e c o r d e d ,  h and l ed  a n d  s to r ed  in  a  w ay t h a t  a l l ow s  i t s  a c c u r a t e  r epo r t ing ,  
i n t e r p r e t a t i o n  a n d  v e r i f i c a t i o n .
N o v a r t i s  s t a f f  o r  t h e  CRO  w o r k i n g  o n  b eh a l f  o f  N o v a r t i s  w i l l  r e v i ew  t h e  d a t a  e n t e r e d  in to  th e  
eCRF s  by  i nv e s t ig a t ion a l  s t a f f  f o r  c om p l e t e n e s s  a n d  a c cu r a cy  a n d  in s t ru c t  t h e  s i t e  p e r s o n n e l  
t o  m a k e  a n y  r equ i r ed  co r r e c t ion s  o r  add i t ion s .  Qu e r i e s  a r e  s en t  to  th e  inv e s t ig a t ion a l  s i t e  u s ing  
a n  e l e c t r o n i c  d a t a  qu e ry .  D e s i g n a t ed  I n v e s t i g a t o r  s i t e  s t a f f  i s  r e q u i r e d  to  r e spond  to  t h e  qu e ry  
a n d  c o n f i rm  o r  c o r r e c t  t h e  d a t a .  I f  t h e  e l e c t r o n i c  qu e ry  sy s t em  i s  no t  u s ed ,  a  p ap e r  D a t a  Qu e r y  
Fo rm  w i l l  b e  s en t  ( e .g . ,  f ax ,  e- m a i l )  to  th e  s i t e .  S i t e  p e r sonn e l  w i l l  comp l e t e  and  s ign  th e  copy,  
t h e n  s e n d  i t  (w i t h  o r i g i n a l  s i g n a t u r e )  b a c k  to  N o v a r t i s  s t a f fo r  CRO  w o r k i n g  o n  b e h a l f  o f  
N o v a r t i s,  w h o  w i l l  m a k e  t h e  c o r r e c t i o n  t o  t h e  d a t a b a s e .
C o n c om i t a n t  m e d i c a t i o n s  e n t e r e d  in to  t h e  d a t a b a s e  w i l l  b e  c o d e d  u s i n g  t h e  WHO  D rug  
R e f e r e n c e  L is t ,  w h i c h  emp loy s  t h e  A n a t om i c a l  T h e r a p e u t i c  C h em i c a l  c l a s s i f i c a t i o n  sy s t em .
M e d i c a l  h i s to ry / cu r r en t  m e d i c a l  c o n d i t i o n s  and  AEs  w i l l  b e  c o d e d  u s i n g  t h e  M ed i c a l  
D i c t ion a ry fo r  R egu l a to ry  A c t iv i t i e s  (M edDRA )  t e rm ino logy .
C e r t a i n  l abo r a to ry  s amp l e s  w i l l  b e  p r o c e s s e d  c e n t r a l l y  a n d  t h e  r e su l t s  w i l l  b e  s e n t  
e l e c t ron i c a l ly  t o  N o v a r t i s  ( o r  a  d e s i g n a t e d  CRO ) .
R andom i z a t ion  c o d e s  i n  P a r t  2  w i l l  b e  t r a c k e d  u s i n g  a n  I n t e r a c t i v e  R e spon s e  T e c h n o l o g y  
( I RT ) .  A n  in t e r n a l  Nov a r t i s  IR T  (N IRT )  sy s t emw i l l  b e  u s e d  in  P a r t  2 .T h e  d a t a  w i l l  b e  s en t  
e l e c t ron i c a l ly  t o  N o v a r t i s  ( o r  a  d e s i g n a t e d  CRO ) .
T h eo c c u r r e n c e  o f  a n y  p ro to co l  d e v i a t i o n s  w i l l  b e  d e t e rm i n e d .  A f t e r  t h e s e  a c t i o n s  h a v e  b e en  
c om p l e t e d  a n d  th e  d a t a b a s e  h a s  b e en  d e c l a r e d  to  b e  comp l e t e  a n d  a c c u r a t e ,  i t  w i l l  b e  lo ck ed  
a n d  t h e  t r e a tm e n t  c o d e s  w i l l  b e  u n b l i n d e d  a n d  m a d e  a v a i l a b l e  fo r  d a t a  a na ly s i s .  A ny  ch ang e s  
to  t h e  d a t a b a s e  a f t e r  th a t  t im e  c a n  o n ly  b e  m ad e  by  j o in t  w r i t t e n  ag r e em en t  b e tw e e n  th e  
G l o b a l  H e a d  o f  C l i n i c a l  I n f o rm a t i o n  S c i e n c e s  a n d  t h e  C l i n i c a l  F r a n c h i s e  H e a d .
8 .4 Da ta  Mon i to r ing  Comm i t teeCo rpo ra te  Con f iden t ia l  In fo rma t ion
A  DMC  w i l l  b e  c o n s t i t u t e d .  T h e  m i s s ion  o f  t h e  DMC  w i l l  b e  to  e n s u r e  th e  e t h i c a l  c o n d u c t  o f  
t h e  s tudy  a n d  to  p ro t e c t  t h e  s a f e t y  i n t e r e s t s  o f  p a t i e n t s  i n  t h i s  s tudy .  T h e  DMC  w i l l  b e  
r e s p o n s i b l e  f o r  r e v i ew i n g  t h e  s a f e t y  a n d  e f f i c a cy  r e s u l t s  f r om  t h e  i n t e r im  an d  f i n a l  a n a l y s e s ,  
a s  w e l l  a s  o v e r s e e i n g  th e  d a t a  a c c r u i n g  in  t h e  t r i a l  a t  r e g u l a r  i n t e r v a l s .  I t  i s  e x p e c t ed  t h a t  t h e  
DMC  m ay c on s i s t  o f  a  n e p h r o l o g i s t ,  t r a n s p l a n t  s u r g e o n ,  s t a t i s t i c i a n ,  a n d  i n f e c t i o u s  d i s e a s e  
s p e c i a l i s t .
D e t a i l s  o n  t h e  w o r k i n g  p r o c e d u r e s  o f  t h e  DMC  a r e  d e s c r ib e d  i n  t h e  DMC  C h a r t e r .
No va r t i s Con f iden t ia l Page  95
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
8 .5 Adjud ica t ion  Comm i t tee
N o t  r e q u i r e df o r  P a r t  1 .
S i n c e  t h e  s tudy  i s  op en- l a b e l  f o r  i n v e s t i g a t o r s ,f o r  P a r t  2  a n  i n d e p e n d e n t  a n d  b l ind ed  
A d j u d i c a t i o n  Comm i t t e e  (AC )  h a s  b e e n  a p p o i n t e d  in  o r d e r  to  c e n t r a l l y  e v a l u a t e  a l l  ev en t s  
r e p o r t e d  a s  a c u t e  r e j e c t ion ,  d e l ay ed  g r a f t  fun c t ion  o r  o t h e r  k idn ey  d y s fun c t ion  in  a n  u n b i a s e d  
m a n n e r .
D e t a i l s  o n  t h e  w o r k i n g  p r o c e d u r e s  o f  t h e  AC  a r e  d e s c r i b e d  in  a  s ep a r a t eAC  c h a r t e r .An  
a d d i t i o n a l  s u p p o r t i v e  PD  a n a l y s i s  w i l l  b e  p e r f o rm e df o r  BPAR  and  tBPAR  b a s e d  o n  
a d j u d i c a t e d  r e s u l t s .  
9 Da ta  ana lys is
D a t a  f r om  P a r t  1  a n d  P a r t  2  w i l l  b e  p r e s e n t e d  s e p a r a t e ly .  
9 .1 Ana lys is  se ts
Pa r t  1  and  Pa r t  2 :
T h e  F u l l  An a lys i s  S e t  w i l l  i n c l u d e  a l l  s u b j e c t s  t h a t  r e c e i v e d  a t  l e a s t  on e  d o s e  o f  s tudy  d rug  
a n d  w h o  w e r e  t r a n s p l a n t e d .
T h e  S a f e ty  A n a l y s i s  S e t  w i l l  i n c l u d e  a l l  s u b j e c t s  t h a t  r e c e i v e d  a t  l e a s t  o n e  d o s e  o f  s t u d y  d rug .
Th e  PK  An a lys i s  S e t  w i l l  in c lud e  a l l  sub j e c t s  w i th  a t  l e a s t  on e  av a i l ab l e  v a l id  ( i . e . ,  no t  f l agg ed  
f o r  e x c l u s i o n )  PK  c o n c e n t r a t i o n  m e a s u rem e n t ,  who  r e c e i v e d  a n y  s tudy  d r u g  a n d  exp e r i en c ed  
n o  p r o t o c o l  d e v i a t i o n s  w i t h  r e l e v a n t  im p a c t  o n  PK  d a t a .
T h e  PD  A n a ly s i s  S e t  w i l l  i n c l u d e  a l l  s u b j e c t s  in  t h e  F u l l  A n a ly s i s  s e t  w i th  a v a i l a b l e  PD  d a t a  
a n d  n o  p r o t o c o l  d e v i a t i o n s  w i t h  r e l e v a n t  im p a c t  o n  PD  d a t a .
F o r  a l l  a n a l ys i s  s e t s ,  s u b j e c t s  w i l l  b e  a n a l y ze d  a c c o r d i n g  t o  t h e  s t u d y  t r e a tm e n t ( s )  r e c e i v e d .
9 .2 Sub jec t  demog raph ics  and  o the r  base l ine  cha rac te r is t ics
Co rpo ra te  Con f iden t ia l  In fo rma t ionA l l  d a t a  f o r  b a ckg round  a n d  d emog r aph i c  v a r i ab l e s  w i l l  b e  l i s t ed  by  t r e a tm e n t  g r o u p  and  
s u b j e c t .  S um m a ry s t a t i s t i c s  w i l l  b e  p rov id ed  by  t r e a tm e n t  g r o u p .
S u b j e c t  d em o g r a p h i c s  w i l l  i n c l u d e  a g e ,  s ex ,  r a c e ,  e thn i c i ty ,  h e igh t ,  w e i g h t  a n d  BM I .  
O t h e rb a s e l i n e  d i s e a s e  c h a r a c t e r i s t i c s  i n c l u d e  r e l e v a n t  m e d i c a l  h i s t o r y ,  c u r r e n t  m ed i c a l  
c o n d i t i o n s ,  r e s u l t s  o f  l a b o r a to ry  s c r e e n s ,  t r an sp l an t  h i s to ry ,  d o n o r  c h a r a c t e r i s t i c s  ( e . g . ,  ag e ,  
s e x ,  r a c e ,  t y p e ,  C IT )  a n d  a n y  o t h e r  r e l e v a n t  i n f o rm a t i o n .  
Summ a ry s t a t i s t i c s  w i l l  b e  p r e s e n t e d  f o r  th e  s u b j e c t s  in  t h e  F u l l  An a lys i s  S e t .  
C a t e g o r i c a l  d a t a  w i l l  b e  d i sp l ay ed  v i a  a b s o l u t e  a n d  r e l a t i v e  f r equ en c i e s  f o r  e a ch  c a t ego ry  
( in c lud ing  a  c a t ego ry  l a b e l e d  a s  “m i s s i n g ”  w h e n  a p p r o p r i a t e ) .
No va r t i s Con f iden t ia l Page  96
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
9 .3 T rea tmen ts  (s tudy d rug ,  rescue  med ica t ion ,  o the r  concom i tan t  
the rap ies ,  comp l iance )
D a t a  fo r  s tudy  d r u g  adm in i s t r a t ion  ( r e s c u e  m ed i c a t ion )  a n d  con com i t an t  t h e r a p i e s  w i l l  b e  
l i s t ed  by  t r e a tm e n t  g r o u p  a n ds u b j e c t .
9 .3 .1 S tudy  med ica t ion
T h e  du r a t ion  (d ay s )  o f  s tudy  m ed i c a t ion  adm in i s t r a t ion  w i l l  b e  summ a r i z ed .  Th i s  w i l l  b e  
c a l c u l a t e d  by  s ub t r a c t ing  t h e  d a t e  o f  th e  l a s t  a dm i n i s t r a t i o n  o f  s tudy  m ed i c a t ion  f r om  th e  d a t e  
o f  f i r s t  adm in i s t r a t ion  and  th en  add ing  th e  do s ing  in t e rv a l  fo r  CFZ533  o r  T a c( i . e . ,2 8d ay s  fo r  
t r e a tm e n t  a dm i n i s t e r e d  on c e  ev e ry  4  w e e k s ) .  I n  c a l c u l a t i n g  th e  d u r a t i o n  o f  t r e a tm e n t ,  d ay so f  
t empo r a ry  i n t e r r u p t i o n  o f  s tudy  m ed i c a t ion  fo r  any  r e a s o n  w i l l  b e  in c lud ed .  F u r t h e r ,  th e  
f r equ en cy  o f  d o s e  c h a n g e s( i n c l u d i n g  t empo r a ry  d o s e  i n t e r r u p t i o n )  w i l l  b e  p r e s e n t e dby  
r e a s o n  f o r  t h e  c h a n g e .
A v e r a g e  d a i ly  d o s e s  w i l l  b e  p r e s e n t e d  by  t r e a tm en t .  “ Z e r o”w i l l  b e  u s ed  f o r  p e r i o d s  o f  
t empo r a ry  in t e r rup t ion  o f  s tudy  m e d i c a t i o n  f o r  a n y  r e a s o n .
T h e  n um b e r  a n d  p e r c e n t a g e  o f  s u b j e c t s  w h o  p r em a tu r e ly  d i s c o n t i n u e d  s tudy  m e d i c a t i o n  w i l l  
b e  summ a r i z ed  by  r e a s o n  f o r  d i s c o n t i n u a t i o n .
9 .3 .2 Concom i tan t  immunosupp ressan ts
T h e  a v e r a g e  d a i ly  do s e  o f  a dm i n i s t e r e d  MMF ,  T a c  a n d  CSw i l l  b e  s umm a r i z e d  by  t r e a tm en t  
a rm  fo r  sub j e c t s  on  s tudy  m ed i c a t ion .  Th e  do s e  o f  the  indu c t ion  ag en t  w i l l  b e  summ a r i z ed  fo r  
e a ch  o f  d ay s  w h e n  i t  w a s  a dm i n i s t e r e d .
T h e  d o s e  o f  a n t i b o d i e s  u s e d  f o r  t h e  t r e a tm e n t  o f  a c u t e  r e j e c t i o n  e p i s o d e s  w i l l  b e  r e c o r d e d  a s  w e l l.
9 .3 .3 O the r  co- med ica t ions
C o n c om i t a n t  m e d i c a t i o n s ,  o t h e r  t h a n  imm u n o s u p p r e s s a n t s  a n d  CS  m e n t i o n e d  a b o v e ,  w i l l  b e  
s umm a r i z e d  by  t h e r ap eu t i c  c l a s s  a n d  p r e f e r r ed  t e rm  by  p r e s e n t i n g  t h e  numb e r  a n d  p e r c en t ag e  
o f  s u b j e c t s  u s i n g  e a c h  m e d i c a t i o n  f o r  e a c h  t r e a tm e n t  g r o u p .
9 .4 Ana lys is  o f  the  p r ima ry v a r iab le (s )
9 .4 .1 Va r iab le (s )
Pa r ts  1  and  2 :
Co rpo ra te  Con f iden t ia l  In fo rma t ionT h e  p r im a ry  v a r i a b l e  i s  tBPAR  a f t e r  3  mon th s  o f  t r e a tm e n t .F o r  t h e  an a ly s i s  in  P a r t  2 ,t h e  
to t a l  “ o n  t r e a tm e n t  t im e ”in  e a c h  t r e a tm e n t  g r o u p  i s  r e q u i r e d .  
 Co rpo ra te  Con f iden t ia l  
In fo rma t ion
No va r t i s Con f iden t ia l Page  97
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
9 .4 .2 S ta t is t ica l  mode l ,  hypo thes is ,  and  me thod  o f  ana lys is
Hand l ing  o f  m iss ing  va lues /censo r ing /d iscon t inua t ions
T h e  p r im a ry  a n a ly s i s  on ly  c on s id e r s  t h e  e v e n t s  “on  t r e a tm e n t ”  ( a p p l y  th ew i n d owd e f i n e d  in  
S e c t i o n9 . 4 . 1) ,  thu s  a c c o u n t i n g  f o r  d i s con t inu a t ion s  f r om  t h e  r a n d om i z e d  t r e a tm e n t  a rm  o r  
s tudy .
Pa r t  1
T h e  n um b e r  o f  p a t i e n t s  w i t h  tBPAR  i s  a s s um e d  t o  f o l l ow  a  b i n om i a l  d i s t r i b u t i o n ,  i . e . ,
ri  ~  B i n om i a l (  n i,  θi  ) ,  w h e r e  ri  i s  t h e  n um b e r  o f  p a t i e n t s  w i th  tBPARi n  t r e a tm e n t  g r o u p  i ,  n i  i s  
t h e  n um b e r  o f  p a t i e n t s  i n  t r e a tm e n t  g r o u p  i  a n d  θ i  i s  th e  p rob ab i l i ty  o f  tBPAR .
T h e  p o s t e r i o r  m e a n  tBPAR  r a t e  w i l l  b e  p r e s e n t e d  t o g e t h e r  w i t h  t h e  9 5%  c r e d i b l e  i n t e r v a l .  
Pa r t  2
T h e  n um b e r  o f  p a t i e n t s  w i t h  tBPAR  i s  a s s um e d  t o  f o l l ow  a  b i n om i a l  d i s t r ib u t i o n ,  i . e . ,
r i  ~  B i n om i a l (  n i ,  θi  ) ,  wh e r e  r i  i s  th e  numb e r  o f  p a t i e n t s  w i th  tBPAR  in  t r e a tm en t  g r o u p  i ,  n i  
i s  t h e  n um b e r  o f  p a t i e n t s  i n  t r e a tm e n t  g r o u p  i  a n d  θ i  i s  th e  p rob ab i l i ty  o f  tBPAR .
T h e  p r im a ry  e f f i c a cy  a n a ly s i s  fo r  t h e  f i r s t  3  mon th s  o f  P a r t  2e v a l u a t e s  w h e t h e r  a  CFZ533  
t r e a tm e n t  a rm  m e e t s  t h e  p r e - d e f i n e d  su c c e s s  c r i t e r i a .   
P r  ( θCFZ 5 3 3 1  –θS oC  <0 .20  |  d a t a )  >  60% .
T h e  r e q u i r e d  po s t e r io r  p r o b a b i l i t i e s  w i l l  b e  e s t im a t e d  f r om  s im u l a t i o n s  o f  t h e  po s t e r io r  
d i s t r i b u t i o n s  o f  θ CFZ 5 3 3  –θS oC  a n d  c om p a r e d  t o  t h e  t h r e s h o l d s  f o r  t h e  l e v e l s  o f  p r o o f .
T h e  p r i o r  d i s t r ibut ion s  w i l l  b e  a s sum ed  to  b e  a  non - i n f o rm a t i v e  B e t a (1 /3 ,1 /3 )  fo r  CFZ533  and  
a n  i n f o rm a t i v e  p r io r  o f  B e t a ( 1 ,  1 3 )  f o r  p l a c ebo .  Th i s  i n f o rm a t i v e  p r io r  c o r r e s p o n d s  to  an  
a p p r o x im a t e  m e a n  r e s p o n s e  r a t e  o f  7%  w i th  a  95%  c o n f i d e n c e  in t e rv a l  o f  ( 0 . 2% ,  24% )  and  
w a s  d e t e rm i n e d  v i a  a  m e t a- a n a l y s i s  o f  c o n t r o l  t h e r a p i e s  ( s e e  S e c t ion  9 .6Co rpo ra te  Con f iden t ia l  In fo rma t ion
) .
T h e  p o s t e r i o r  m e a n  tBPAR  r a t e s  f o r  e a c h  t r e a tm en t  g r o u p  a n d  f o r  th e  d i f f e r e n c e  in  m e an  
r e s p o n s e  r a t e s  b e tw e e n  t r e a tm e n t s  w i l l  b e  p r e s e n t e d  t o g e t h e r  w i t h  9 5%  c r e d i b l e  i n t e r v a l s .  Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  98
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
9 .4 .3 Suppo r t ive  ana lyses
Pa r t  2
T h e  tBPAR(o r  BPAR )r a t e  w i l l  b e  an a l y z ed  a t  6  mon th s  a n d  12  mon th s  po s t  t r a n s p l a n t a t i o n  
u s i n g  t h e  s am e  m e t h o d  a s  d e s c r i b e d  f o r  t h e  m o n t h  3  a n a ly s i s  inS e c t ion  9 .4 .2.
9 .5 Ana lys is  o f  seconda ry and  exp lo ra to ry  va r iab les
9 .5 .1 E f f icacy
O t h e r  e f f i c a cy  v a r i a b l e s  w i l l  b e  a n a l y ze d  s im i l a r ly  t o  t h e  p r im a ry  e f f i c a cy  e n d p o i n t ,  a l though  
w i t h o u t  t h e  n o n- in f e r io r i ty  t e s t :
tBPAR  a t  M o n t h s  3 ,  6  a n d  1 2
BPAR  a t  M o n t h s  3 ,  6  a n d  1 2
Gr a f t  l o s s  a t  M o n t h s  6  a n d  1 2
De a t h  a t  M o n t h s  6  a n d  1 2
Gr a f t  l o s s  o r  d e a t h  a t  M o n t h s  6  an d  1 2
An t ibodym e d i a t e dtBPAR  a t  Mon th  12
F o r  e a c h  o f  t h e  e f f i c a c y  e ndpo in t s  (p r im a ry  a n d  s e cond a ry ) ,  s imp l e  ev en t  r a t e  e s t im a t e s  
( p r o p o r t i o n  o f  e v e n t s )  w i l l  b e  o b t a in e d  a n d  e a ch  CFZ 5 3 3  t r e a tm e n t  a rm  e v e n t  r a t e  w i l l  b e  
c om p a r e d  w i th  t h e  con t ro l  a rm  e v e n t  r a t e s  u s ing  Z -s t a t i s t i c s  b a s ed  on  tw o - s i d e d  95%  
c o n f i d e n c e  i n t e r v a l s  f o r  d i f f e r e n c e s  i n  e v e n t  r a t e s .
A s  s u p p o r t i ve  a n a l y s e s ,  BPAR  a n d  tBPAR  w i l l  a l s o  b e  a n a l y ze d  u s i n g  t h e  a d j u d i c a t e d  r e su l t s .Co rpo ra te  Con f iden t ia l  In fo rma t ion
9 .5 .2 Pha rmacodynam ics
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis Confidential Page 99
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Total soluble CD40 and total soluble CD154
These data will be summarized by treatment and subject. Descriptive statistics will also be 
provided such as mean, median, standard deviation, minimum and maximum, by time point 
and treatment .
9.5.3 Safety
Unless otherwise specified, safet y analy ses include all data collected, including after 
discontinuation of randomized treatment.
9.5.3.1 Main safety  endpoint: estimated GFR using the MDRD formula
The key secondary  and safet y variable is renal function as assessed by eGFR (MDRD 
formula). This will be evaluated at Month 12 by comparing the mean eGFR values between 
groups .
The MDRD formula is defined as follows ( Leve y et al 2003 ):
GFR [mL/min/1.73m2] = 
186.3*(C-1.154)*(A-0.203)*G*R 
C is the serum concentration of creatinine [mg/dL ]
A is age [y ears]
G=0.742 when gender is female , otherwise G=1
R=1.21 when race is black, otherwise R=1.
Local laboratory  serum creatinine values will be used for all renal function data analysis. 
Serum creatinine results are in units of umol/L , so the following formula should be used to 
convert to the required unit of mg/dL :
C[mg/dL ] = serum concentration of creatinine [umol/L ] / 88.4.
Estimated GFR will be determined and summarized in each part of the study . 
Handling of missing values/censoring/discontinuations
The analysis will be made on the FAS population. The following imputation method will be 
applied for patients with missing eGFR values:
Patients that lose their graft will be assigned a value of zero for their missing GFR value.
Patients that die or are lost to follow -up with a functioning graft will have an imputed 
value using the last -observation -carried -forward (LOCF) method.
For pat ients that discontinue randomiz ed treatment the eGFR will be considered missing 
after apply ing the windows defined in Section 9.4.1 .
Novartis Confidential Page 100
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Graft loss patients do not have a functioning graft; he nce the lowest possible GFR value (zero) 
will be assigned to such patients. In contrast, patients that die with a functioning graft, die for 
different reasons (e.g., suicide, car accident, cancer). Similarly , patients who are lost to 
follow -up have renal function, but missing values for various reasons (e.g., moving from the 
area or not being able to make the site visit during the Month 6 or Month 12 visit window). 
Patients who have a functioning graft at the time of death or are Lost to Follow -up with a 
functioning graft will be anal yzed via an imputation method that employ s LOCF.
9.5.3.2 Other safety  endpoints
Vital signs
All vital signs data will be listed by treatment, subject, and visit/time and if ranges are 
available, abnormalities (and relevant orthostatic c hanges) will be flagged. Summary  statistics 
will be provided by  treatment and visit/time.
ECG evaluations
All ECG data will be listed by  treatment, subject and visit/time; abnormalities will be flagged. 
Summary  statistics will be provided by treatment and visit/time.
Clinical laboratory  evaluations
All laboratory  data will be listed by  treatment, subject, and visit/time and if normal ranges are 
available, abnormalities will be flagged. Summary  statistics will be provided by  treatment and 
visit/time.
Adverse events
All information obtained on AEs will be display ed by  treatment and subject.
AEs and infections collected are to be coded with the MedDRA dictionary  that gives preferred 
term and primary  system organ class information. AEs and infection preferred terms are to be 
analyzed as a whole under the heading of AEs for each treatment arm. The incidence of AEs 
will be summarized by  body  system, severity and relationship to study  drug b y the following:
AEs by  primary  SOC and PT
AEs rated to have relationship to study  drug by  SOC and PT
AEs by  primary  SOC, PT, and maximum severity
SAEs by  SOC and PT
SAEs rated to have relationship to study  drug by  SOC and PT
Deaths b y SOC and PT
AEs leading to discontinuation of a study  drug by SOC and PT
AEs leading to dose ad justment or interruptions of a study  drug b y SOC and PT
infections by  type of infection (viral, bacterial, fungal, and others) and microorganism 
of infection
serious infections b y type of infection and micro -organism of infection
new onset diabetes mellitu s (as defined in Section 6.6.4.4 )
Novartis Confidential Page 101
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
AEs by  standardized MedDRA query  (SMQ) levels (broad and narrow search)
AEs by  standardized MedDRA query  (SMQ) and preferred term (broad and narrow search )
Multiple Occurrences for Tables:
In all tables about incidence rates of AEs / Infections, if a patient has multiple occurrences of 
an AE, this patient will be counted only once in the corresponding AE category . If a patient 
has multiple AEs within a system organ class , s/he will be counted only once for that class. If 
a patient has multiple severit y ratings for an AE while on treatment, s/he is only counted 
under the maximum rating. 
Information pertaining to AEs noted during the study  will be listed by patient, includ ing the 
verbatim term given by the Investigator, the PT and SOC given by the MedDRA dictionary, 
start and end date, causality , severity , and relationship to study  drug as assessed by the 
Investigator.
BK-polyoma viremia and nephropathy  
The following variables will be anal yzed descriptively :
occurrence of BK -polyoma viremia an y time post -transplantation “on treatment”
occurrence of BK -polyoma viremiaan y time after switching a patient to SoC treatment
occurrence of BK-polyoma virus nephropathy  any time post-transplantation “on treatment”
occurrence of BK -polyoma viremia any time after switching a patient to SoC treatment.
The difference of the investigational regimens to the control regimen will be summarized by 
risk ratios and appropriate CI s.
EBV, CMV andTB
All EBV, CMV and TB surveillance data will be listed by treatment, subject, and visit/time 
and if normal ranges are available, abnormalities will be flagged. Summary  statistics will be 
provided b y treatment and visit/time.
Laboratory  data 
Abnormalities according to clinically  notable criteria will be identified. A by -subject listing of 
individual subject laboratory  data will be generated. Values outside of the clinically  notable 
limits will be flagged. Shift tables describing changes from randomization/enrollment based 
on the clinical notable criteria will be presented. 
Descriptive statistics (mean, standard deviation, minimum, median and maximum) of 
quantitative laboratory  variables, including change from randomization/enrollment, will be 
generated b y visit.
No va r t i s Con f iden t ia l Page  102
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
New  onse t  d iabe tes  me l l i tus  (NODAT )
T h e  i n c i d e n c e  o f  sub j e c t s  d e v e l o p i n g  n ew  on s e t  d i a b e t e s  m e l l i tu s  a f t e r  t r an sp l an t a t ion  
(NODAT )  w i l l  b e  s umm a r i z e d  by  t r e a tm e n t  g roup .  T h e  p r o b a b i l i t i e s  o f  d e v e l o p i n g  NODAT  
w i l l  b e  c om p a r e d  b e tw e en  t r e a tm e n t  g r o u p s  a t  6  and  1 2  mon th s  p o s t- t r a n s p l a n t  u s i n g  log i s t i c  
r e g r e s s i o n  m o d e l s  w i th  H bA 1 c  l e v e l s  a t  r andom i z a t ion / en ro l lm en t  a s  p r e d i c t i v e  v a r i ab l e s .  
D e a t h ,  g r a f t  lo s s ,  o r  lo s s  to  f o l l ow  u p  w i thou t  NODAT  b e fo r e  Mon th  12  w i l l  no t  b e  c o u n t e d  
a s  d ev e lop ingNODAT .  Th i s  an a ly s i s  w i l l  b e  p e r fo rm ed  u s i n g  sub j e c t s  in  t h e  FAS  popu l a t ion  
w h o  d o  n o t  h a v e  DM  a t  r a n d om i z a t i o n / e n r o l lm e n t .
9 .5 .4 Mode l  based  dose-exposu re  response  ana ly s is
N o t  a p p l i c a b l e .
9 .5 .5  Pha rmacok ine t ics
CFZ 5 3 3  p l a sm a  con c en t r a t ion  d a t a  w i l l  b e  l i s t e d  by  t r e a tm e n t ,  sub j e c t ,  a n d  v i s i t / s am p l i n g  
t im e  po in t .  D e s c r i p t i v e  summ a rys t a t i s t i c s  w i l l  b e  p r o v i d e d  by  t r e a tm en t  a n d  v i s i t / s amp l ing  
t im e  po in t ,  i n c l u d i n gt h e  f r equ en cy  ( n ,  % )  o f  c o n c e n t r a t i o n s  b e l ow  t h e  LLOQ ,  w h i c h  w i l l  b e  
r e p o r t e d  a s  z e r o .  Summ a ry s t a t i s t i c s  w i l l  i n c l u d e  m e a n  ( a r i t hm e t i c  a n d  g e om e t r i c ) ,  SD ,  CV  
( a r i t hm e t i c  a n d  g e om e t r i c ) ,  m e d i a n ,  m in imum  and  m ax imum .  C o n c e n t r a t io n s  b e l ow  LLOQ  
w i l l  b e  t r e a t e d  a s  z e r o  in  summ a ry  s t a t i s t i c s .  A  g e om e t r i c  m e a n  w i l l  no t  b e  r e p o r t e d  i f  th e  
d a t a s e t  i n c l u d e s  z e r o  v a l u e s .
I f  d a t a  p e rm i t ,  PKp a r am e t e r s  w i l l  b e  c a l cu l a t ed  a s  d e s c r ib ed  in  S e c t ion6 . 7 . 3a n d  w i l l  b e  
l i s t ed  by  t r e a tm e n t  a n d  sub j e c t .  C o n c en t r a t i o n s  b e low  t h e  l im i t  o f  qu an t i f i c a t ion  w i l l  no t  b e  
c o n s i d e r e d  f o r  t h e  c a l cu l a t ion  o f  PKp a r am e t e r s .  D e s c r i p t i v esumm a ry  s t a t i s t i c s  w i l l  i n c l u d e  
m e a n  ( a r i t hm e t i c  a n d  g e om e t r i c ) ,  SD ,  a n d  CV  ( a r i thm e t i c  a n d  g eom e t r i c ) ,  m e d i a n ,  m i n im um  
a n d  m ax imum .  A ne x c e p t i o n  to  t h i s  i s  Tm a x  w h e r e  m e d i a n ,  m in imum  a n d  m ax imum  w i l l  b e  
p r e s e n t e d .
A  d o s e- ind ep end en t ,  mod e l - b a s e d  a n a l y s i s  o f  IV  a n d  SC  d o s i n g  m ay b e  u s ed  to  d e t e rm i n e  th e  
b io av a i l ab i l i ty  o f  t h e  SC  a dm i n i s t r a t i o n  in  t h i s  s tudy  ( s e e  S e c t i o n6 .7 .3f o r  m o r e  d e t a i l s ) .  
A l s o ,any  d o s e ( con c en t r a t ion )- e x p o s u r e  r e l a t ion sh ip  s h o u l d  be  d e r i v edu s i n g  s am e  th e  
a p p r o a c h .  S u c h  a n a ly s i s  w i l lb e  r e p o r t e d  i n  a  s e p a r a t e  s t a n d a l o n e  r e p o r t .
9 .5 .6 Pha rmacok ine t ic  /  pha rmacodynam ic  in te rac t ionsCo rpo ra te  Con f iden t ia l  In fo rma t ion
T h e  r e l a t ion sh ip  b e tw e e n  CFZ 5 3 3  con c en t r a t ion  (PK )a n d  PD  v a r i a b l e sw i ll  b e  exp lo r ed  
g r a p h i c a l ly .  M o d e l i n g  o f  PK /PD  d a t a  u s ing  a  p o p u l a t io n  a p p r o a c h  m ay b e  p e r f o rm e d  a s  
a p p r o p r i a t e  a n d  w i l l  b e  r epo r t ed  in  a  s ep a r a t e  s t and a lon e  r epo r t .Th e  b ro ad  p r i n c i p l e s  ou t l in ed  
in  th e  FDA  Gu id an c e  fo r  I ndu s t ry :  Popu l a t i o n  P h a rm a c o k i n e t i c s  w i l l  b e  fo l low ed .
No va r t i s Con f iden t ia l Page  103
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
D rug- d rug  in te rac t ions
Th i s  s tudy  i s  a l s o  c o l l e c t i n g  d a t a  to  do cum en t  p o t e n t i a l  T h e r a p e u t i c  P r o t e i n  D r u g  I n t e r a c t i o n s  
(TPD I )  w h e n  CFZ533  i s  g i v e n  in  c om b i n a t i o n  w i th  myc o p h e n o l a t e  m o f e t i l  a n d  T a cin  
d en o v ok idn ey  t r an sp l an t  p a t i en t s .
To  ev a lu a t e  th e  po t en t i a l  fo r  CFZ533  to  c au s e  TPD I v i a  ind i r e c t  ( t a rg e t  b ind ing )  m e ch an i sm s,  
a n  exp lo r a to ry  p o p u l a t i o n  p h a rm a c o k i n e t i c  (PPK )  a p p r o a c h  m ay b e  c o n d u c t e d ,a im i n g  to  
id en t i fy  u n e x p e c t e d  TPD Is  w i th  p l a n n e d  c o- th e r ap i e s  (m o n i t o r i n g  t rough  c o n c e n t r a t i o n s  o f  
T a ca n d  MPA) ,  and  to  p r o v i d e  a  f i r s t  r i s k  a s s e s sm en t  in  d e  n o v o
Co rpo ra te  Con f iden t ia l  In fo rma t iont r a n s p l a n t  p a t i e n t s.  
Th i sa p p r o a c h  i s  a im i n g  to  e v a l u a t e  CFZ 5 3 3  ( i )  a s  a  p e r p e t r a t o r ,  w i th  p o t e n t i a l  i n t e r a c t i o n s  
w i th  d r u g s  s p e c i f i c  to  t h e  t a r g e t  i n d i c a t i o n  (m y c o p h e n o l a t e  m o f e t i l  and  T a c) ,  o r  ( i i )  a s  a  
v i c t im  d r u g ,  t r e a t ing  con com i t an t  m e d i c a t i o n s  a s  c o v a r i a t e s ,  by  a s s e s s ing  a  d r u g  i n t e r a c t i o n  
e f f e c t  o n  c l e a r a n c e .Th i s  exp lo r a to ry  a p p r o a c h  shou ld  b e  g e n e r a t i n g  hy po th e s i s ,  w i th  f i n d i n g s  
to  b e  c o n f i rm e d  th rough  a  p r o s p e c t i v e  poo l ed  PPK  a p p r o a c h  b a s ed  on  d a ta  c o l l e c t e d  in  Ph a s e  
I I I  a n d  P h a s e  I I ,  t o  e n s u r e  u n b i a s e d  a n d  c o n c l u s i v e  a n a ly s i s  r e s u l t s .
S u c h  exp lo r a to ry  a n a ly s i s  app ly ing  a  p o p u l a t i o n  p h a rm a c o k i n e t i c  app ro a ch  m ayb e  r e p o r t e d  
i n  a  s e p a r a t e  s t a n d a l o n e  m o d e l i n g  r e p o r t .
Novartis Confidential Page 104
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
9.6 Sample size calculation
All Parts: 
The stopping rules as defined in Section 5.5.10 are designed to ensure that a CFZ533 
treatment arm will be stopped if there is a high proba bility  (>90%) that the true tBPAR rate is 
greater than 20%. 
Figure 9
-1indicates the probability  of stopping for an arm for various true tBPAR rates and 
shows that the stopping rules ensure that the chance of stopping an arm are sufficiently  high 
for true high tBPAR rates while remaining appropriately  low when the true rates are low.
Figure 9-1 Probability  of stopping a c ohort for various true tBPA R rates
Part 2
Operating characteristics
The sample size justification for Part 2 considers the probability  of progressing further 
development or not progressing based on the planned safet y stopping rules and the success 
criteria for the planned sample size. 
The safet y stopping rules (see Section 5.5.10 ) ensure that the study  will not continu e if:
Pr (θCFZ533 > 0.20 |  data) > 90%

Novartis Confidential Page 105
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
The success criteria (see Section 9.4.2 ) are met if :
Pr (θCFZ533 – θSoC <0.20 |  data) > 60% .
Figure 9-2shows the chances of continuing development (i.e., of not meeting the safet y 
stopping rules and meeting the success criteria) on the y-axis for a range of true values of the 
tBPAR rate for CFZ533 (x-axis) and for three possible control rates (blue and grey curve s). 
Theprobability of moving is high when CFZ533 has a low true tBPAR rate and is comparable 
to control. For example, if the true CFZ533 rate is less than 20% and the true control rate is 
around 10%, there is a greater than 80% probability  of progressing to Part 3.
Conversel y, when the true tBPAR rate for CFZ533 is high, the probability  of not continuing is 
high. For example, there is an approximately  80% probability  of not progressing when the 
true CFZ533 rate is more than 25% greater than the true contro l rate. 
Figure 9-2 Probability  of progressing for different true values of tBPA R for 
CFZ533 and control

Novartis Confidential Page 106
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
These calculations assume that the primary  efficacy  variable, rate of tBPAR, follows a 
binomial distribution. The prior distribution for the control tBPAR rate, Beta(1, 13is 
estimated from a Bayesian meta -analysis of tBPAR rates from four previous studies using a 
control treatment similar to the one used in this study . The four studies were selected from the 
studies used in a previous Novartis generated meta -analy sis studies and are summarized in 
Table 9-
1.
Table 9-1 Summary  of historical control data
Study Treatment Number of 
patients with 
tBPA RTotal number 
of patientstBPA R rate
1 -Vincenti et al 2007 B+Tac+MMF+CS 24 346 0.069
2 -Silva et al 2007 B+Tac XL+MMF+CS 17 214 0.079
3 -Silva et al 2007 B+Tac+MMF+CS 8 212 0.038
4 -Scholten et al 2006 B+Tac+ MMF(0.5g)+CS 4 63 0.063
B=basiliximab
Prediction of the control rate for a future trial resulting from the Bayesian meta -analysis is 
shown in Figure 9-
3.
Figure 9-3 Results of Bay esian meta -analysis prediction
Figure 9 -3shows estimates of response rate and 95% credible intervals for each study based on study 
data alone (dashed lines) and from the meta -analysis (solid lines). The overall prediction for response
rate in a future study is shown in red together with the mean and 95% credible interval from the 
posterior distributions and n*, the prior number of observations that these data would contribute to a 
future analysis.

No va r t i s Con f iden t ia l Page  107
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
T o  a l low  fo r  a  s imp l e  r andom i z a t ion  r a t io  fo r  a l lo c a t ion  o f  p a t i en t s  to  t r e a tm en t  g roup s ,  i t  w a s  
d e c id ed  to  r edu c e  th e  con t ro l  a rm  to  15  p a t i en t s ,  comp a r ed  to  30  fo r  th e  CFZ533  a rm s .  Thu s  a  
p r i o r  b e t a  d i s t r ibu t ion  o f  B e t a  (1 ,  1 3 )  w a s  c h o s e n ,  w h i c h  h a s  a  m e an  v a lu e  o f  7  w i th  95%  C I 
( 0 . 2 ,  2 4 )  a n d  a n  a p p r o x im a t e  w e i g h t  o f  1 4  p a t i e n t s .
9 .7 Powe r  fo r  ana lys is  o f  key  seconda ry v a r iab les
T a b l e9 - 2p r o v i d e s  80%  a n d  9 5%  C Is  fo r  b e tw e e n- t r e a tm e n t  d i f f e r e n c e  (CFZ 5 3 3 - co n t r o l  
r e g im e n )  b a s ed  on  a n  a s sum ed  SD  a n d  d i f f e r en c e  f o r  eGFR MDRD.  S i n c e  th i s  i s  a n  exp lo r a to ry  
p h a s e  2  t r i a l ,  ev id en c e  o f  r e n a l  b en e f i t  w i l l  b e  b a s ed  o n  a  80%  C I .  I n  l in e  w i th  th e  
SYMPHONY  s tudy  ( Ekb e rge ta l2 0 0 7) ,  ad i f f e r en c e  o f  6 .5  mL/m in /1 .73m2b e tw e e n  
t r e a tm e n t  r e g im e n s  i s  c o n s i d e r e d  t o  b e  t h e  l ow e r  l im i t  o f  c l i n i c a l l y  r e l e v a n t  b e n e f i t .
Tab le  9 -2 Two -s ided  80  and  95  pe rcen t  examp le  C Is  fo r  be tween- t rea tmen t  
d i f fe rence  (CFZ533- Con t ro l  reg imen )  o f  ca lcu la ted  eGFR  (MDRD ) ,  
assum ing  d ropou t  ra te  =  30  pe rcen t  (n  =  53 /g roup )
Obse rved  S tanda rd  
Dev ia t ionObse rved  d i f fe rence  in  eGFR MDRD
CFZ533  –con t ro l80%  C I 95%  C I
16 4 .0 ( - 0 .0 ,  8 .0 ) ( - 2 .2 ,10 .2 )
5 .0 (1 .0 ,  9 .0 ) ( -1 .2 ,  11 .2 )
6 .0 (2 .0 ,  10 .0 ) ( -0 .2 ,  12 .2 )
7 .0 (3 .0 ,  11 .0 ) (0 .8 ,  13 .2 )
8 .0 (4 .0 ,  12 .0 ) (1 .8 ,  14 .2 )
18 4 .0 ( - 0 .5 ,  8 .5 ) ( -3 .0 ,11 .0 )
5 .0 (  0 .5 ,  9 .5 ) ( -2 .0 ,12 .0 )
6 .0 (  1 .5 ,10 .5 ) ( -1 .0 ,13 .0 )
7 .0 (  2 .5 ,11 .5 ) (  0 .0 ,14 .0 )
8 .0 (  3 .5 ,12 .5 ) (  1 .0 ,15 .0 )
20 4 .0 ( - 1 .0 ,  9 .0 ) ( -3 .7 ,  11 .7 )
5 .0 ( -0 .0 ,  10 .0 )  ( -2 .7 ,  12 .7 )
6 .0 (1 .0 ,  11 .0 ) ( -1 .7 ,  13 .7 )
7 .0 (2 .0 ,  12 .0 ) ( -0 .7 ,  14 .7 )
8 .0 (3 .0 ,  13 .0 ) (0 .3 ,  15 .7 )Co rpo ra te  Con f iden t ia l  In fo rma t ion
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  108
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
10 E th ica l  cons ide ra t ions
10 .1 Regu la tory  and  e th ica l  comp l iance
Th i s  c l i n i c a l  s tudy  w a s  d e s i g n e d  a n d  s h a l l  b e  im p l em e n t e d  a n d  r epo r t ed  in  a c c o r d a n c e  w i th  
t h e  ICH  H a rmon i z ed  T r i p a r t i t e  G u i d e l i n e s  f o r  Good  C l i n i c a l  P r a c t i c e ,  w i th  a p p l i c a b l e  lo c a l  
r e g u l a t i o n s  ( i n c l u d i n g  E u r o p e a n  D i r e c t i v e  2 0 0 1 / 2 0/EC ,  US  C o d e  o f  F e d e r a l  R e g u l a t i o n s  T i t l e  
2 1 ,  a n d  J ap an e s e  M in i s t ry o f  H e a l th ,  L a b o r ,  and  W e l f a r e ) ,  a n d  w i th  t h e  e th i c a l  p r in c i p l e s  l a id  
d ow n  i n  t h e  D e c l a r a t i o n  o f  H e l s i n k i .
10 .2 In fo rmed  consen t  p rocedu resCo rpo ra te  Con f iden t ia l  In fo rma t ion
E l i g i b l e  s u b j e c t s  m ay o n ly  b e  i n c l u d e d  in  t h e  s tudy  a f t e r  p r o v i d i n g  w r i t t en  (w i t n e s s e d ,  w h e r e  
r e q u i r e d  by  l aw  o r  r e g u l a t i o n ) ,  IR B / IEC- a p p r o v e d  i n f o rm e d  con s en t ,  o r ,  i f  i n c ap a b l e  o f  do ing  
s o ,  a f t e r  su ch  con s en t  h a s  b e e n  p rov id ed  by  a  l eg a l ly  a c c e p t a b l e  r e p r e s e n t a t i v e  o f  t h e  sub j e c t .  
I n  c a s e s  wh e r e  t h e  sub j e c t ’ s  r e p r e s e n t a t i v e  g iv e s  c o n s e n t ,  th e  sub j e c t  s h o u l d  b e  in fo rm ed  
a b o u t  t h e  s tudy  t o  t h e  ex t en t  p o s s i b l e  g i v e n  h i s / h e r  u n d e r s t a n d i n g .  I f  t h e  sub j e c t  i s  c a p a b l e  o f  
d o i n g  so ,  h e / s h e  shou ld  i n d i c a t e  a s s e n t  by  p e r son a l ly  s ig n ing  a n d  d a t ing  t h e  w r i t t en  in fo rm ed  
c o n s e n t  d o c um e n t  o r  a  s e p a r a t e  a s s e n t  fo rm .  I n f o rm e d  con s en t  mu s t  b e  o b t a i n e d  b e fo r e  
c o n d u c t i n g  a n y  s tudy - sp e c i f i c  p ro c edu r e s  ( i . e . ,  a l l  o f  th e  p ro c edu r e s  d e s c r ib ed  in  th e  p ro to co l ) .  
T h e  p r o c e s s  o f  o b t a i n i n g  in fo rm ed  con s en t  shou ld  b e  d o c um e n t e d  in  th e  sub j e c t  sou r c e  
d o c um e n t s .
N o v a r t i s  w i l l  p r o v i d e  to  I nv e s t ig a to r s  in  a  s ep a r a t e  d o c um e n t  a  p r o p o s e d  i n f o rm e d  con s en t  
f o rm  t h a t  c om p l i e s  w i t h  t h e  IC H  GCP  g u i d e l i n e  a n d  r egu l a to ry  r e q u i r em e n t s  a n d  i s  
No va r t i s Con f iden t ia l Page  109
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
c o n s i d e r e d  app rop r i a t e  fo r  th i s  s tudy .  Any  ch ang e s  to  th e  p ropo s ed  con s en t  fo rm  sugg e s t ed  by  
t h e  I n v e s t i g a t o r  mu s t  b e  a g r e e d  to  by  N ov a r t i s  b e f o r e  subm i s s ion  to  t h e  IRB / IEC ,  a n d  a  c o p y  
o f  t h e  a p p r o v e d  v e r s i o n  m u s t  b e  p r o v i d e d  t o  t h e  N o v a r t i s  m o n i t o r  a f t e r  IR B / IEC  a p p r o v a l .
Wom en  o f  c h i l d  b e a r i n g  p o t e n t i a l  sh o u l d  b e  in f o rm e d  t h a t  t a k i n g  t h e  s t u d y  d r u g  m ay i nvo lv e  
u n k n ow n  r i sk s  to  th e  f e tu s  i f  p r egn an cy  w e r e  to  o c cu r  du r ing  th e  s tudy  a nd  ag r e e  th a t  in  o rd e r  
to  p a r t i c i p a t e  in  t h e  s tudy  t h ey  m u s t  adh e r e  to  t h e  c o n t r a c e p t i o n  r equ i r em en t  f o r  t h e  du r a t ion  
o f  t h e  s tudy .  I f  t h e r e  i s  any  q u e s t i o n  t h a t  t h e  s u b j e c t  w i l l  no t  r e l i ab ly  c omp ly ,  th ey  s h o u l d  no t  
b e  e n t e r e d  i n  t h e  s t u d y .
I n  t h e  ev en t  t h a t  Nov a r t i s  w a n t s  to  p e r f o rm  t e s t i n g  o n  th e  s am p l e s  t h a t  a r e  no t  d e s c r i b e d  in  
th i s  p ro to co l ,  add i t ion a l  In s t i tu t ion a l  R ev i ew  Bo a rd  and /o r  E th i c s  Comm i t t e e  app rov a l  w i l l  b e  
o b t a i n e d .
10 .3 Respons ib i l i t ies  o f  the  inves t iga to r  and  IRB / IEC
T h e  p r o t o c o l  a n d  th e  p r o p o s e d  in fo rm ed  con s en t  f o rm  mu s t  b e  r ev i ew ed  a n d  a p p r o v ed  by  a  
p r o p e r ly  c o n s t i t u t e d  I n s t i tu t ion a l  R e v i ew  Bo a rd / In d e p e n d e n t  E t h i c s  C omm i t t e e /R e s e a r c h  
E t h i c s  B o a r d  ( IRB / IEC /REB )  b e fo r e  s tudy  s t a r t .  A  s i g n e d  and  d a t e d  s t a t em e n t  t h a t  th e  
p r o t o c o l  a n d  in fo rm ed  con s en t  h a v e  b e en  a p p r o v e d  by  t h e  IR B / IEC /REB ,  mu s t  b e  g i v e n  to  
N o v a r t i s  b e f o r e  s tudy  i n i t i a t ion .  P r i o r  to  s tudy  s t a r t ,  t h e  I n v e s t i g a t o r  i s  r e q u i r e d  to  s ign  a  
p r oto co l  s ign a tu r e  p ag e  con f i rm ing  h i s /h e r  ag r e em en t  to  condu c t  th e  s tudy  in  a c co rd an c e  w i th  
t h e s e  d o c um e n t s  a n d  a l l  o f  t h e  i n s t r u c t i o n s  a n d  p r o c e d u r e s  f o u n d  in  th i s  p r o t o c o l  a n d  to  g i v e  
a c c e s s  to  a l l  r e l e v a n t  d a t a  a n d  r e co rd s  to  Nov a r t i s  m o n i t o r s ,  a u d i t o r s ,  N o v a r t i s  C l i n i c a l  
Qu a l i ty A s s u r a n c e  r e p r e s e n t a t i v e s ,  d e s i g n a t e d  a g e n t s  o f  Nov a r t i s ,  IR B s / IEC s /REB s ,  and  
r egu l a to ry  a u t h o r i t i e s  a s  r e q u i r e d .  I f  an  in sp e c t ion  o f  t h e  c l i n i c a l  s i t e  i s  r e q u e s t e d  by  a  
r egu l a to ry  a u t h o r i ty ,  t h e  I nv e s t ig a to r  mu s t  i n f o rm  N o v a r t i s  imm ed i a t e ly  t h a t  th i s  r e q u e s t  h a s  
b e e n  m a d e .
10 .4 Pub l ica t ion  o f  s tudy p ro toco l  and  resu l tsCo rpo ra te  Con f iden t ia l  In fo rma t ion
N o v a r t i s  a s s u r e s  t h a t  t h e  k ey  d e s i g n  e l em e n t s  o f  th i s  p r o t o c o l  w i l l  b e  p o s t e d  in  a  p u b l i c ly  
a c c e s s i b l e  d a t a b a s e  su ch  a s  c l i n i c a l t r i a l s . g o v .  I n  a d d i t i o n ,  u p o n  s tudy  c omp le t i o n  and  
f in a l i z a t ion  o f  t h e  s tudy  r e p o r t  t h e  r e s u l t s  o f  t h i s  t r i a l  w i l l  b e  e i t h e r  s u bm i t t e d  f o r  p u b l i c a t i o n  
a n d / o r  p o s t e d  i n  a  p u b l i c l y  a c c e s s i b l e  d a t a b a s e  o f  c l i n i c a l  t r i a l  r e s u l t s .
Novartis Confidential Page 110
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
11 Protocol adherence
This protocol defines the study  objectives, the study procedures and the data to be collected 
on study  participants. Additional assessments required to ensure safet y of subjects should be 
administered as deemed necessary  on a case by case basis. Under no circumstances should an 
Investigator collect addition al data or conduct any additional procedures for any research 
related purpose involving any  investigational drugs.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If the 
Investigator feels a protocol deviation would impr ove the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Novartis 
and approved by the IRB/IEC/REB it cannot be implemented. All significant protocol 
deviations will be recorded and reported i n the CSR.
11.1 Protocol A mendments
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, Health Authorities where required, and the IRB/IEC/REB. 
Only  amendments that are required for subject safet y may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendments, the Investigator is expected to take any immediate action required for the safet y 
of any subject included in this study , even if this action represents a deviation from the 
protocol. In such cases, Novartis should be notified of this action and the Health Authorities 
(where required) and the IRB/IEC/REB at the study  site should be informed within 
10working day s or less, if required by local regulation.
Novartis Confidential Page 111
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
12 References
Available upon request.
Andrass y J, Zeier M, Andrassy K (2004) Do we need screening for thrombophilia prior to 
kidney  transplantation? Nephrol Dial Transplant: 19(Suppl 4): iv64.
American Diabetes Association (2010). Diagnos is and classification of diabetes mellitus. 
Diabetes Care;33(Suppl 1):S62-9.
Astragraf XL™ (tacrolimus extended release capsules) package insert, NDA 204096: Astellas, 
approved July  19, 2013 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204096s0 00lbl.pdf (Accessed on 
14th February  2014)
CellCept®(mycophenolate mofetil 500 mg tablets) package insert, NDA 050722: Roche, 
revised label approved September 27, 2013, original June 19, 1997 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050722s030s031,050723s029s030
,050758s028s029,.pdf (Accessed on 14th February 2014)
CHMP guideline on clinical investigation of immunosuppressants in solid organ 
transplantation (2009) 
http://www.ema.europa.eu/docs/en_GB/document_library /Scientific_guideline/2009/09/WC5
00003593.pdf (accessed 14th February  2014)
Clatworthy  MR (2011) Targeting B cells and antibody  in transplantation. Am J 
Transplant;11:1359 -67.
Contin C, Pitard V, Delmas Y, et al (2003) Potential role of soluble CD40 in the humoral 
immune response impairment of uraemic patients. I mmunology ;110(1):131 -40.
DerSimonian R and Laird N (1986) Meta -analysis in clinical trials. Controlled Clinical 
Trials;7:177 -88.
Ekberg H, Tedesco -Silva H, Demirbas A, et al (2007) Reduced exposure to calcineurin 
inhibitors in renal transplantation. N Engl J Med;357(25):2562 -75.
FDA Workshop, 2012: Endpoints in Clinical Trials of Kidney  Transplantation. Transcript at 
http://www.fda.gov/Drugs/NewsEvents/ucm305308.htm
Food and Drug Administration CDER Statistical Review of BLA 125288/S -0000 (June 15, 
2011) http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125288Orig1s000StatR.pdf 
(Accessed on 14thFebruary  2014)
Goldwater R, Keirns J, Blahunkab P, et al (2013) A phase 1, randomized ascending single -
dose study  of antagonist anti -human CD40 ASKP1240 in healthy  subjects. Am J 
Transplant;13:1040 -6.
Harland R, Klintmalm G, Yang H, et al. (2015) ASKP1240 in De Novo Kidney  Transplant 
Recipients. Am J Transplant ;15(S3):Abstract # 3012
Novartis Confidential Page 112
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Hochberg Y (1988) A sharper Bonferroni procedure for multiple tests of significance. 
Biometrika;75(4):800 -2.
Kaplan EL and Meier P (1958). Nonparametric estimation from incomplete observations. J 
Am Statist Assoc;53(282):457 -81.
Kasiske BL, Israni AK, Sny der JJ, et al (2011) The relationship between kidney function and 
long-term graft survival after kidney  transplant. Am J Kidney  Dis;57(3):466 -75.
Kawai T, Andrews D, Colvin RB, et al (2000). Thro mboembolic complications after 
treatment with monoclonal antibody  against CD40 ligand. Nature Medicine; 6(2):114.
Komura K, Fujimoto M, Matsushita T, et al (2007) Increased serum soluble CD40 levels in 
patients with sy stemic sclerosis. J Rheumatology ;34(2) :353-8.
Levey  A, Coresh J, and Balk E (2003) National Kidney  Foundation Practice Guidelines for 
Chronic Kidney  Disease: Evaluation, Classification, and Stratification. Ann I ntern 
Med;139:137 -147.
Lougaris V, Badolato R, Ferrari S, et al (2005) Hyper immuno globulin M syndrome due to 
CD40 deficiency : clinical, molecular, and immunological features . Immunol Rev;203:48 -66.
Lowe PJ, Tannenbaum S, Wu K, et al (2010) On setting the first dose in man: quantitating 
biotherapeutic drug -target binding through pharmacokinetic and pharmacody namic models. 
Basic & Clinical Pharmacology  & Toxicology ;106(3):195 -209.
Ma A, Dun H, Song L, et al (2014) Pharmacokinetics and pharmacody namics of ASKP1240, 
a fully  human anti -CD40 antibody , in normal and renal transplanted Cy nomolg us monkey s. 
Transplantation ;97(4):397 -404
Matas AJ, Smith JM, Skeans MA, et al (2013) OPTN/SRTR Annual Data Report: Kidney. 
Am J Transplant;13(Suppl 1):11-46.
Naesens M, Ku ypers DR and Sarwal M (2009) Calcineurin inhibitor nephrotoxicity . Clin J 
Am Soc Neph rol;4(2):481 -508.
Nulojix®(belatacept) package insert, BLA 125288: Bristol Myers Squibb, revised label 
approved April 8, 2013, original June 15, 2011. 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125288s030lbl.pdf (Accessed on 
14thFebruary 20 14)
Okimura K, Maeta K, Kobay ashi N, et al. (2014) Characterization of ASKP1240, a fully  
human antibody  targeting human CD40 with potent immunosuppressi ve effects. Am J 
Transplant ;14(6):1290 -1299
Prograf®(tacrolimus capsules) package insert, NDA 050708: Astellas, revised label 
September 4, 2013, approved April 8, 1994. 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050708s043,050709s036lbl.pdf 
(Accessed on 14thFebruary  2014)
Novartis Confidential Page 113
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Scholten EM, Rowshani AT, Cremers S, et al (2006) Untreated rejection in 6-month protocol 
biopsies is not associated with fibrosis in serial biopsies or with loss of graft function. J Am 
Soc Nephrol;17:2622 -32.
Schwabe RF, Engelmann H, Hess S, et al (1999) Soluble CD40 in the serum of healthy  
donors, patients with chronic re nal failure, haemodialy sis and chronic ambulatory  peritoneal 
dialy sis (CAPD) patients. Clin Exp I mmunol;117(1):153 -8.
Simulect®(basiliximab) package insert, BLA 103764: Novartis, revised label approved 
September 2005, original May  12, 1998. 
http://www.pha rma.us.novartis.com/product/pi/pdf/simulect.pdf (Accessed on 14thFebruary 
2014)
Silva HT, Yang HC, Abouljoud M, et al (2007) One -year results with extended -release 
tacrolimus/ MMF, tacrolimus/MMF and cy closporine/MMF in de novo kidney  transplant 
recipient s. Am J Transplant;7:595 -608.
Sis B, Mengel M, Haas M, et al (2010) Banff 09 meeting report: antibody  mediated graft 
deterioration and implementation of Banff working groups. Am J Transplant;10:464 -71.
Solez K, Colvin RB, Racusen L C, et al (2008) Banff 07 classification of renal allograft 
pathology : updates and future directions. Am J Transplant;8:753 -60.
Sood P, Senanay ake S, Sujeet K, et al (2012) Management and outcome of BK viremia in 
renal transplant recipients: a prospective single -center study . Trans plantation;94(8):814 -21.
Tabrizi MA and Roskos LK (2007) Preclinical and clinical safet y of monoclonal antibodies. 
Drug Discov Today ;12(13 -14):540 -7.
van Kooten C and Banchereau J (2000). CD40 -CD40 ligand. J Leukoc Biol;67(1):2 -17.
Vincenti F, Charpentier B, Vanrenterghem Y, et al (2010). A phase III study of belatacept -
based immunosuppression regimens versus cy closporine in renal transplant recipients 
(BENEFIT stud y). Am J Transplant;10:535 -46.
Vincenti F, Mendez R, Pescovitz M, et al (2007) A phase I/II randomized open- label 
multicenter trial of efalizumab, a humanized anti- CD11a, anti -LFA -1 in renal transplantation. 
Am J Transplant;7:1770 -7.
Vincenti F, Ramos E, Brattstrom C, et al (2001) Multicenter trial exploring calcineurin 
inhibitors avoidance in renal transplantation. Transplantation;71(9):1282-7.
Yang H, Vincenti F, Klintmalm G, et al (2012) A phase 1b, randomized, double-blind, 
parallel group, placeb o-controlled, s ingle-dose, pharmacokinetic, pharmacody namic, Safet y 
and tolerability  study of ASKP1240 in de novo kidney  transplantation [abstract]. 
Transplant;94(10S):80.
No va r t i s Con f iden t ia l Page  114
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
13 Append ix  1 : Samp le  Log  tab le  –a l l  ma t r ices
B lood  Log  (Pa r t  1 ) :Co rpo ra te  Con f iden t ia l  
In fo rma t ion
Co rpo ra te  
Con f iden t ia l  
In fo rma t ion
No va r t i s Con f iden t ia l Page  115
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
No va r t i s Con f iden t ia l Page  116
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
B lood  Log  (Pa r t  2) : Co rpo ra te  
Con f iden t ia l  
In fo rma t ionCo rpo ra te  
Con f iden t ia l  
In fo rma t ion
No va r t i s Con f iden t ia l Page  117
Amended  P ro toco l  Ve rs ion  v03  (C lean ) P ro toco l  No .  CCFZ533X2201
Co rpo ra te  Con f iden t ia l  In fo rma t ion
Novartis Confidential Page 118
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
14 Appendix 2: US-Specific CellCept(R) Pregnancy  and Safety  
Information
Use of CellCept®during pregnancy  is associated with an increased risk of first trimester 
pregnan cy loss and an increased risk of congenital malformations, especially  external ear 
and other facial abnormalities including cleft lip and palate, and anomalies of the distal 
limbs, heart, esophagus, and kidney .
Females of reproductive potential must be made aware of the increased risk of first 
trimester pregnancy  loss and congenital malformations with MPA products and must be 
counseled regarding pregnancy  prevention and planning.
For those females using Cellcept®at an y time during pregnancy  and those be coming 
pregnant within 6 weeks of discontinuing therap y, the Investigator or healthcare 
practitioner should report the pregnancy  to the M ycophenolate Pregnancy Registry 
(1-800-617- 8191). The Investigator or healthcare practitioner should strongl y 
encourage the patient to enroll in the pregnancy  registry .
Risks and benefits of CellCept®should be discussed with the patient. When appropriate, 
consider alternative immunosuppressants with less potential for embry ofetal toxicity . 
Incertain situations, the patient and her healthcare practitioner may  decide that the 
maternal benefits outweigh the risks to the fetus. If this drug is used during pregnancy , or 
if the patient becomes pregnant while taking this drug, the patie nt should be apprised of 
the potential hazard to the fetus. 
To prevent unplanned exposure during pregnancy , females of reproductive potential 
should have a serum or urine pregnancy  test with a sensitivity  of at least 25 mI U/mL 
immediately  before starting CellCept®. Another pregnancy  test with the same sensitivity  
should be done 8 to 10 day s later. Repeat pregnancy  tests should be performed during 
routine follow -up visits. Results of all pregnancy  tests should be discussed with the patient.
Females of repro ductive potential taking CellCept®must receive contraceptive counseling 
and use acceptable contraception (see Table 14-1 for Acceptable Contraception Methods). 
Patients must use acceptable birth contro l during entire CellCept®therap y, and for 
6weeks after stopping CellCept®, unless the patient chooses abstinence (she chooses to 
avoid heterosexual intercourse completel y).
Patients should be aware that CellCept®reduces blood levels of the hormones in t he oral 
contraceptive pill and could theoreticall y reduce its effectiveness.
Novartis Confidential Page 119
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Table 14-1 Acceptable Contraception Methods for Females of Reproductive 
Potential*
Option 1
Methods to Use A loneIntrauterine device (IUD)
Tubal sterilization
Patient’s partner had a vasectom y
OR
Option 2
Choose One Hormonal 
Method A ND One Barrier 
MethodHormone Methods
choose 1Barrier Methods
choose 1
Estrogen and 
Progesterone
Oral contraceptive pill
Transdermal patch
Vaginal ring
Progesterone -only
Injection
ImplantANDDiaphragm with spermicide
Cervical cap with spermicide
Contraceptive sponge
Male condom
Female condom
OR
Option 3
Choose One Barrier Method 
From Each Column ( must 
choose two methods )Barrier Methods
choose 1Barrier Methods
choose 1
Diaphragm with 
spermicide
Cervical cap with 
spermicide
Contraceptive spongeANDMale condom
Female condom
*Females of reproductive potential include girls who have entered puberty and all women who have a 
uterus and have not passed through menopause.
Novartis Confidential Page 120
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
15 Appendix 3: Stopping rules 
Transition rules are based on both efficacy  and safety  results from Part 2. In Part 2, treatment 
arms are as follows:
A:CFZ533 10mg/kg (IV );
B is Control
Then the rules are as follows:
If A isterminated for an y reason, then STOP the study .
The following rules are for terminating treatment group(s) from Part 2:
For safety:
Terminate the treatment group if there are two (2) or more patients presenting with 
PTLD or PML in that group.
For toxicities, AEs / infections, and causalities, case -by-case review is needed to 
determine an y treatment group(s) should be terminated.
For efficacy (based on the number of patients with tBPAR):
If no tBPAR for SoC , then any  group with tBPAR ≥ 7 will be terminated.
If one tBPAR for SoC, then an y group with tBPAR ≥ 8 will be terminated.
If more than one tBPAR for SoC, then any  group with tBPAR ≥ 9 will be terminated.
Novartis Confidential Page 121
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
16 Appendix 4: Guidelines for MMF dose reduction
An Investigator may interrupt temporaril y or reduce the dosage of study  medication MMF 
ifin his/her opinion this is clinicall y warranted, in response to any causally  associated AE 
(e.g., neutropenia, thrombocy topenia, leucopenia, hyperlipidemia, hypertrigly ceridemia or 
gastrointestinal intolerance). The following guidelines should be followed:
Dose reduction or temporary interruption may be performed for MMF
Implementation of dose reduction will be based on thrombocy topenia, leukopenia, 
neutropenia, or other AEs which are suspected to be related to study  medication, and in the 
opinion of the Investigator, are clinicall y warranted. Thefollowing guidelines should be used 
for both dose reduction and, once the event has resolved, restarting or increasing the dose of 
MMF back to original levels. 
Dose Reduction Guidelines
Platelets
platelet count < 100,000/mm³ dose may be reduced at the discretion of the Investigator
platelet count < 75,000/mm³ a second dose reduction should be considered
platelet count < 50,000/mm³ MANDATORY interruption of medication
WBC
WBC < 3500/mm³ dose may be reduced at the discretion of the Investigator
WBC < 2500/mm³ a second dose reduction should be considered
WBC < 2000/mm³ MANDATORY interruption of medication
All these changes must be rec orded on the MMF Dosage Administration Record eCRF.
Novartis Confidential Page 122
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
17 Appendix 5: Tacrolimus drug -drug interactions
Please refer to most recent national prescribing information for current labeling 
recommendations. 
Drug interactions
Due to the potential for additive or synergistic impairment of renal function, care should be 
taken when administering Tac with drugs that may be associated with renal dysfunction. 
These include, but are not limited to, aminogl ycosides, amphotericin B, and cisplatin. Initial 
clinical experience with the co-administration of Tac and cyclosporine resulted in 
additive/sy nergistic nephrotoxicity .
Drugs that may  alter tacrolimus concentrations
Since Tacis metabolized mainly  by the CYP3A enzy me sy stems, substances known to inhibit 
these enzymes may  decrease the metabolism or increase bioavailability  of Tacas indicated by 
increased whole blood or plasma concentrations. Drugs known to induce these enzyme 
systems may result in an increased metabolism of Tac or decreased bioavailability  as 
indicated by decreased whole blood or plasma concentrations. Monitoring of blood 
concentrations and appropriate dosage adjustments are essential when such drugs are used 
concomitantly .
Novartis Confidential Page 123
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
*Drugs that may  increase tacrolimus blood concentrations
Calcium
Channel
BlockersAntifungal
Agents Macrolide
AntibioticsGastrointestinal
Prokinetic
AgentsOther Drugs
diltiazem
nicardipine
nifedipine
verapamilclotrimazole
fluconazole
itraconazole
ketoconazole**
voriconazoleclarithromycin
erythromycin
troleandomycincisapride
metoclopramidebromocriptine
chloramphenicol
cimetidine
cyclosporine
danazol
ethinyl estradiol
methylprednisolone
lansoprazole***
omeprazole
protease inhibitors
nefazodone
magnesium -aluminum 
hydroxide
**In a study of 6 normal volunteers, a significant increase in Tacoral bioavailability (14±5% vs. 30±8%) 
was observed with concomitant ketoconazole administration (200 mg). The apparent oral clearance of 
Tac during ketoconazole administration was signific antly decreased compared to Tac alone 
(0.430±0.129 L/hr/kg vs. 0.148±0.043 L/hr/kg). Overall, IV clearance of Tac was not significantl y 
changed by ketoconazole co -administration, although it was highly variable between patients.
*** Lansoprazole (CYP2C19, CYP3A4 substrate) may potentially inhibit CYP3A4 -mediated m etabolism 
of Tac and thereby substantially increase Tac whole blood concentrations, especially in transplant 
patients who are intermediate or poor CYP2C19 metabolizers, as compared to those patient s who are 
efficient CYP2C19 metabolizers.
*Drugs that may  decrease tacrolimus blood concentrations
Anticonvulsants Antimicrobials Herbal Preparations Other Drugs 
carbamazepine
phenobarbital
phenytoinrifabutin
caspofungin
rifampinSt. John’s W ort sirolimus
* This table is not all inclusive.
St. John’s Wort (Hypericum perforatum) induces CYP3A4 and P-glycoprotein. Since Tacis a 
substrate for CYP3A4, there is the potential that the use of St. John’s Wort in patients 
receiving Taccould result in re duced Taclevels.
In a single -dose crossover study  in health y volunteers, co-administration of Tac and 
magnesium -aluminum hy droxide resulted in a 21% increase in the mean TacAUC and a 10% 
decrease in the mean TacCmax relative to Tacadministration alone.
In a study  of 6 normal volunteers, a significant decrease in Tacoral bioavailability  (14±6% vs. 
7±3%) was observed with concomitant rifampin administration (600 mg). Inaddition, there 
was a significant increase in Tac clearance (0.036±0.008 L/hr/kg vs. 0.053±0.010 L/hr/kg) 
with concomitant rifampin administration.
Novartis Confidential Page 124
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Interaction studies with drugs used in HIV therapy  have not been conducted. However, care 
should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized 
by CYP3A (e.g., nelfinavir, ritonavir) are administered concomitantly  with Tac. Similarl y, 
care should be exercised when HCV protease inhibitors (e.g., boceprevir and telaprevir), also 
metabolized by  CYP3A, are administered concomitantly with Tac.
Tac may affect the PKof other drugs (e.g., pheny toin) and increase their concentration. 
Grapefruit juice affects CYP3A- mediated metabolism and should be avoided.
Other Drug Interactions
Immunosuppressants may affect vaccination. Therefore, during treatment with Tac, 
vaccination may be less effective. The use of live vaccines should be avoided; live vaccines 
may include, but are not limited to measles, mumps, rubella, oral polio, BCG, yellow fever, 
and TY 21a t yphoid ( Prograf®PI1994 ) 
Novartis Confidential Page 125
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
18 Appendix 6: Blinding and unblinding
Randomization data are kept strictly  confidential. Prior to final clinical database lock, 
unblinding is allowed only for authorized personnel as described in the table below.
Table 18 -1 Blinding levels
Time or Event
Role 1 2 3 4 5 6 7
Drug Supply UI UI UI UI UI UI UI
Randomization Office UI UI UI UI UI UI UI
Subject B B UI UI UI UI UI
Treating Physician B B UI UI UI UI UI
Primary Investigator B B UI UI UI UI UI
Study Monitor B B UI UI UI UI UI
Clinical Trial Leader B B B UI UI UI UI
Data Manager B B UI UI UI UI UI
PK Bioanalytics B UI UI UI UI UI UI
PK Expert B B B UI UI UI UI
Statistician B B B UI UI UI UI
Translational Medicine Expert B B B UI UI UI UI
Modeler B B B UI UI UI UI
Programmer B B B UI UI UI UI
Data Monitoring Committee B B B UI UI UI UI
UGAllowed to be unblinded on treatment group level
UIAllowed to be unblinded on individual patient level
BRemains blinded
1Generation of randomization list, QC and lock randomization list
2Patient allocation to treatment
3Treatment administration
4Safety emergency event (unblinding of a single subject)
5Interim analysis (all patients included in the analysis have completed the study)
6Interim analysis (some patients included in the analy sis have not yet completed the study)
7Database lock
Novartis Confidential Page 126
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
19 Appendix 7: Clinically  notable laboratory  values
Laboratory  variable Standard units SI units
Liver function and related variables
SGOT (ASAT) ≥3 × ULN ≥3 × ULN
SGPT (ALAT) ≥3 × ULN ≥3 × ULN
Bilirubin ≥3 × ULN ≥3 × ULN
Renal function, metabolic and electroly te variables
Urea 5 ULN 5 ULN
Creatinine After W k4: ≥3 mg/dL After W k4: ≥265 μmol/L
OR OR
>30% above value >30% above value
from preceding visit from preceding visit
Uric acid M ≥12 mg/dL M ≥714 μmol/L
F ≥9 mg/dL F ≥535 μmol/L
Glucose <45 mg/dL <2.5 mmol/L
>250 mg/dL >13.9 mmol/L
Cholesterol ≥350 mg/dL ≥9.1 mmol/L
Triglycerides ≥750 mg/dL ≥8.5 mmol/L
CK (MB) None None
Potassium ≤3.0 mEq/L ≤3 mmol/L
≥6.0 mEq/L ≥6 mmol/L
Calcium ≤6 mg/dL ≤1.5 mmol/L
≥13 mg/dL ≥3.2 mmol/L
Hematology  variables
Hemoglobin <7 g/dL <4.39 mmol/L
Platelets (thrombocytes) <50 k/mm3<50 × 109/L
≥700 k/mm3≥700 × 109/L
Leukocytes ( WBCs) ≤2.0 k/mm3≤ 2.0 × 109/L
≥16 k/mm3≥16 × 109/L
Hematology  variables: differential
Granulocytes (poly, neutrophils) ≤1,000/mm3≤1 x 109/L
Eosinophils ≥12% ≥12%
Lymphocytes ≤1,000/mm3≤1× 109/L
Vital sign variables Notable criteria
Systolic BP (mm/Hg) outside of 90 ≤ SBP ≥200 mm/Hg
Diastolic BP (mm/Hg) outside 50≤ DBP ≥120 mm/Hg
Novartis Confidential Page 127
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
20 Appendix 8: Banff ’09 Meeting Report: A ntibody  Mediated 
Graft Deterioration and Implemen tation of Banff Working 
Groups 1 
Normal
Antibody -mediated rejection –due to circulating anti -donor antibodies, C4d, and allograft 
pathology :
C4d deposition without morphologic evidence of acute rejection – C4d, anti -donor 
antibodies, no signs of acute or chronic rejection, no ATN- like minimal inflammation.
Acute antibod y-mediated rejection –C4d, anti -donor antibodies, and acute tissue injury , 
such as: (“suspicious for” if antibody  not demonstrated)
Type I –ATN -like minimal inflammation
Type II –Capilla ry involvement and/or thromboses
Type III – Arterial changes
Chronic antibody -mediated rejection –evidence of chronic tissue such as glomerular 
double contours, peritubular capillary  basement membrane multilay ering, interstitial 
fibrosis/tubular atroph y (IFTA), or fibrous intimal thickening in arteries. Borderline 
changes “suspicious” for acute T cell-mediated cellular rejection. No intimal arteritis 
present, but there are foci of mild tubulitis with mild interstitial infiltration. Threshold for 
rejection diagnosis is not met.
Tcell mediated rejection
Type IA -Significant interstitial infiltration (> 25% of parenchy ma) and foci of 
moderate tubulitis (> 4 mononuclear cells/tubular cross section or group of 10 tubular 
cells).
Type IB -Significant interstit ial infiltration (> 25% of parench yma) and foci of severe 
tubulitis (> 10 mononuclear cells/tubular cross section or group of 10 tubular cells).
Type IIA - Mild to moderate intimal arteritis
Type IIB -Severe intimal arteritis comprising > 25% of the lumen al area
Type III -Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid 
change and necrosis of medial smooth muscle cells (with accompan ying lymphocytic 
inflammation)
Interstitial fibrosis and tubular atroph y**
Grade I -Mild interst itial fibrosis and tubular atrophy  without (a) or with (b) specific 
changes suggesting chronic rejection
Grade II -Moderate interstitial fibrosis and tubular atrophy  (a) or (b)
Grade E III -Severe interstitial fibrosis and tubular atrophy  and tubular los s (a) or (b)
Novartis Confidential Page 128
Amended Protocol Version v03 (Clean) Protocol No. CCFZ533X2201
Other: Changes not considered to be due to rejection (e.g., post -transplant 
lymphoproliferative disorder, nonspecific changes, acute tubular necrosis, etc.), 
specificall y:
Chronic hy pertension -Arterial/fibrointimal thickening with reduplicat ion of elastica, 
usually  with small artery  and arteriolar hy aline changes.
Calcineurin toxicity  -Arteriolar h yalinosis with peripheral h yaline nodules and/or 
progressive increase in the absence of h ypertension or diabetes. Tubular cell injury  
with isometr ic vacuolization.
Chronic obstruction - Marked tubular dilatation. Large Tamm -Horsfall protein casts 
with extravasation into interstitium, and/or ly mphatics.
Acute bacterial p yelonephritis -Intratubular and peritubular neutrophils with 
destruction of the tubular epithelium.
Viral infection -Viral inclusions on histology  and immunohistology  and/or electron 
microscop y.
*The recommended format of report is a descriptive narrative signet followed by numeric al 
codes (Banff ‘09) in parentheses. Categorization should in the first instance be based solel y on 
pathologic changes, and then integrated with clinical data as a second step. More than one 
diagnostic category  may  be used if appropriate.
**Glomerular and vascular lesions help define ty pe of chronic nephropathy; chronic/recurrent 
rejection can be diagnosed if ty pical vascular lesions are seen. Grades I , II and III may  include 
nonspecific vascular and glomerular sclerosis, but severit y is graded by tubuloint erstitial 
features.
1 (Siset al 2010 )